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Abstract 
 
Since the inception of deep sequencing, isomiRs are consistently observed to be 
produced by most miRNA genes in a variety of cell types. Here I use northern blotting 
to show that isomiRs are not a sequencing artefact and I also observed that different 
cell lines and tissue types expressed distinctive isomiR patterns. All tested isomiRs 
could be immunoprecipitated with Argonaute proteins 1 or 2, indicating that they are 
functional.  
 
IsomiRs with differences at the 5' end have a different seed sequence compared to the 
canonical/ annotated microRNA. Bioinformatics analysis predicts that 5' isomiRs will 
target large numbers of different mRNAs compared to their canonical counterpart and 
vice versa. These predictions were supported by my in vitro luciferase assays, which I 
used to establish that isomiR-9 has gained the ability to target DNMT3B and NCAM2 
mRNA but has lost the ability to target CDH1. During this study I identified a number 
of new targets of miRNAs in vitro, all of which were confirmed by mutagenesis of the 
predicted target sites.  
 
Moreover, I have made RNA sponge vectors that can distinguish between miR-9 and 
isomiR-9. The “isomiR-9 sponge” could specifically sequester isomiR-9 at a better 
efficiency than the canonical miR-9, which has just one base difference at the 5' end, 
and vice-versa. This adds further assurance that isomiRs can recognise different 
targets to canonical/ annotated microRNAs and also establishes a useful research tool 
for future studies.  
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Taken together, this study shows that isomiRs are capable of targeting 3' UTRs, can 
associate with Argonaute proteins and may have different target mRNAs to canonical 
mRNAs. I also discuss some examples of miRNA genes whose evolution is likely to 
have been influenced by isomiR production, which adds further support to the view 
that isomiRs are of biological and evolutionary importance.  
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Chapter 1 Introduction 
 
1.1 The discovery of RNA interference 
In 1998, Fire and colleagues reported that the injection of double stranded RNA 
caused the degradation of mRNA encoded by the gene unc-22 of the small nematode 
Caenorhabditis elegans. They termed this effect RNA interference and showed that it 
was sequence specific and effective at concentrations far lower than the target unc-22 
mRNA, indicating the involvement of amplification effect in this process (Fire et al., 
1998).  
 
In parallel, David Baulcombe’s group (Hamilton et al., 1999) discovered 
posttranscriptional gene silencing (PTGS) in plants. Both viral infection and 
transgenic expression in plants can induce PTGS, which targets both cellular and viral 
mRNA. It was inferred that PTGS operates through the generation of small RNA 
molecules of 21 to 25 nucleotides, which are now known as small interfering RNAs 
(siRNAs). Consequently, work on both animals and plants together revealed a highly 
conserved mechanism of RNA interference that had evolved at least in part for 
combating viral infection.  
 
Two biochemistry groups were able to recapitulate RNA interference in cell free 
extracts from Drosophila cells, which led to the establishment of three phases of the 
RNA interference reaction: cleavage of a long dsRNA into shorter dsRNA segments 
by Dicer; the loading of single stranded RNA into the RISC (RNA-induced silencing 
complex) and the targeting and degradation of mRNA by this complex (Tuschl et al., 
1999; Hammond et al., 2000; see below). Subsequently mutations of C.elegans that 
17 
 
confirm resistance to RNA interference were found to disrupt genes that encoded 
components of RISC (Fire, 2007). 
      
1.2 The discovery of microRNAs 
Lee et al., (1993) identified two overlapping transcripts of the lin-4 gene of C. elegans, 
of approximately 22 and 61 nts that inhibited the expression of lin-14 through 
complementarity to the 3' untranslated region (UTR) of lin-14 mRNA. The 61 
nucleotides molecule can also fold into a double-stranded “hairpin” (Lee et al., 1993). 
They suggested that lin-4 inhibits translation of lin-14 through an antisense RNA-
RNA interaction. A similar conclusion was made by another group who reported that 
there were 7 conserved sites in the 3' UTR of lin-14, which were complementary to a 
portion of lin-4 RNA (Wightman et al., 1993).  
 
Subsequently, it was shown that lin-4 and a second gene let-7 acted in a sequential 
stage specific expression pattern that regulates the timing of C.elegans development. 
The let-7 gene encodes a 21-nucleotide RNA that is complementary to the 3' UTR of 
genes lin-14, lin-28, lin-41, lin-42 and daf-12. Let-7 is expressed at the adult but not 
embryonic stage. Let-7 was also identified in humans, fruit flies, chickens, frogs, 
zebrafish, molluscs and sea urchins and the binding site in its target was conserved in 
some of these organisms (Reinhart et al., 2000; Pasquinelli et al., 2000). In 2001, 
three groups published their discovery of large number of similar small RNA 
molecules, referred to as microRNAs, in C.elegans and subsequently mouse (Lee et 
al., 2001; Lau et al., 2001; Lagos-Quintana et al., 2001, 2002). Remarkably, the 
cytoplasmic cellular machinery that mediates RNA interference is also responsible for 
18 
 
the generation of microRNAs (miRNAs). As described below, there are additional 
processing steps for miRNA generation that take place in the nucleus.   
 
1.3 Non-coding RNAs 
MicroRNAs belong to one of the classes of non-coding RNAs. Non-coding RNAs are 
functional RNAs that do not translate into protein. They comprise: transfer 
RNA (tRNA); ribosomal RNA (rRNA); small nucleolar RNA (snoRNA); microRNA; 
small interfering RNA (siRNAs); small nuclear RNA (snRNA); piwi-interacting RNA 
(piRNA), and long ncRNA (Figure 1.1; Morin et al., 2008). MicroRNAs are the most 
abundant and to date, approximately 1600 pre-miRNAs and 2040 mature human 
miRNAs have been identified (miRBase, August 2012, Griffith-Jones et al., 2004; 
Kozomara et al., 2011). MicroRNAs are about 19-25 nucleotides in length and are 
now known to have important post-transcriptional roles in almost every cellular 
process in eukaryotes. These processes include the regulation of developmental 
timing and signalling pathways, apoptosis, metabolism, myogenesis and cardiogenesis, 
brain development, and human pathologies like viral diseases, genetic disorders and 
cancer (Esquela-Kerscher et al., 2006; Kloosterman et al., 2006a; Shi et al., 2008). 
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Figure 1.1  
Distribution of sequence count of 8 major classes of small RNAs in the hESCs 
small RNA library. They are represented as a fraction of the total sequences that has 
at least one perfect alignment to the human reference genome. MiRNA represents the 
most abundantly expressed class, i.e., >50% of the 8 classes of small RNAs. snRNA – 
small nuclear RNA; tRNA – transfer RNA; rRNA – ribosomal RNA; scaRNA – 
Small Cajal body-specific RNA; mRNA – messenger RNA. Reproduced from Morin 
et al., (2008).  
 
 
 
1.4 MicroRNA  
1.4.1 Biogenesis 
MicroRNA genes can be located between genes as well as within the intron or exon 
regions of other genes in the human genome (Figure 1.2). The miRNA genes are 
transcribed into primary miRNA (pri-miRNA) by RNA polymerase II (Lee et al., 
2004; Cai et al., 2004) or in some instances polymerase III (Borchert et al., 2006). 
These primary transcripts range from hundreds to thousands of nucleotides in length 
and can encode multiple precursor miRNAs (Breving et al., 2010).  
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Figure 1.2 Examples of genomic location of miRNA genes, also indicated is whether 
the direction of transcription is the same or opposite of the host gene.   
 
 
Pri-miRNA undergoes processing by Drosha, an RNase III endonuclease (Lee et al., 
2003). Drosha forms a microprocessor complex with DGCR8 (DiGeorge syndrome 
critical region gene 8), which is called Pasha in Drosophila and PASH-1 in C. elegans 
(Yeom et al., 2006; Han et al., 2009; Breving et al., 2010). This complex binds to 
stem loops within pri-miRNA and can excise and release precursor miRNA (pre-
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miRNA) (Basyuk et al., 2003; Lee et al., 2003) (Figure 1.3). DGRC8 assists Drosha to 
cleave ~ 11 bp away from the ssRNA-dsRNA junction (Han et al., 2006). The hairpin 
of pre-miRNA is ~ 70 nt in length. Not all miRNAs are dependent upon Drosha-
mediated processing, these include miRNAs called mirtrons that are processed by 
splicing (Berezikov et al., 2007; Chan et al., 2007).  
 
The pre-miRNA is then transported into the cytoplasm by Exportin-5 (Yi et al., 2003; 
Murchison et al., 2004). Here, the pre-miRNA is further processed by Dicer, also an 
RNase III endonuclease, resulting in the generation of a ~ 22 nt miRNA-miRNA* 
duplex (Grishok et al., 2001; Ketting et al., 2001), leaving the 5’ phosphate and 2 nt 
3’ overhang characteristic of processing by an RNase III.  
 
 
Figure 1.3 Biogenesis of miRNA.  
MiRNA genes are transcribed into primary miRNA (pri-miRNA) transcripts that 
undergo processing by Drosha. The resulting hairpin precursor miRNAs (pre-
miRNAs) are transported to the cytoplasm by exportin 5 (XPO5 on figure). The Dicer 
complex removes the loop region from pre-miRNAs, and one strand of the resulting 
duplex is bound by Argonaute to form an miRNA-induced silencing complex 
(miRISC), which targets mRNAs for regulation. While the other strand, which is 
often called the star strand (miRNA*), is degraded. Taken from Pasquinelli, 2012. 
Copyright permission obtained from author and Nature Publishing Group. 
 
1.4.2 The complexity of miRNA regulation 
The regulation of miRNA biogenesis is under transcriptional, post-transcriptional and 
feedback loops controls. Studies have shown that miRNAs expression differ in 
developmental stages and tissue types. Therefore, precise control of miRNA 
biogenesis is crucial in the maintenance normal cellular function (Kim et al., 2009).  
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Transcriptional control 
Various Pol II-associated transcription factors are involved in the control of miRNA 
transcription. For instance, in the studies of myogenesis, Rao et al., (2006) found that 
myogenin and myoD1 bind to regions upstream to muscle specific miRNAs (miR-1 
and miR-133 cluster) and likely to regulate their expression. Meanwhile, Chen et al., 
(2006) showed that miR-1 and miR-133 are regulated by serum response factor (SRF). 
 
Post-transcriptional control 
The primary miRNA let-7 is found in both undifferentiated stem cells and 
differentiated cells. However, interestingly mature let-7 is only identified in 
differentiated cells, because it is under post-transcriptional control. Many studies have 
established that the RNA binding protein Lin28 is responsible for the inhibition of let-
7 maturation (Nam et al., 2008; Kim et al., 2009; Lehrbach et al., 2010). RNA editing 
is another post-transcriptional control mechanism, where adenine is altered to inosine 
by adenine deaminases (Yang et al., 2006; Kawahara et al., 2007). In addition, there 
are other proteins that are involved in the post-transcriptional regulation of miRNAs 
(Siomi et al., 2010; Guil et al., 2007; Davis et al., 2008; Trabucchi et al., 2009).  
 
Feedback loop control 
Two types of feedback loops have been observed: (1) single negative feedback and (2) 
double negative feedback. Martinez and colleagues analysed the transcription factors 
that are associated with miRNAs and predicted targets of miRNAs which are also 
transcription factors and found that many of the transcription factors are repressed by 
the same miRNA that activated it (Martinez et al., 2008). Let-7 and lin28 are an 
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example of a double negative feedback loop. Lin28 blocks let-7 biogenesis, whereas 
let-7 suppresses lin28 protein synthesis (Kim et al., 2009). 
 
1.4.3 Mechanism of target selection 
Mature miRNA is held at both ends by an Argonaute protein in the RNA-induced 
silencing complex (RISC) that guides the miRNA towards  target mRNAs resulting in 
reduced protein production, via mechanisms that are still under investigation, namely 
mRNA destabilisation, deadenylation or translational repression. In animals, miRNAs 
usually form incomplete complementary duplexes with their mRNA targets, which 
are normally located at the 3' UTR. The canonical site of target recognition is the 
“seed region” which is located at nucleotides 2 to 7 or 2 to 8 at the 5' end of the 
miRNA and often has perfect complementarity pairing to the target mRNA (Bartel, 
2009). Atypical sites have also been described such as the interaction between let-7 
and lin-41 in C. elegans. In this example, imperfect pairing of the seed region at the 5' 
end is compensated for by pairing at the 3' end (Vella et al., 2004; Bartel, 2009; 
Pasquinelli, 2012). Recently, central pairing (nucleotides 4 to 15) been shown to lead 
to Ago2 mediated target cleavage (Shin et al., 2010). 
 
1.4.4 Argonaute protein 
Human Ago1, Ago3 and Ago4 genes are located on chromosome 1, whereas the Ago2 
gene is on chromosome 8 (Hock et al., 2008). In addition, Ago2 is the only one with 
‘slicer’ activity and therefore capable of cleaving target mRNA (Liu et al., 2004).  
Ago2 also mediates the action of interfering RNA. Argonaute protein consists of 3 
domains: PIWI, MID and PAZ. The PAZ domain recognises the 2 nucleotides at the 
3’ overhang of the miRNA duplex that is produced by Dicer (Cenik et al., 2011). The 
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5' monophosphate of the miRNA is buried within the MID domain, while the 3' end is 
exposed at the PAZ domain. Based on the structure of Ago2, it favours binding of 
small RNAs that begin with an adenosine (A) or uridine (U) at the 5' end. These 
features of Ago proteins might be important in the loading of miRNA into the RISC 
complex.   
 
 
 
1.4.5 Star strands 
In general, one strand of the RNA duplex denoted as the guide strand preferentially 
accumulates (Schwarz et al., 2003). This strand is often assumed to be the dominant 
functional product that is incorporated into the RISC to direct translational repression 
or degradation of mRNA (Hutvagner, 2005). The opposite strand is referred to as the 
passenger or star strand (miR*) and usually is less frequently sequenced (Lagos-
Quintana et al., 2002; Aravin et al., 2003; Lim et al., 2003). In some instances both 
miR and miR* are equally expressed (Kloosterman et al., 2006b; Stark et al., 2007).  
 
In the cloning and sequencing data of Chan (unpublished; see chapter 5) of human 
embryonic stem cells (hESCs), miR-302a* was detected as the dominant strand, in 
fact, it was sequenced 20 times more than the guide strand of miR-302a, suggesting 
that it might be a functional strand. Indeed, recent studies have demonstrated that the 
star strand of a precursor miRNA can be associated with Argonaute proteins 
(Ghildiyal et al., 2010) and the inhibitory effect of miR* has been shown in cultured 
cell and transgenic animals (Okamura et al., 2008). 
 
Many deep sequencing studies indicate that the dominant strand of the mature miRNA 
can switch in different tissues and at different developmental times (Ro et al., 2007; 
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Ruby et al., 2007; de Wit et al., 2009; Chiang et al., 2010). The predicted targets of 
miR and miR* differ significantly (Griffiths-Jones et al., 2011). The process of 
switching between miR and miR* in different tissues is referred to as arm switching 
and is suggested to be a fundamental mechanism in the evolution of miRNA function 
(de Wit et al., 2009; Griffith-Jones et al., 2011).  
 
In Drosophila, reports showed that star strands are associated with Ago proteins 
(Ghildiyal et al. 2010; Okamura et al., 2008). Recently, miR-24-2* was found to be 
preferentially expressed in MCF7 breast cancer cells where it might have a tumour 
suppression role. Ectopic expression of miR-24-2* resulted in reduced cell survival 
through the suppression of protein kinase C alpha (PKCα) (Martin et al., 2012). 
Interestingly, in a study where either miR-10a or miR-10a* was transfected into 
Group B coxsackievirus (RLuc-CVB3) infected HEK cells, only miR-10a* was found 
to up-regulate the biosynthesis of CVB3. The authors suggested that miR-10a* might 
be involved in viral pathogenesis (Tong et al., 2013). Bioinformatics analysis showed 
that a substantial fraction of miRNA* species are stringently conserved over 
vertebrate evolution, with greatest conservation in their seed regions (Yang et al., 
2011). It was also found that the 3' UTR target sites that match the seed sequence of 
miRNA* species are under demonstrable selective conservation (Okamura et al., 
2008). 
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1.5 IsomiRs 
1.5.1 The identification of isomiRs 
The advent of high-throughput deep sequencing has led to the detection of large 
numbers of miRNAs (Morin et al., 2008; Lee et al., 2010; Cloonan et al., 2011). In 
these miRNA libraries, miRNAs encoded by the same gene frequently exhibited 
variation in length from the canonical sequence annotated in miRBase, as a result of 
an addition or deletion at the 5' or 3' ends or both. These variants were termed as 
isomiRs (Neilsen et al., 2012). They can be categorised into 5' isomiRs, 3' isomiRs 
and mixed 5' and 3' isomiRs.  
 
To date, isomiRs have been detected in a variety of cell lines and cancers such as 
hESCs, endothelial cells, 293T cells, prostate cancer, gastric cancer, breast cancer and 
leukemic cells (Morin et al., 2008; Bar et al., 2008; Kuchenbauer et al., 2008; 
Lipchina et al., 2011; Voellenkle et al., 2012; Watahiki et al., 2011; Li et al., 2012; 
Chang et al., 2012). Currently, the isomiR databases that are available in the web 
include miRBase (Griffith-Jones et al., 2004), YM500 (Cheng et al., 2012), Hood lab 
(Institute of Systems Biology, 2012), miRGator v3.0 (Cho et al., 2012; Narry Kim lab) 
and SeqBuster (Pantano et al., 2010) (Table 1.1). 
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Table 1.1 List of isomiR databases  
 
 
Despite the large number of isomiRs that have been detected, there is relatively little 
experimental proof that they are functional (Fernandez-Valverde et al., 2010; 
Burroughs et al., 2011; Fukunaga et al., 2012; Humphreys et al., 2012; Lloren et al., 
2013). Dominant isomiRs were found to be differentially expressed across Drosophila 
melanogaster development and tissues (Fernandez-Valverde et al., 2010). Burrough et 
al., (2011) showed that isomiRs can associate with Ago protein. Using an assay that 
shows Ago2 cleaves target mRNA at nucleotide positions 10 and 11 from the 5' end 
of small RNA (Beitzinger et al., 2007), Azuma-Mukai et al., (2008) showed that 5' 
isomiRs were able to participate in Ago2-mediated RNA cleavage. 
 
It was subsequently shown that altering the Dicer partner proteins could change the 
choice of the cleavage site, producing isomiRs with different target specificities and 
function in Drosophilia (Fukunaga et al., 2012). Recently, Lloren et al., (2013), 
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analysed gene expression by microarray after transfecting miR-101 and isomiR-101 
into SH-SY5Y cells. They found that isomiR-101 has an overall weaker inhibitory 
effect than miR-101 and largely targeted the same set of genes. Only two of the genes 
that were found to be down-regulated in isomiR-101 transfected cells were not 
regulated by miR-101. 
 
1.5.2 Origin of isomiRs  
There has been some concern that isomiRs are simply sequencing artefacts.  However, 
“spike in” synthetic RNA oligonucleotide experiments indicate that isomiR 
identification far exceeds error rates (Wyman et al., 2011). 3' isomiRs are the most 
frequently observed isomiRs (Wyman et al., 2011; Lee et al., 2010; Burroughs et al., 
2011; Newman et al., 2011). Although not as frequent, 5’ isomiRs were also detected. 
This heterogeneity in length is thought to arise in part from imprecise cleavage by 
Drosha or Dicer, which would be expected to give rise to equivalent numbers of 3' or 
5' isomiRs that will otherwise match the parent gene and for this reason are referred to 
as templated (Neilsen et al., 2012). Non-templated refers to post-transcriptional 
modifications such as A to I editing that may not match the parent gene. The excess of 
3' isomiRs that are observed are thought to arise by trimming, adenylation or 
uridylation (Han et al., 2011; Liu et al., 2011; Wyman et al., 2011; Heo et al., 2012). 
In addition, Liu et al., (2011) showed that knockdown of Nibbler (a 3' to 5' 
exoribonuclease) was accompanied by loss of some 3' isomiRs.  
 
The 3' ends of miRNA extend from the PAZ domain of the Argonaute protein and are 
therefore available to exonucleolytic attack (Schirle et al., 2012; Elkayam et al., 2012), 
whereas the 5' ends of miRNAs are buried within the MID domain and are protected 
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(Neilsen et al., 2012). Wu et al., (2009) showed that alternative processing of primary 
miRNA by Drosha and DGCR8 can generate precursor miRNA with or without 5' end 
variation. Eventually, these precursor miRNAs may undergo 3' end modification 
which produces mature miRNAs having 5', 3' or mix variations (Wu et al., 2009).  
 
In principle, 5' isomiRs have different seed regions to their canonical miRNA and 
therefore could have a different subset of target genes. Although miRBase (August 
2012) has included isomiRs in their database, miRNAs are still annotated as a single 
mature miRNA sequence.  
 
 
1.6 Target prediction programs 
As a result of the use of cloning and high throughput deep sequencing, thousands of 
miRNAs have been discovered. Target prediction programs have been created to 
attempt to generate predictions of miRNA targets based on genome wide 
computational search for miRNA and mRNA UTR complementary sites. The initial 
clue came from the observation that lin-4 complementarity to multiple conserved sites 
to the 3' UTR of lin-14 mRNA is required for the repression of lin-14 (Lee et al., 1993; 
Wightman et al., 1993; Bartel., 2009).  
 
The most significant contribution to target recognition was the identification of 
Watson-Crick miRNA-mRNA perfect complementarity of 6 to 8 bp at the 5' end of 
miRNA and 3' UTR of mRNA (Lewis et al., 2003; Rakewsky et al., 2004). As a result, 
the initial method of target prediction was based on complementarity of the miRNA to 
the target site and the predicted free energy of the miRNA-mRNA duplex (Rakewsky 
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et al., 2004; Rakewsky et al., 2006). Subsequently, a new generation of miRNA target 
prediction programs emerged in 2005 that are based on more extensive bioinformatics 
analysis using cross-species comparison (Lewis et al., 2005). 
 
In TargetScan (Lewis et al., 2005), miRNA targets are predicted by searching for 
Watson-Crick base pairing matches between the seed region and 3' UTRs that are 
conserved via whole genome alignment. Based on a prediction study, more than 5300 
human genes were predicted targets of miRNA, which represented 30% of the human 
gene set (Lewis et al., 2005). Figure 1.4 illustrated the conserved predicted miRNA 
target sites in the 3' UTR of NCAM2 (long red arrows). Intriguingly, there are a few 
other conserved sites (short yellow arrows) that are not predicted target sites of any 
canonical/ annotated miRNA (Figure 1.4). These sites could be undiscovered target 
sites of isomiRs or perhaps targets of RNA binding proteins. Another related example 
is the mRNA encoded by the BACE2 gene, there are 3 highly conserved sites and one 
of these is a predicted target site of let-7. Notably, one of the remaining two 
conserved sites is a target site of isomiR-9 (Figure 1.4, see Chapter 3). 
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Figure 1.4 Conserved miRNA target sites in the 3' UTR of NCAM2 and BACE2.  
Long red arrows represent known miRNA target sites. Short yellow arrows denote 
conserved sites that are not known to be a target of any canonical/ annotated miRNA. 
Reproduced and modified from USCS genome browser.  
 
 
Table 1.2 lists some of the miRNA target prediction programs that are available on 
the web. These programs differ in their selection criteria like the stringency of seed 
complementarity and measurement of base pairing stability and selection of different 
UTR sequence (Bartel, 2009; Ritchie et al., 2009). Different prediction databases 
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predict different sets of target genes, for example the predicted targets generated from 
TargetScan and MiRanda overlap by 39.5% only (Ritchie et al., 2009). The 
differences in prediction might result from the used of different 3' UTR sequence in 
the prediction programs (Bartel, 2009). So far, only a handful of these predictions 
have been experimentally validated (Rosa et al., 2009; Barroso-delJesus et al., 2011). 
 
 
 
Table 1.2 List of target prediction tools. All target prediction programs depend on 
seed target complementarity. In addition, some include conservation and/or free 
energy measurement. Adapted from Bartel, (2009). 
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A large scale approach using mass spectrometry to measure protein level reduction 
after miRNA transfection has revealed that a 7mer-A1 match, which has only 6 
complementary base pairs (Figure 1.5) was more effective than a complete 1-7mer 
Watson-Crick match (Baek et al., 2008). Therefore, an A in the UTR which aligns 
with miRNA nucleotide 1 favours miRNA-mediated protein down-regulation, even 
when the A in the UTR does not participate in a Watson-Crick interaction. This also 
explains the preferential conservation of an A at position 1 of UTR target sites (Lewis 
et al., 2005). In animals, the currently recognised canonical types of miRNA target 
sites that involve the seed region include 7mer-A1, 7mer-m8 and 8mer (Figure 1.5). 
Other atypical types include 3' supplementary and compensatory sites that have 
pairing at the seed region as well as additional pairing at the 3' end to enhance target 
recognition, usually at position 13 to 16 nucleotides from 5' end (Bartel, 2009). 
Recently, other atypical sites have also been discovered, known as central pairing that 
has 11 to 12 contiguous Watson-Crick pairing at the centre but lacks pairing at both 
the seed region and 3' end (Shin et al., 2010).  
 
 
Figure 1.5 Examples of the canonical type of miRNA – mRNA target interaction. 
Vertical line represents Watson-Crick base pairing.  
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Farh and colleagues reported that the predicted non-conserved target sites 
outnumbered the conserved ones by ten to one (Farh et al., 2005). Using reporter 
assays, the authors showed that a large proportion of the non-conserved target sites 
can function. However, analysis of mRNA and miRNA expression profile revealed 
that 3' UTR with non-conserved target sites are most often found in genes that are 
expressed in tissue where the complementary miRNA is absent (Farh et al., 2005). 
 
Grimson et al., (2007) showed there were other features in the 3' UTR that increased 
target site efficacy such as: (1) target sites that are positioned away from the centre of 
long UTRs. One possible explanation is that sites at the centre would have the 
opportunity to fold from segments at either sides but sites near the end would not 
(Bartel, 2009). (2) An AU-rich nucleotide composition near the site and (3) 
positioning within the 3' UTR at least 15 nt from the stop codon. In fact, by at large 
conserved 7-mer target sites were preferentially found in the above mentioned areas 
(Gaidatzis et al., 2007; Grimson et al., 2007; Majoros et al., 2007).  
 
UTRs may contain multiple targeting sites.  The repression response in a 3' UTR with 
multiple sites is nearly the same as that observed in the sum of each site 
independently (Grimson et al., 2007; Nielsen et al., 2007), showing that there is an 
additive effect  in these cases (Doench et al., 2003). In theory, miRNAs might also act 
synergistically. Bartel, (2009) suggested that cooperative miRNA function could 
provide a mechanism where repression can become more sensitive to small changes in 
miRNA expression levels, which greatly enhances their regulatory effect. It was also 
found that repression was enhanced when the distance between two target sites was 
between 13 and 35 nucleotides (Saetrom et al., 2007). 
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Other factors that could influence targeting include (1) the presence of naturally 
occurring decoy mRNA that might compete with 3' UTR in miRNA binding, thus 
reducing the amount of free miRNA (Franco-Zorrilla et al., 2007; Poliseno et al. 
2010). (2) Competing RNA-binding proteins like deadend 1 (DND1) that might shield 
target sites from miRNA RNA-induced silencing complex (miRISC) binding (Kedde 
et al., 2007). (3) There are factors that might associate with the RISC and influence its 
regulation either positively or negatively, for example NHL2 and meiotic P26 (Mei-
P26) (Neumüller et al., 2008; Hammell et al., 2009). 
 
In addition to 3' UTRs, experiments showed that miRNA targeting can also occur at 
the 5' UTR and open reading frame (ORF) (Kloosterman et al., 2004; Lytle et al., 
2007). Indeed, a large number of targets in the ORF were observed by computational 
genome wide analyses (Farh et al., 2005; Lewis et al., 2005; Lim et al., 2005; Easow 
et al., 2007: Grimson et al., 2007; Baek et al., 2008). However, ORF targeting is 
probably less frequent and less effective than 5' UTR and 3' UTR targeting, probably 
due to displacement of the silencing complex at this position by the translation 
machinery (Bartel, 2004; Bartel, 2009). 
 
In addition, Argonaute protein could also influence the processing and loading of 
miRNAs.  For example Ago2 favours the binding of small RNAs that begin with an 
adenosine (A) or uridine (U) at the 5' end (Frank et al., 2010; Cenik et al., 2011).  
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1.7 MicroRNA sponges 
MicroRNA sponges were first described by Ebert et al., (2007) and Franco-Zorrilla et 
al., (2007). These sponges are decoy mRNAs that compete with endogenous mRNA 
for base pairing with miRNAs (Figure 1.6). The first naturally occurring RNA sponge 
was discovered in a plant (Franco-Zorrilla et al., 2007). The authors reported that a 
non–protein coding gene called induced by phosphate starvation (IPS1) from 
Arabidopsis thaliana contained a motif with sequence complementarity to miR-399. 
Interestingly, the pairing is interrupted by a mismatched loop at the expected miRNA 
cleavage site (nucleotides 10-11), which protected it from cleavage by Argonaute. 
Hence, IPS1 RNA is not cleaved but instead sequesters miR-399. In addition, IPS1 
overexpression resulted in increased accumulation of the miR-399 target PHO2 
mRNA which encodes an E2 ubiquitin conjugase–related protein. 
 
 
Figure 1.6 RNA sponge competes with target mRNA for binding with miRNA. 
Sponge RNAs (in red) contain binding sites (small grey rectangle) for miRNA of 
interest (grey hexagons). Target mRNAs are in blue. Blue oval represents protein 
output. Taken from Ebert et al., (2010a). Copyright permission obtained from author 
and Elsevier. 
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Naturally occurring miRNA sponges have also been reported in mammalian cells. 
These sponges are transcribed from pseudogenes (Poliseno et al., 2010). PTENP1 is 
an example of a naturally occurring RNA sponge. Its 3' UTR has similar conserved 
binding sites with that of the 3' UTR of PTEN. PTENP1 was found to be selectively 
lost in human cancer and appears to act as a decoy for miRNAs that target PTEN. It 
was found that knockdown of PTENP1, increased the abundance of PTEN targeting 
miRNAs, which led to a reduction of PTEN mRNA and protein levels (Poliseno et al., 
2010). Based on alignment studies, other possible pseudogenes have been identified 
that could act as decoys for  miR-145, the miR-1 family, miR-182, miR-143 and let-7 
which are thought to regulate OCT4, CX43, FOXO3B and KRAS1P respectively 
(Poliseno et al., 2010). These natural miRNA decoys have been termed as 
“competitive endogenous RNAs” (ceRNAs) (Poliseno et al., 2010; Cesana et al., 2011; 
Karreth et al., 2011; Sumazin et al., 2011). 
 
For cells that are difficult to transfect, viral vectors can be used to stably express RNA 
sponges (Ebert et al., 2010a, b). Haraguchi et al., (2009) described another type of 
transgenic expression RNA sponge termed TuD RNAs or ‘‘tough decoy’’. Their 
prototype decoy consisted of a stem loop hairpin with the miRNA binding site located 
at the single stranded loop region. After comparing various models of their tough 
decoys, the most effective one has two multiple binding sites which are flanked by 
two stem structures (Figure 1.7). It was also found that these RNA decoys were stable 
and could achieve long term suppression of miRNA (Haraguchi et al., 2009). As some 
miRNAs have been found to be very stable and to have in-vivo half lifes of more than 
a week (van Rooij et al., 2007; Bail et al., 2010), RNA sponges might be an effective 
way to sequester and thereby inhibit miRNA activity.   
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Figure 1.7 TuD RNA or tough decoy.This decoy RNA contains two multiple binding 
site (MBS) regions, which are flanked by two stem structures through 3-nt linker. 
Taken from Haraguchi et al., (2009). 
 
 
1.8 MicroRNA and Stem Cells 
1.8.1 MicroRNA and human embryonic stem cells  
Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst 
stage of an embryo (Martin, 1981; Thomson et al., 1998). They are pluripotent and 
therefore have the ability to differentiate into any type of specialised cells in the three 
embryonic germ layers (endoderm, ectoderm and mesoderm) and can also replicate 
indefinitely in the undifferentiated state (Martinez et al., 2010). More importantly, 
hESCs have a normal karyotype, maintain high telomerase activity, and exhibit 
remarkable unlimited expansion in culture. Hence, hECSs are a useful in-vitro system 
to study the mechanisms underlying human development (Odorico et al., 2001). 
 
A network of transcriptional factors and RNA binding proteins have been identified, 
known as “stemness factors” that are involved in the maintenance of stem cell identity. 
These factors include Oct4, Sox2, Nanog, Lin28 and Klf4 (Marson et al., 2008). Card 
et al., (2008) showed that Oct4 and Sox2 bind to the conserved promoter region of the 
miR-302 cluster and regulate its expression. In addition, the miR-302 cluster might 
also be involved in cell cycle regulation by its repression of cyclin D1 (Card et al., 
2008). Similarly to Oct4, the miR-302 cluster was found to be down-regulated upon 
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differentiation (Card et al., 2008). Inhibition of miR-302 resulted in downregulation 
of pluripotency markers, whereas overexpression of miR-302 lead to upregulation of 
these genes (Rosa et al., 2009). Similarly, Barroso-delJeus et al., (2008) also found 
that there were conserved binding sites for Oct4, Sox2 and Rex1 upstream to the miR-
302 cluster indicating that they might be regulators of the cluster. 
 
It was also found that let-7 induced stem cell differentiation through the repression of 
multiple stemness factors include Lin28, Sall4 and c-Myc, where let-7 binding sites 
were found in their 3' UTRs (Melton et al., 2010). The global loss of miRNAs in 
DGCR8 deficient ESCs resulted in defects in proliferation and differentiation 
(Gangaraju et al., 2009). In addition, Dicer-deficient mice die at early stages of 
development (Martinez et al., 2010). Therefore, maintenance of self-renewal and 
induction of differentiation of ESCs is tightly regulated by miRNAs (Figure 1.8). 
 
 
 
Figure 1.8 Regulation of self-renewal and differentiation by miRNAs. The left part of 
the figure shows miRs that facilitate, directly induce, or inhibit reprogramming of iPS 
cells. The right part summarizes miRs that were shown to control ESC maintenance 
and differentiation. Taken from Heinrich et al., (2012). Copyright permission obtained 
from author and Wolters Kluwer Health. 
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1.8.2 Reprogramming using the miR-302 cluster 
Cloning and deep sequencing of hESCs consistently identified the miR-302 cluster as 
the most abundant and specific miRNA in stem cells (Suh et al., 2004, Bar et al., 2008, 
Morin et al., 2008; Lipchina et al., 2011; Chan, unpublished). MiR-302 is a 
polycistronic cluster that houses 5 precursor miRNAs, i.e. miR-302b, miR-302c, miR-
302a, miR-302d and miR-367. In the human genome, it is 688 nt in length and located 
in intron 8 of the Larp7 gene in chromosome 4 (see Chapter 5).  Interestingly, it is 
possible to reprogram a differentiated cell back to its unspecialised state, also known 
as an induced pluripotent stem cell (iPSC). This can be achieved by introducing 
stemness genes, namely oct4, sox2, klf4 and c-myc (OSKM) transcription factors 
(Takahashi et al., 2006). Recently, it was found that the miR-302 cluster alone can 
reprograme both mouse and human fibroblasts to iPSCs with high efficiency (1-10%) 
(Anokye-Danso et al., 2011; see Chapter 5). 
 
Several groups have addressed the mechanism of somatic cell reprogramming by 
miRNAs (Rosa et al., 2011; Lin et al., 2011; Hu et al., 2013). Lin et al., (2011) 
suggested that the mechanism of reprogramming by the miR-302 cluster involves 
targeted suppression of four epigenetic regulators including Lysine-specific 
demethylase 1 (LSD1 also known as KDM1 or AOF2), Lysine-specific histone 
demethylase 2 (AOF1), MECP1-p66 and methyl CpG binding protein 2 (MECP2), 
leading to global demethylation. As global demethylation naturally occurs in 2 stages 
of development, i.e., (1) during early embryogenesis and (2) at the initial stage of 
gametogenesis, the authors suggested that global demethylation can reset the cell back 
to its pluripotent state (Lin et al., 2011).  
 
41 
 
Studies have also shown that the miR-302 cluster is involved in the maintenance of 
pluripotency and is involved in the regulation of a number of cell signalling pathways 
including TGFb/nodal signalling and cyclin D1 regulation (Rosa et al., 2009; 
Lipchina et al., 2011; Wang et al., 2008; Card et al., 2008; Subramanyam et al., 2011; 
Sun et al., 1999).  
 
The combination of target prediction, miRNA perturbation and PAR-CLIP 
experiments has given great insight into the targets of the mir-302 cluster. Using these 
assays, Lipchina and colleagues (2011) identified 146 high confidence targets of miR-
302 cluster. Furthermore, inhibition of the miR-302 cluster reduced proliferation 
whereas overexpression increased proliferation of stem cells (Lipchina et al., 2011). 
 
Generating disease-specific or patient-specific iPSCs provides the opportunity to 
study the diseases in an in vitro situation with greater flexibility and to gain 
mechanistic insight into the disease (Bellin et al., 2012). iPSCs can also be used for 
drug screening and development of patient-specific therapy and for the study of rare 
genetic disorders. In addition, it might be useful for the exploration of cell-based and 
gene repair therapies (Figure 1.9; Robinton et al., 2012). For example, iPSC models 
have been used to study cardiomyocytes with Type 1 long QT syndrome and using 
this model it was found that treatment with propanolol, a β-adrenergic receptor 
blocker, attenuated the QT phenotype. Meanwhile, Itzhaki et al., (2011) found that 
nifedipine, a calcium channel blocker improved Type 2 long QT syndrome phenotype. 
Agarwal et al., (2010) studied the biology of telomerase using an iPSC model of 
dyskeratosis congenital, a disorder of telomere maintenance. In addition, other iPSC 
disease models that have been reported include Alzheimer’s disease (Israel et al., 
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2012), Huntington’s disease (Camnasio et al., 2012), Parkinson’s disease (Soldner et 
al., 2009), Timothy syndrome (Yazawa et al., 2011), Pompe’s disease (Huang et al., 
2011), spinal muscular atrophy (Ebert et al., 2009) and familial dysautonomia (Lee et 
al., 2009). 
 
 
Figure 1.9 Application of iPSCs in a patient specific model. Patient-specific iPS cells 
- in this case derived by ectopic co-expression of transcription factors in cells isolated 
from a skin biopsy and used in one of the two pathways. Taken from Robinton et al., 
(2012). Copyright permission obtained from author and Nature Publishing Group. 
 
All of the above studies would be helped by improvements in iPSC reprogramming 
efficiency. Therefore, studies are necessary to find better techniques to improve 
reprogramming efficiency. My aim was to determine if miR-302 cluster can 
reprogram human fibroblast back to its pluripotent state and to identify targets of 
miR-302a*.   
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1.8.3 MicroRNAs and neural progenitor/ stem cells 
Neural stem cells (NSC) are multipotent cells that can differentiate into cells of the 
central nervous system (CNS) such as neurons, astrocytes, and oligodendrocytes 
(Alvarez-Buylla et al., 2002). NSCs can be derived from embryonic stem cells 
(Gerrard et al., 2005) or adult nervous system and can be cultivated in-vitro 
(Bonnamain et al., 2012), in the presence of growth factors like bFGF (Vescovi et al., 
1993) and EGF (Reynolds et al., 1992). Transplantation of NSCs or recruitment of 
endogenous adult NSCs might be a potential strategy for the treatment of spinal cord 
injury (Ronaghi et al., 2010). Moreno-Manzano et al., (2009) reported that 
transplantation of ependymal stem progenitor cells that were derived from adult rat 
spinal cord that suffered a traumatic lesion lead to a functional motor recovery.  
 
In cloning and deep sequencing of NSC, a subset of miRNAs was noted to be highly 
expressed and some were highly specific to NSC (Lipchina et al., 2011; Chan, 
unpublished). In both Lipchina et al., (2011) and Chan sequencing results, miR-9 was 
one of the top 3 most abundant and specific miRNAs in NSC. MiR-9 is a highly 
conserved miRNA and expressed primarily in the CNS (Kapsimali et al., 2007). The 
human genome has three miR-9 genes termed hsa-miR-9-1, hsa-miR-9-2 and hsa-
miR-9-3, which encode an identical mature miR-9 (5p) and miR-9* (3p). The hsa-
miR-9-1 gene is located in the intron 2 of C1orf61 gene in chromosome 1. The hsa-
miR-9-2 is located in the exon of the LINC00461 gene in chromosome 5. The hsa-
miR-9-3 gene is located in an intergenic region, although it partially overlaps with a 
non-coding RNA (LOC254559) on chromosome 15. 
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Remarkably, expression of miR-9/9*, miR-124 and neuroD2 converted human 
fibroblasts to neurons (Yoo et al., 2011). Expressing neuroD2 alone did not produce 
neurons but its inclusion enhanced this process. Expression of miR-9 and miR-124 
was enough to cause a reduction in proliferation and to induce neuron-like 
morphology, but the efficiency was low (Yoo et al., 2011). Bonev et al., (2011) 
reported that depletion of miR-9 reduced neuronal differentiation, both at the 
forebrain and hindbrain in Xenopus Tropicalis. 
 
Le and colleagues (2009) used retinoid acids to induce the differentiation of 
neuroblastoma cells into neuron-like cells. In the process, they measured miRNA 
levels by microarray and northern blotting, and identified 6 miRNAs that were 
consistently upregulated during the process of differentiation, namely miR-7, miR-
124a, miR-125b, miR-199a, miR-199a* and miR-214. Subsequently, the authors 
showed that ectopic expression of miR-124a and miR-125b significantly increased the 
percentage of differentiated cells with neurite outgrowth. Using a microarray, they 
found 388 genes that were repressed by ectopic expression of miR-125b. Out of these 
388 genes, 164 were targets of prediction programs. Ten target genes of miR-125b 
were validated by reporter assays. These genes are involved in metabolism, 
proliferation and apoptosis (Le et al., 2009).  
 
MiR-9 was reported to have an association with neurological disorders (Yuva-
Aydemir et al., 2011). It has been reported that alcohol increased miR-9 expression in 
supraoptic nucleus neurons and striatal neurons in an adult rat brain (Pietrzykowski et 
al., 2008). Increased levels of miR-9 were also found post-mortem, in the brains of 
patients with Alzheimer disease (Lukiw et al., 2007). In contrast, miR-9 was 
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downregulated in cerebral ischemia due to middle cerebral artery occlusion in rats 
(Jeyaseelan et al., 2008).  
 
It is certain that miRNAs play an essential role in the maintenance of pluripotency and 
differentiation of human embryonic stem cells. Identifying the specific targets of 
miRNAs during hESC differentiation will help to elucidate the regulation of this 
complex mechanism.  
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1.9 Project Aims 
 
1. To determine if isomiRs are functional and whether 5’ isomiRs can inhibit the 
expression of different mRNAs compared to the canonical/ annotated miRNA.  
 
2. To test if it is possible to inhibit specific isomiRs by using sponge vectors.  
 
3. To identify targets of miR-302a* and to determine if miR-302a* is important for 
the induction of pluripotent stem cells from somatic cells.  
 
 
 
Hypothesis 
 
As 5' isomiRs have different seed region to their canonical or annotated counterparts, 
my hypothesis is that 5' isomiRs could have different sets of target genes.  
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Chapter 2 Materials and Methods 
 
2.1 Cell culture 
2.1.1 General cell culture 
All culture dishes (Corning, Costar), flasks (Corning), and serological plugged 
pipettes (Corning, Costar) used were suitable for sterile tissue culture. Unless 
otherwise stated, all cell lines used in the experiment were cultured in D10 media 
(Dulbeco’s Modified Medium (DMEM) (Invitrogen, Gibco) supplemented with 10% 
(v/v) heat inactivated Foetal Bovine Serum (FBS) (PAA Laboratories), 50 U/ml 
penicillin/streptomycin (Invitrogen, Gibco) and 200 μM glutamine (Invitrogen, 
Gibco). Experiments were carried out in sterile condition, in a Class II flow cabinet 
and all cells were maintained at 37°C in 5% CO2.  
 
Generally, cells were passaged twice weekly or once they reached approximately 80% 
confluency. Prior to incubating with 0.25% trypsin (Invitrogen, Gibco) for 5 minutes 
at 37oC in 5% CO2, cells were washed in PBS. Subsequently, the cells were re-
suspended in D10 media and centrifuged at 1000 rpm for 5 minutes. Then, the cell 
pellet was resuspended in D10 and plated to the required density. 
 
2.1.2 Freezing cell lines 
After washing with PBS, adherent cells were incubated with 1 ml of 0.25% trypsin in 
a 6-well plate. Then, 9 mls of D10 media was added to inactivate the trypsin. The 
cells were centrifuged at 1000 rpm for 5 minutes and re-suspended in D10 media with 
10% dimethyl sulfoxide and promptly aliquoted into 1 ml cryotubes. The cells were 
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frozen slowly in a cryo freezing container containing isopropyl alcohol at -80°C for at 
least 48 hrs. Subsequently, they were stored either in -80oC or in liquid nitrogen. 
 
2.1.3 Production of mouse embryonic fibroblast-conditioned medium (MEF-CM) 
for hESCs culture 
Mouse embryonic fibroblasts (MEF) were grown and expanded in D10 media to 
passages 3 or 4 depending on the speed of cell growth. Cells were then trypsinised 
and collected into 50ml Falcon tubes and counted. Followed by irradiation at 40 
Grays (4000 rads), centrifuged at 800rpm for 4 minutes and plated at 18.8 x 106 cells 
into gelatin-coated T225 flasks with D10 media. Subsequently, 150 ml KSR media 
(KO DMEM and KO serum replacement, supplemented with 4ng/ml Fibroblast 
Growth Factor basic (FGF2) (Peprotech))(Knockout™ DMEM is a basal medium 
from Invitrogen, optimized for growth of undifferentiated embryonic and induced 
pluripotent stem cells and Knockout™ Serum Replacement from Invitrogen, is a 
defined, serum-free formulation optimized to grow and maintain undifferentiated ES 
cells in culture) was added to replace D10 media the next day. Collection was carried 
out continuously for 7 days. The collected media, called mouse embryonic fibroblast-
conditioned media (MEF-CM) was stored at -80○C. Upon use, MEF-CM was thawed 
in water-bath at 37oC and L-glutamine and P/S before added being filtered and kept at 
4○C. 
 
2.1.4 Preparation of matrigel coated plates  
5 mls of stock matrigel (Invitrogen, Gibco) was slowly thawed at 4○C overnight and 
diluted with 5 mls of cold KO-DMEM. This solution was aliquoted, 1 ml working 
volume into 15-ml tube on ice and stored at -20○C. Upon use, matrigel was slowly 
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defrosted at 4○C and finally diluted with 14 mls of cold KO-DMEM. 1 ml per well of 
the diluted matrigel was plated onto a 6-well plate, and incubated overnight at 4○C. In 
case of urgency, the incubation time could be shortened to an hour at room 
temperature before use. 
 
2.1.5 Human embryonic stem cells culture 
H1, H7 and T5 (transgenic H1 with Oct4-EGFP) hESCs were cultured in MEF-CM 
supplemented with 4-8 ng/ml FGF2 in matrigel coated plates and media changed daily. 
Cells were routinely passaged at a 1:3 dilution after treatment with 200U/ml 
collagenase IV (Invitrogen) and mechanic dissection. 
 
2.1.6 Freezing and resuscitating hESCs  
hESCs were harvested similar as routine propagation except during mechanical 
dissection step 1x freezing mix (KO serum replacement and 10% DMSO) was added 
instead of MEF-CM. 1 ml aliquots were frozen overnight at -80○C in cryo freezing 
container before being transferred to liquid nitrogen for long-term storage. Frozen 
cells were revived by thawing rapidly at 37○C and resuspended in 10 mls of MEF-CM. 
Cells were centrifuged at 800rpm for 5 minutes to removed the DMSO, and then 
plated on a matrigel coated 6-well plate containing MEF-CM with FGF2. 
 
2.1.7 Neural progenitor/stem cell differentiation from hESCs  
hESCs was differentiated to neural lineage following the published protocol (Gerrard 
et al., 2005). Briefly, confluent hESCs were split with EDTA/ PBS in 1:5 ratios into 
culture dishes coated with poly-L-lysine/laminin and cultured in N2B27 media 
(DMEM/F12 / neurobasal media (1:1) (Invitrogen), 100x N-2 supplement (Invitrogen), 
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50x B-27 supplement (Invitrogen), L-glutamine and P/S) supplemented with 
100ng/ml mouse recombinant noggin (R&D systems). At this stage, cells were 
defined as passage 1 (P1). Medium was changed every other day. Cells of P1 and P2 
were split by collagenase IV into small clumps and continuously cultured in N2B27 
medium plus noggin until formation of neural progenitor/ stem cells at P3. 
 
2.1.8 Culture of neural progenitor/stem cells (NSCs)  
Preparation of poly-L-lysine/laminin  
Poly-L-Lysine (PLL) was diluted 1 in 6 with phosphate buffer solution (PBS) and 
then 1ml was added per well of a 6-well plate. Subsequently, it was incubated in hood 
at room temperature for 1 hour. Mouse laminin (Sigma) was diluted with 6mls of PBS 
to a final concentration of 20 μg/ml, plated 1ml per well of a 6-well plate and 
incubated overnight at 4○C.  
 
Culture of neural progenitor/stem cells  
NSCs were disassociated into single cell by TrypLE express (Invitrogen) and cultured 
in N2B27 media supplemented with 20ng/ml FGF2 and/or 20ng/ml Epidermal 
Growth Factor (EGF) (Peprotech).  
 
2.2 Luciferase assay 
All the constructs that were used for luciferase assays were listed in supplementary 
figure 2.3, and a full list of the primers used for cloning are given in table 2.6. 
Reporter vectors were constructed by the insertion of predicted 3’UTR containing 
miRNA target sites downstream of the gene encoding for firefly luciferase in the 
pGL3-Control vector (Promega). Assays were performed in 24-well plates using 
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HEK293 cells seeded at 50,000 cells per well a day prior to the time of transfection in 
D10 media without phenol red, and incubated for 48 hrs. Renilla luciferase was used 
as the internal control. A green fluorescent protein (GFP) expressing vector driven by 
the EF-1 alpha promoter was used to enable visualization of transfection efficiency. 
All experiments were performed in triplicates, as follows: 
 
For each well of a 24-well plate, the following 5 components were added to give a 
final transfection volume of 50 μl: 200-400 ng of the reporter firefly luciferase 
construct; 25 ng of the renilla luciferase vector; 1-2 μl of HiPerfect transfection 
reagent (Qiagen) and synthetic miRNAs (known as miRNA miScript mimics, Qiagen) 
diluted to a range of 1 – 40 nmol, all diluted in Opti-MEM (Invitrogen). The mixture 
was then incubated at room temperature for 20 minutes before being added to the 
wells dropwise gently. The cells were incubated at 37oC with 5% CO2 for 48 hours. 
 
After incubation, the cells were lysed by adding 100 μl of Glo lysis buffer (Promega) 
and incubated for 5 minutes. Two equal amounts of lysates (50 μl) were transferred to 
a white wall 96-well plate and added an equal volume of Bright Glo reagent 
(Promega) to one of the well and Renilla Glo reagent (Promega) to the other well. 
Next the firefly and renilla luciferase reading were taken using the Partha 
Luminescence program on a plate reader (Wallac 1420 Victor2, PerkinElmer). The 
two datasets were combined to allow the standardization of the firefly luciferase 
reading against the renilla luciferase reading for the final result. 
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2.3 Plasmid preparation 
2.3.1 Recovery of plasmid from bacterial stab culture 
Plasmid construct with full length DNMT3B gene was obtained from Addgene 
(Plasmid 35522: pcDNA3/Myc-DNMT3B1) (Chen et al., 2005), and received as 
bacterial stab culture. LB agar plate with 100 μg/ml ampicillin was used to grow the 
bacteria. The bacteria growing within the punctured area of the stab culture was 
obtained by a sterile pipette tip and run lightly over the agar plate, and then spread 
evenly over the entire surface of the plate using a sterile spreader. The plate was 
incubated overnight in a 37oC incubator.  
 
A sterile pipette was used to pick up a single colony from the plate the next morning, 
and inoculated to 5 mls of 2x YT media containing 100 μg/ml ampicillin. 2xYT 
(Yeast Extract Tryptone) medium is nutritionally rich and developed for growth of 
recombinant strains of Escherichia coli. YT medium was prepared using 16 gms 
tryptone, 10 gms bacto-yeast extract, 5 gms NaCl and added water up to 1 litre. This 
was incubated at 37oC with constant shaking. In the evening, it was entire transferred 
to a 500ml flask contain 150-200 mls 2x YT media and returned to the incubator with 
constant shaking. The bacteria were harvested the next day by spinning at 3,000 g at 
4oC for 10 minutes. Plasmid was extracted using Mini, Midi or Maxi Prep (Qiagen).  
 
2.3.2 Plasmid isolation  
Plasmid DNA was purified by HiSpeed plasmid kit (Qiagen) following the 
manufacturer’s protocol. Briefly, the bacteria pellet was resuspended in buffer P1 
(Mini - 250μl, Midi – 4 mls and Maxi – 10 mls) and mixed well by vortexing. The 
cell mixture was added buffer P2, mixed vigorously by inverting (until the mixture 
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appear uniformly blue due to Lyseblue reagent) and incubated at room temperature 
for 5 minutes prior to the addition 4 mls of pre-chilled buffer P3 which was mixed 
vigorously until it was completely colourless. Lysate was then poured into the 
QIAfilter cartridge and incubated at room temperature for 10 minutes. Meanwhile, the 
QIAGEN-tip was equilibrated by applying 4 mls (Midi) or 10 mls (Maxi) with QBT 
Buffer. The lysate was then filtered into the equilibrated QIAGEN-tip and allowed to 
flow through by gravity flow. The column was washed by 20 mls (Midi) or 60 mls 
(Maxi) QC washing buffer. Subsequently, the plasmid DNA was eluted from the filter 
by 5 mls (Midi) or 15 mls (Maxi) QF buffer. To precipitate the plasmid DNA, 3.5 mls 
(Midi) or 10.5 mls (Maxi) of isopropanol was added and incubated for 5 minutes. The 
mixture was then transferred to a syringe fitted with QIAprecipitator. Using constant 
pressure the mixture was filtered through the QIAprecipitator. The DNA was then 
washed with 2 mls of 70% ethanol. Finally, 1 ml of TE buffer (TE buffer, pH 8.0 or 
10 mM Tris-HCl, pH 8.5) was used to elute the DNA.  
 
2.3.3 Ligation  
The ligation reaction was prepared as followed; 2 μl 5X ligation buffer, 3:1 inserts: 
vector ratio, 1 unit of T4 DNA ligase and toped up with dH2O to 10μl. The reaction 
mix was incubated at room temperature for 2 hours, and was ready for transformation.  
 
2.3.4 Plasmid transformation  
Plasmid (1-5 μl) and 25 μl competent cells (DH5α) (New England Biolabs) were 
mixed and incubated on ice for 20 minutes prior to heat shock at 42○C for 45 seconds. 
The mix was put back on ice for 2 minutes before adding 200 μl 2x YT media and 
plated on LB-agar plate with appropriate selection antibiotics.  
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2.4 Total RNA extraction 
Total RNA was extracted from cells using Trizol (Invitrogen) as per manufacturer’s 
instructions. A sub-confluent to confluent cells in a 6-well plate generated 
approximately 20-90 μg of total RNA. 1 ml of trizol reagent was used per well in a 6-
well plate. Total RNA was precipitated by isopropanol and washed with 75% ethanol. 
Finally, the RNA pellet was resuspended in 20 - 30 μl of water treated with 0.1% 
diethylpyrocarbonate (DEPC). The samples were quantified by measuring 1 μl on a 
nanodrop. All RNA samples were promptly stored at -80oC. 0.5 μl of the sample was 
removed for quality check on a 1.5% TBE agarose gel containing 0.1 μg/ml of 
Ethidium Bromide (Sigma). The samples were run at 100 V for 1 hr and the quality of 
the 28S and 18S rRNA bands were checked under UV light. 
 
2.5 First strand cDNA synthesis  
100 ng of sample RNA and 0.1-0.5 μg of random hexamers were made up to 4.5 μl 
with dH2O and denatured at 65
oC for 10 mins. The mixture was then added 1 μl of 
100 mM DTT, 2 μl of 5 x first strand buffer, 0.5 μl of RNase out (40 U/μL) 
(Invitrogen), 1 μl of 10 mM dNTPs, and lastly 1 μl of SuperScript™ III reverse 
transcriptase enzyme (200U/μL) (Invitrogen). The sample was incubated at 42oC for 
30 minutes and then 50oC for 30 minutes. The sample was stored at -20oC. 
 
2.6 Primer design and alignment  
A Primer-BLAST was conducted using the NCBI search engine, with the sequence of 
designed primers as a query sequence. Database of human genome and reference 
sequence for RNA were compared to identify the specificity and size of PCR products. 
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2.7 PCR reaction 
The PCR reaction was set up using the gene specific primers (refer to table 2.3 for the 
list of primers). Briefly, 1.25 μl of the RT sample was added to 1.25 μl of mix forward 
and reverse primers (10 uM), 1 μl of 10 mM dNTPs, 2 μl of 10 x buffer and 1 μl of 
Taq polymerase (Promega) and made up to 25 μl with water. The PCR reaction was 
set at 94oC for 2 minutes, followed by 30 cycles of 94oC for 30 sec, 55oC for 30 sec, 
72oC for 30 sec, and terminated at 72oC for 5 mins (Note – extension time was 
determined based on a rate of extension of 1 kb/min). 
 
All PCR products were run on TAE agarose gels to check the product sizes. Briefly, 1 
- 2% (w/v) agarose, depending on fragment sizes, was dissolved in 1x TAE and left to 
cool before adding 0.1 μg/ml ethidium bromide (Sigma-Aldritch). Samples were 
mixed with 1/6 volume of 6 x loading dye containing bromophenol blue and then 
loaded into the wells of the gel along with a 1 Kb ladder (New England Biolabs) or a 
100 bp ladder (New England Biolabs). Gels were run at 120 V for ½ to 1 hour and 
then visualised for bands on a UV light box. 
 
2.8 Mutagenesis using PCR to generate mutant UTR 
Mutant UTR was synthesized by 3 steps PCR. This was performed using 4 primers, 
i.e. 2 mutagenic primers and 2 non-mutagenic primers (see below, * represents mutant 
site). Initially, 2 mutagenic primers (b + c) were designed with multiple point 
mutations in the seed target site. First PCR was performed using primer “a” and 
mutagenic primer “b”, which will synthesis the first front half of the DNA with 
mutation at the seed target site. Then primer “d” and mutagenic primer “c” were used 
in the second PCR and generated the second half of the DNA. The first and second 
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PCR products generated the first and second halves of the UTR that have mutant seed 
target site but it was not a complete sequence. Finally, a third PCR was performed 
using primers “a” and “d” on the mixture of two PCR products to generate the 
complete UTR with mutant seed target site (Figure 2.1).  
 
  
Figure 2.1 Mutagenesis by PCR 
 
2.9 Lentivirus preparation 
2.9.1 Production of lentivirus 
One day prior to transfection, 1.5x106 HEK293 cells were seeded in a 10 cm tissue 
culture plate containing 15mls of D10 (DMEM with glutamax and hepes (Invitrogen), 
P/S and 10% heat inactivated FBS). The next morning, replaced medium with 12 mls 
of fresh D10 and performed transfection in the afternoon. Performed a plasmid DNAs 
mix of 15 μg lentivector, 10μg pCMV∆8.91 packaging construct and 5 μg VSV-g 
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envelope construct, in a ratio of 3:2:1 (Lentivector: Packaging: Envelope). Calcium 
phosphate transfection kit (Invitrogen) was used in the transfection. 
 
Then, sterile water and calcium phosphate were added to a total volume of 500 μl. 
Followed by, 500 μl of 2x HBS added drop-wise into the plasmid/ calcium phosphate 
mix, while mixing them rigorously and incubated at room temperature for 30 minutes. 
25µM chloroquine (Sigma) was added to the media just before the addition of 
plasmid/ calcium phosphate mix, gently drop-wise. The cells were incubated 
overnight at 37oC with 5% CO2. After 18 hours post-transfection, the cells were 
washed twice with D10 and replaced with 8 mls fresh media. The media containing 
lentivirus was harvested continuously for 2 days, concentrated and stored at -80oC. 
 
2.9.2 Preparation for lentiviral infection 
The cells were split a day prior to infection and seeded at 50,000 cells in a 24-well 
plate. The next day, 4 μg/ml polybrene (Sigma) was added, just before the addition 
10-20 μl of viral particle to the media. The cells were incubated overnight and 
replaced with fresh media the following day. Total RNA extraction using Trizol or 
protein extraction using RIPA buffer was performed after 48 or 72 hours. 
 
2.10 Flow cytometry analysis  
Cells were detached by trypsinised and washed with PBS. Cells were analyzed in 
FACScan (BD Biosciences) using CELLQUEST software (BD Biosciences). Ten 
thousand cells were acquired for each sample. WinMDI software was used to plot the 
results. 
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2.11 Ligation of PCR product into pGEM-T easy vector  
The PCR products were cloned into pGEM-T easy vector (Promega) following 
manufacturer protocol. In brief, 2-3 μl of the PCR sample was added to 1 μl of 
pGEM-T easy vector, 5 μl of 2 x rapid ligation buffer, 1 μl of T4 DNA ligase, and 
made up to 10 μl with water. The ligation reaction was incubated at room temperature 
for 2 hrs. It was then added to 50 μl of DH5α competent cells and incubated on ice for 
20 minutes. The cells were subjected to heat shock for 30 sec at 42oC, and then placed 
on ice for 2 minutes. LB plate supplemented with 100 μg/ml ampicillin was pre-
warmed at 37oC. 200 μl of 2x YT media was added to the cells and spread evenly 
onto the pre-warm LB plate and incubated at 37oC overnight. Colonies were picked 
the next day. Plasmids were purified, digested and sequenced to validate cloning 
products (Figure S2.1). 
 
2.12 Construction of pGL3 and pMIR reporter vectors 
pGEM-T easy vector (Promega, A1360) was used to clone all PCR products (Table 
2.1 listed all the primers used in the cloning of reporter vectors), prior to insert into a 
reporter vector. pGL3-control (Promega, E1741) and pMIR-REPORT™ miRNA 
expression reporter (Invitrogen, AM5795) vectors were used to generate the reporter 
constructs below. All 3’ UTRs were cloned into XbaI and FseI sites at positions 1934 
and 1953 respectively in pGL3-control vector (Figure S2.2). In pMIR-REPORT 
vector, UTRs were inserted into SpeI and SacI sites at positions 525 and 519 (Figure 
S2.3). 
1) pGL3 – BTG1 UTR (520bp) 
2) pGL3 – BTG2 UTR (698bp) 
3) pGL3 – CDH1 UTR (680bp) 
4) pGL3 – DNMT3B UTR (470bp) 
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5) pGL3 – Lefty1 UTR (401bp) 
6) pGL3 – PTEN UTR (417bp) 
7) pGL3 – Rock1 UTR (305bp) 
8) pGL3 – SP3 UTR (795bp) 
9) pMIR – NCAM2 UTR (307bp) 
10) pMIR – HMGA2 UTR (433bp) 
11) pMIR – ZNF148 UTR (429bp) 
12) pGL3 – Mutant BTG1 UTR 
13) pGL3 – Mutant CDH1 UTR 
14) pGL3 – Mutant DNMT3B UTR 
15) pGL3 – Mutant PTEN UTR 
16) pMIR – Mutant NCAM2 UTR 
17) pMIR – Mutant HMGA2 UTR 
 
 
Primers 
 
Sequences 
    1 BTG1 UTR  Fwd atgctagctgccatagtttggacagtac 
 
(miR-302a) Rev atggccggccaatgtacagagagctggctg 
 Size 520bp 
    2 BTG1  Normal gacttttacctagcacttaaatatgtat 
 
Mutant UTR Fwd gacttttacctcgtatctgaatatgtat 
  
Rev atacatattcagatacgaggtaaaagtc 
Size 329bp an 207bp 
    3 BTG2 UTR  Fwd atgctagcttggaaccacatgaaagtct 
 
(isomiR-367) Rev atggccggccggtggccatcctggccaaat 
 Size 698bp 
    4 CDH1 UTR  Fwd  ATGCTAGCCTCACTCCTGAATTCAGTTG 
 
(miR-9) Rev  ATGGCCGGCCGATCCAAATCAAGATCCTCA 
 Size 680bp 
    5 CDH1  Normal TGCTGCAGCCAAAGACAGAG 
 
Mutant UTR Fwd  TGCTGCAGACGTATGCAGAG 
 
 
Rev CTCTGCATACGTCTGCAGCA 
 Size 400bp and 300bp 
    6 DNMT3B UTR  Fwd  ATGCTAGCGCAGAGCCACCTGACTCTTG 
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(isomiR-9) Rev  ATGGCCGGCCTAATAGGTCCCGTGCAGACT 
 Size 470bp 
    7 DNMT3B  Normal TGGCTAAGATACCAAAACCACAGT 
 
Mutant UTR Fwd TGGCCAAGATGCAACCACCACAGT 
 
 
Rev ACTGTGGTGGTTGCATCTTGGC 
 Size 300bp and 200bp 
    8 LEFTY1 UTR  Fwd  ATGCTAGCGTAGCCATCGAGGGACTTGA 
 
(miR-302a) Rev  ATGGCCGGCCTGGATTGGGGATGCACAA 
 Size 401bp 
    9 PTEN UTR  Fwd  ATGCTAGCGTAGGGTACAAGTTTAATGT 
 
(miR-367) Rev  ATGGCCGGCCTAACAAATGGACATCTGATT 
 Size 417bp 
    10 PTEN  Normal  AATTTTGTGCAATATGTTCATAACGAT 
 
Mutant UTR Fwd  AATTTTACGCGTAATGTTCATAACGAT 
  
Rev  CACAGCCATCGTTATGAACATTACGCGTAAAAT 
Size 375bp and 65bp 
    11 Rock1 UTR  Fwd  atgctagcGTAGAAGGTTGCACCAACAT 
 
(isomiR-302a) Rev  atggccggccACATATCCATCAGTGCGGCT 
 Size 305bp 
 
   
12 NCAM2 UTR  Fwd AGTCTAGAACAATATTACAGGGGCTTGA 
 
(isomiR-9) Rev ATGGGCCCATAGAGCACTTTAGCCACAT 
 Size 307bp 
 
   
13 NCAM2  Normal CCTATGACCAAAACTATTCCATTG 
 
Mutant UTR Fwd CCTATGGCTTAGGCTATTCCATTG 
 
 
Rev CAATGGAATAGCCTAAGCCATAGG 
 Size 254bp and 80bp 
    14 HMGA2 3'UTR Fwd AGTCTAGATAGTCAATCACTGCACTGCA 
 
(miR-9) Rev ATGGGCCCTGGCTCTGTAGGAAGTAGAT 
 Size 433bp 
    15 HMGA2  Normal GTTTAGAACACCAAAGATAAGGACTA 
 
Mutant UTR Fwd GTTTAGAACTGCACTGCTAAGGACTA 
  
Rev TAGTCCTTAGCAGTGCAGTTCTAAAC 
size 302bp and 168bp 
    16 SP3 UTR Fwd ATGCTAGCACAAATCAAGTTTCCAAGCA 
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(miR-302a*) Rev ATGGCCGGCCGCTCTTACAAGACCAGCAAT 
 Size 795bp 
    17 ZNF148 UTR  Fwd ATGCTAGCGAAGTGAGTACCAATGTGCT 
 
(miR-302a*) Rev ATGGCCGGCCCACTAAGTTTTGCGGTCTTC 
 Size 429bp 
    
 
Table 2.1 Primer sequences for reporter vector/ UTR cloning 
 
2.13 Restriction endonuclease digestion  
Digestion mix was prepared in a 1.5 mls DNase free eppendorf tube and incubated at 
37○C for the required period of time and the digested product was analysed by 
agarose gel electrophoresis. The digestion mix consisted of 1 μg DNA, 2 μl 10x 
restriction enzyme buffer (1 – 4 depending on which enzyme was used), 0.5 μl of each 
restriction enzyme (New England Biolabs) and water upto a total volume of 20 μl. 
 
2.14 Northern hybridisation 
2.14.1 Total RNA separation in denaturing gel, semi-dry blot and UV 
crosslinking  
20 – 40 μg of total RNA was separated on a 15% polyacrylamide denaturing gel (7M 
Urea) in 0.5 x TBE buffer at 250 V. Six pieces of Whatman filter paper, and 1 piece 
of Hybond N+ nylon membrane (GE healthcare Amersham) was cut to the same size 
as the gel and soaked in 0.5 x TBE. Three pieces of filter paper were then placed on 
the semi-dry blot apparatus and the membrane was layered on top. The gel was 
positioned on top of the membrane before the remaining 3 pieces of filter paper were 
also added to the gel sandwich (Figure 2.2). A long pipette was used to squeeze out 
the bubbles within the gel sandwich by rolling over the top, and any excess liquid 
surrounding the sandwich was wiped away. The semi-dry apparatus was run at 3.3 
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mA/cm2 of the gel sandwich for 35 minutes (~5 V). The membrane was washed in 0.5 
x TBE for 5 minutes, and then placed on top of a piece of filter paper or plastic saran 
wrap and UV cross-linked at 1200 μJoules, twice. 
 
 
 
Figure 2.2  
Arrangement of gel sandwich 
 
 
 
2.14.2 Labelling of oligonucleotide probe by 32P γATP 
Oligonucleotide probes complementary to the targets miR-21, miR-9* and miR-302a* 
(Table 2.2) were labelled with 32P γATP. Procedure was performed with necessary 
radioactive precaution. In brief, 0.5 μl of the oligonucleotide probe (50 μM) was 
added to 1 μl of polynucleotide kinase (PNK) buffer, 1 μl of PNK enzyme, 1 μl of 32P 
γATP and toped up to 10 μl with water. The sample mix was incubated at 37oC for 1 
hour. To remove any excess 32P γATP, an ethanol precipitation step was performed by 
adding 70 μl of Tris-EDTA pH 8.0 (TE) buffer, 20 μl of ammonium acetate (10 M) 
and 1 μl of glycogen to the sample. Finally, 250 μl of -20oC 100% ethanol was added 
to the sample and left on ice for 1 hour. The sample was then centrifuged at 1300 rpm 
at 4oC for 20 minutes. The supernatant was removed and resuspended in 100 μl TE. 
The radioactivity of the precipitate and the removed supernatant were checked with a 
Geiger counter and the precipitate was stored at -80oC. A reading of 2:1 ratio between 
precipitate and supernatant was considered as a successful labelling.  
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Name 
 
Sequence 
miR302a* Mature acuuaaacguggauguacuugcu 
 
probe agcaagtacatccacgtttaagt 
   
miR-9* Mature auaaagcuagauaaccgaaagu 
 Probe actttcggttatctagctttat 
   
miR-21 Mature uagcuuaucagacugauguuga 
 Probe tcaacatcagtctgataagcta 
   
 
Table 2.2 
Probe sequences for northern hybridisation 
 
 
2.14.3 Hybridisation 
The membrane was washed with 2 x SSC and 0.1% SDS with gentle agitation for 5 
minutes at room temperature. 15 mls of hybridisation buffer consisting of 7.5 ml of 20 
x SSC, 1.5 ml of 50 x Denhardt’s solution, 0.375 ml of 20% SDS, and water was pre-
warmed to 42oC. The membrane was placed inside a 50 ml falcon tube with the 
transferred RNA side facing upwards, and pre-hybridised with 5 mls of the 
hybridisation buffer with constant rotation at 42oC for 30 minutes. The solution was 
removed and fresh hybridisation buffer was added to the tube along with 50 -100 μl of 
the 32P γATP labelled oligonucleotide probe or digoxigenin (DIG) labelled locked 
nucleic acid (LNA) probe (Exiqon). The probe was hybridised to the membrane 
overnight at 42oC. 
 
For membrane hybridised with 32P γATP labelled probe, it was washed twice in 2 x 
SSC + 0.1% SDS at room temperature and exposed to an x-ray film in a cassette with 
intensifying screen at -80oC overnight or up to 5 days. For membrane hybridised with 
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DIG-labelled LNA probe, it was washed twice with 2 x SSC and 0.1% SDS at 42oC 
for 15 minutes, followed by washed twice with 0.1 x SSC and 0.1% SDS 42oC for 5 
minutes. Then, the membrane was briefly rinsed with 1 x SSC at 42oC for 10 minutes. 
Subsequently, the membrane was incubated in blocking buffer (Roche) or 1x Maleic 
acid with 1% BSA for 3 hours at room temperature. The solution was replaced by 
fresh blocking buffer added with anti-DIG antibody (1:10,000) (Roche) and incubated 
at room temperature for 30 minutes. The membrane was then washed in DIG wash 
buffer (Roche) 4 times for 15 minutes each. The membrane was incubated in 
development buffer (Roche) for 5 minutes. Then, Disodium 3-(4-methoxyspiro {1,2-
dioxetane-3,2'-(5'-chloro)tricycle [3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD) 
(1:100) substrate solution was added to the development buffer and applied to the 
surface of the membrane and incubated for 5 minutes. After that, the membrane was 
placed in a heat-sealable plastic bag and any extra buffer was squeezed out, and 
incubated at 37oC for 15 minutes in the dark. Finally, the membrane was exposed to 
X-ray films in a cassette at room temperature for a suitable amount of time depending 
on the signal intensity. 
 
2.15 Western blotting 
2.15.1 Cell lysis and protein extraction by RIPA buffer 
Cells were washed 1x in PBS at 4oC and lysed in 50-200 μl of RIPA buffer directly in 
the wells (the amount of RIPA buffer depends on the size of tissue culture plate and 
the cell confluency). Cells were scraped using a cell scraper and the lysates were 
transferred to a 1.5 ml eppendorf. It was kept at 4oC for 5 minutes and followed by 
centrifuge at 13,000 x g for 10 minutes at 4oC to pellet any insoluble debris. The 
sample/ supernatant was transferred to a new eppendorf and stored at -20oC.  
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2.15.2 SDS-PAGE electrophoresis 
Cell lysates were run on a 12% (w/v) resolving with 4% (w/v) stacking acrylamide 
gel. The bottom and top atrium of the tank (Invitrogen) were filled with 1 x SDS 
running buffer. 1:4 Laemmli was added to each sample protein. A bromophenol dye 
was added to each well followed by the samples. Samples were loaded at equal 
amount and the gel was run at 120 volts for 2 to 3 hours. 10μl colorplus prestained 
protein ladder (New England Biolabs) was also loaded for subsequent determination 
of the size of the band.  
 
2.15.3 Nitrocellulose wet transfer 
Gels were transferred using a semi-dry blotting system (Biorad) onto a nitrocellulose 
membrane (0.2 μm pore size). Gels were carefully removed from the plastic cassette 
(1 mm) (Invitrogen) and layered into the permeable folding apparatus in the following 
order; a sponge layer, 2 sheets of Whatman chromatography paper, the nitrocellulose 
sheet (Hybond-ECL, GE healthcare Amersham), the gel, 2 further sheets of Whatman 
blotting paper (Whatman), and finally another sponge layer. The gel sandwich was 
soaked in a tray filled with transfer buffer and any air bubbles were removed by 
rolling a tube across the sandwich. The gel sandwich was placed on the platform of 
the transfer apparatus and transfer buffer was poured onto it until it was soaked. The 
transfer apparatud lid was then attached and protein was transferred for 1 hour and 45 
minutes at 300 mA (<15 volt). The nitrocellulose membrane was stained with 
Ponceau S (Sigma) for general proteins as a loading control and indication of 
successful transfer. The membrane was scanned or photographed at this point to 
obtain a permanent record. 
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2.15.4 Antibody hybridisation 
The membrane was washed with 1 x TBS-T buffer for 5 - 10 minutes, rolling at room 
temperature in a 50 ml falcon tube (Appleton Woods) to remove any residual ponceau 
staining. The wash buffer was then removed and replaced with 4 ml of 5% milk in 1 x 
TBS-T, blocked for 30 minutes at room temperature. Then, 5% milk in 1 x TBS-T 
was added 1:500 dilution of the DNMT3B antibody (rabbit polyclonal IgG, Santa 
Cruz, sc-20704) or NCAM2 (mouse monoclonal IgG, Santa Cruz, sc-136328) and 
incubated at 4oC overnight rolling. The membrane was then washed 3 times with 1 x 
TBS-T buffer for 10 minutes, before incubated for 2 hours rolling at room 
temperature with 4 ml of 2% milk in 1 x TBS-T added with 1:10,000 dilution of anti-
rabbit or anti-mouse IgG horse radish peroxidase (HRP) secondary antibody (Sigma). 
The membrane was then washed 3 times with 1 x TBS-T buffer for 10 minutes. 
Membranes were developed using the Immobilon chemiluminescent HRP substrate (1 
ml of solution A and 1 ml of solution B) (Millipore). The membrane was laid flat on 
cling film and the HRP substrate was left on the membrane for 5 minutes. Finally, the 
membrane was taken to the dark room and light emission was detected by GRI 
biomax film and developed with a developing machine (Kodak). Whenever necessary, 
the membrane blot was stripped by rolling with western blot stripping buffer (Thermo 
Scientific) twice for 30 minutes at room temperature. It was then washed extensively 
with 1 x TBS-T and re-probed.  
 
2.16 Argonaute immunoprecipitation 
Cells from 8 wells of 6-well plate were washed with PBS and lysed with 10 ml of NP-
40 lysis buffer. The cells were spun at 3,000 x g for 30 minutes at 4oC, and the 
supernatant was added to a fresh 15 ml falcon tube. 2 mls of Argonaute 1 (Ago1) and 
67 
 
Argonaute 2 (Ago2) hybridoma supernatants were added, these were supplied by 
Gunter Meister, Max-Planck Institute, Germany. The tubes were rolled at 4oC 
overnight and then 80 μl of protein-G beads (Santa Cruz) was added to the lysate and 
rolled at 4oC for 2 hrs. The beads were then spun down at 3,000 x g for 5 minutes and 
washed with 3 x 10 mls of NP-40 wash buffer and 1 x 10 mls of PBS, before 
resuspended in 200 μl of TE buffer. Next the beads solution was transferred to a 1.5 
ml eppendorf tube and an equal volume of phenol pH 8 was added. The tube was 
vortexed for 1 minute and then spun at maximum speed for 2 minutes at room 
temperature. The resultant aqueous phase was pipetted into a fresh 1.5 ml tube and 
ethanol precipitated with 1 μl of glycoblue (Ambion), 1/10 volume of 3M sodium 
acetate and 3 x volumes of 100% ethanol, overnight at -20oC or on ice for 2 hrs. The 
precipitated RNA was resuspended in DEPC-treated water and stored at -80oC or 
directly loaded onto a 15% denaturing PAGE gel for northern hybridisation.  
 
 
2.17 Construction of sponge (reporter and expression vectors) 
2.17.1 Generation of pMIR reporter sponge constructs with 6 multiple miRNA 
binding sites and 2 multiple miRNA binding sites 
The design of sponges was described in detail in chapter 4. MiR-9 (CDH1) sponge 
(Eurogentec) was excised from pUC57 by XbaI and HindIII at position 425 and 471 
respectively and ligated into pMIR report between SpeI and HindIII at position 525 
and 463 in a multiple cloning site downstream to luciferase sequence. This generated 
pMIR-miR9 sponge reporter vector (Figure S2.4).  
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IsomiR-9 (DNMT3B) sponge (Eurogentec) was excised from pUC57 by SalI and 
HindIII at position 448 and 471 respectively and then ligated into pMIR report 
between XhoI and HindIII at position 545 and 463 in a multiple cloning site 
downstream to luciferase sequence. This generated pMIR-isomiR9 sponge reporter 
vector (Figure S2.4). 
 
pMIR sponges with 2 binding sites was created by excising a segment of the sponge 
(133bp) containing 4 binding sites using SpeI restriction enzyme. Thus, produced 
pMIR-miRNA sponges with 2 multiple binding sites. Clone 3 of pMIR- miR-9 
(CDH1) sponge and all clones of pMIR-isomiR9 (DNMT3B) sponge were 
successfully generated (Figure S2.5). 
 
2.17.2 Generation of pcDNA3.1(+) miR-9 and isomiR-9 sponges expression 
vectors  
MiR9 (CDH1) and isomiR9 (DNMT3B) sponges were ligated into pcDNA3.1(+) 
(Invitrogen) at EcoRI (Position 952)/ApaI (Position 1001) and HindIII (Position 
911)/XbaI (Position 991) respectively (Figure S2.6). These expression sponges have 6 
multiple binding sites and their expression are driven by CMV promoter.  
 
2.18 Generation of DNMT3B coding region along with its full length 
3’UTR 
The coding region of DNMT3B was amplified from a plasmid (Plasmid 35522: 
pcDNA3/Myc-DNMT3B1) obtained from addgene. This plasmid contained an insert 
of the full length (2562bp) of the coding region of DNMT3B. The 3’UTR of 
DNMT3B (1560bp) was then amplified from human genomic DNA (Promega, long 
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PCR kit). PCRs of the coding region of DNMT3B (DC1) and 3’UTR of DNMT3B 
(DC2) were performed (94-2mins, 94-30sec, 60-30sec, 65-2mins (31 cycles) and 72-
10mins; GoTaq® Long PCR Master Mix (M4021), Promega) (Figure S2.7). Finally, 
PCR was performed to generate the DNMT3B with the full length 3’UTR (DC12) 
(94-2mins, 94-30sec, 60-30sec, 65-4mins (30 cycles) and 72-10mins) (Figure S2.7). 
1.25µl of mixed 50ng/µl DC1 and DC2 was used as template in the PCR. Primers 
used in the PCR were listed in Table 2.3. DNMT3B along with its full length 3’UTR 
was cloned into pcDNATM3.1(+) (Invitrogen) between BamHI and XbaI at position 
929 and 991, respectively (Figure S2.8). 
 
No Name  Sequence 
1 DC1F(DNMT3B 
coding 
region) 
Fwd ATGGATCCATGAAGGGAGACACCAGGCATCTCA 
 DC1R(DNMT3B 
coding 
region) 
Rev GTCTGTGTAGTGCACAGGAAAGCCA 
   Expected size: 2451bp 
2 DC2F 
DNMT3B 3'UTR 
Fwd TGGCTTTCCTGTGCACTACACAGAC 
 DC2R 
DNMT3B 3'UTR 
Rev ACTCTAGAAGGTAAACTCTAGGCATCCGTCATCT 
   Expected size: 1560bp 
 
Table 2.3 Primer sequences for DNMT3B expression vector cloning  
 
2.19 Construction of miRNA expressing pTRIPZ lentivector  
Human genomic DNA (RP11-148B6; chromosome 4) comprising miR-302 cluster, 
accompanied by 120 bp upstream and 150 bp downstream to the cluster was amplified 
by PCR (Primers listed in Table 2.4). The amplified product is 975 bp in length. The 
amplified fragment was ligated into pGEM-T easy vector and verified by sequencing 
(Figure S2.9). Subsequently, it was excised and ligated into XhoI and MluI restriction 
70 
 
sites, at position 3806 and 4064 respectively of pTRIPz inducible lentiviral vector (a 
gift from Dr Laki Buluwela, Imperial College London). This cluster consists of 5 
precursor miRNAs in the following sequence, miR-302b, miR-302c, miR-302a, miR-
302d and miR-367. 
 
No Primers 
 
 Sequence 
1 miR-302cl Fwd TACTCGAGATCTTTGGGAACTAGTTCAG 
  Rev TCACGCGTGGATACTGGAGATCTAAAAG 
 
 
Table 2.4 Primers for amplification of miR-302 cluster from human genomic DNA. 
 
Table 2.5 lists the primers used in the detection of pluripotency and neural related 
gene expression and Table 2.6 lists the primers used in the sequencing of pGEM-T 
easy vector. 
 
Primers  
 
Sequence 
Product 
size 
1 GAPDH  Fwd tgcaccaccaactgcttagc 80bp 
  
Rev ggcatggactgtggtcatgag 
 
     
2 Oct3/4 Fwd cttgctgcagaagtgggtggaggaa 167bp 
  
Rev ctgcagtgtgggtttcgggca 
 
     
3 Sox2  Fwd cccccggcggcaatagca 448bp 
  
Rev tcggcgccggggagatacat 
 
     
4 Nanog  Fwd agcctctactcttcctaccacc 278bp 
  
Rev tccaaagcagcctccaagtc 
 
     
5 Lin28A Fwd ggggaatcaccctacaacct 82bp 
  
Rev acttccctatccaggccact 
 
     
6 Nestin Fwd CAGCTGGCGCACCTCAAGATG 209bp 
  Rev AGGGAAGTTGGGCTCAGGACTGG  
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7 PAX6 Fwd AACAGACACAGCCCTCACAAAC 275bp 
  Rev CGGGAACTTGAACTGGAACTGAC  
 
Table 2.5 Primer sequences used in the detection gene expression 
 
No Primers 
 
 Sequence 
1 pUC/M13 Fwd CGCCAGGGTTTTCCCAGTCACGAC 
  Rev TCACACAGGAAACAGCTATGAC 
 
 
Table 2.6 pUC/M13 sequencing primers for pGEM-T easy vector 
 
 
2.20 Reagents and constructs 
2.20.1 Northern hybridisation reagents 
15% denaturing PAGE  
21 g urea, 2.5 ml 10 x TBE, 18.75 ml of 40% (w/v) 19:1 acrylamide:bis-acrylamide, 
adjust volume to 50 ml with water.  
Add 350 μl of 10% (w/v) ammonium persulphate (APS) and 17.5 μl of TEMED 
 
Denaturing loading dye 
10 ml deionized formamide, 200 μl 0.5 M EDTA pH 8.0, 1 mg xylene cyanol FF, 1 
mg bromophenol blue 
 
Non-denaturing loading dye 
0.02% w/v 1 M EDTA pH 8.0, 0.25% w/v xylene cyanol FF, 0.25% w/v bromophenol 
blue, 15% Ficoll in water 
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2.20.2 Western blotting reagents 
Antibodies 
Primary  
DNMT3B rabbit polyclonal IgG (Santa Cruz, sc-20704) 
NCAM2 mouse monoclonal IgG (Santa Cruz, sc-136328) 
 
Secondary 
Peroxidase conjugated Goat anti-rabbit IgG (Sigma Aldrich) 
Peroxidase conjugated Goat anti-mouse IgG (Sigma Aldrich) 
 
Polyacrylamide 12% gel 
10.15 ml Deionised water, 20 ml 30% Acrylamide/Bis solution (Biorad), 18.75 ml 1 
M Tris (pH 8.8), 0.5 ml 10 % SDS, 0.5 ml 10% ammonium persulphate, 30 μl 
TEMED 
 
Polyacrylamide stacking gel 
6.8 ml Deionised water, 1.7 ml 30% Acrylamide /Bis solution (Biorad), 1.25 ml 1 M 
Tris (pH 6.5), 0.1 ml 10 % SDS, 0.1 ml 10 % ammonium persulphate, 10 μl TEMED 
 
RIPA/SDS lysis buffer 
1% Nonidet P-40, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, 150 mM 
NaCl, 10 mM Tris pH 8.0, 2 nM NaF (RIPA/SDS was stored at 4°C and 10μl per ml 
of protease inhibitor mix and aprotinin was added just before used) 
 
 
73 
 
Protease inhibitor mix 
20 mg/ml phenyl methyl sulfonyl fluoride (PMSF), 20 mg/ml 1-10 phenanthroline, 20 
mg/ml Benxamine. Dissolved in ethanol and stored at -20°C. 
 
Laemmli lysis buffer 
20% Glycerol, 2% SDS, 0.1 M Tris pH 6.8, 10% ß-Mercaptoethanol, 7 M Urea  
 
Laemmli loading dye 
20% Glycerol, 2% SDS, 0.1 M Tris pH 6.8, 7 M Urea, 10% w/v bromophenol blue 
10x Running buffer: 121g Tris base, 578g Glycine, 40g SDS, water to 4 litres 
 
Transfer buffer 
25 mM Tris base, 0.2 M Glycine, 20% Methanol 
 
Ponceau S 
0.2 % Ponceau Red, 5% Acetic acid 
 
Blocking buffer 
5% non fat milk/TBS plus 0.15% TWEEN 20 
 
2.20.3 Immunoprecipitation reagents 
NP-40 lysis buffer 
25 mM Tris HCl pH 7.4, 150 mM KCl, 0.5% NP-40, 2 mM EDTA 
Add fresh 1mM NaF, 0.5 mM DTT, 1% proteinase inhibitors and 10 U/ml RNase out  
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NP-40 wash buffer 
300 mM KCl, 50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 0.1 % NP-40 
 
Figure 2.3, 2.4 and 2.5 show map of vectors used in the cloning of reporter vectors 
and expression vectors. 
2.21 Vectors used in reporter assay cloning 
      
    A. pGEM®-T easy vector                                        B. pGL3-Control Vector  
 
 
         
C. pMIR-REPORT™ Reporter Vector                       D. pRL-SV40 Vector           
 
 
Figure 2.3 Vectors used in luciferase assays 
pGEM-T easy vector (A), pGL3-Control vector (B) and pMIR-REPORT™ Reporter 
vector (C) were used in the cloning of reporter constructs. pRL-SV40 was used as 
normalisation control. pGEM-T easy, pGL3-Control and pRL-SV40 vectors map 
reproduced from Promega technical manual. pMIR-REPORT™ Reporter vector map 
reproduced from Invitrogen technical manual.  
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2.22 Vector used in cloning for sponge and DNMT3B expressions 
 
 
Figure 2.4  
pcDNA3.1(+) vector in the cloning of sponge and DNMT3B expression vector.  
pcDNA3.1(+) was used in the cloning for construction of sponge and DNMT3B 
expression vector. Vector map reproduced from Invitrogen technical manual. 
 
2.23 Vector used in cloning for miR-302 cluster expression 
 
Figure 2.5  
pTRIPz inducible lentiviral vector in the cloning of miR-302 cluster expression 
vector. pTRIPz inducible lentiviral vector was used in the cloning for construction of 
miR-302 cluster expression vector. Vector map reproduced from Thermo Scientific 
Open Biosystems technical manual. 
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2.24 List of cell lines used in my thesis 
 
No Cell lines Characteristics Origins 
1 HEK293 Human 
embryonic 
kidney cells 
These cells are easy to 
transfect. 
Nick Dibb’s lab. 
2 MRC5 Human lung 
fibroblasts 
These cells were derived 
from normal lung tissue of 
a 14-week-old male fetus 
and are capable of 42 to 46 
population doublings 
before the onset of 
senescence. 
Nick Dibb’s lab. 
3 H1 Human 
embryonic stem 
cells 
These cells were derived 
from blastocyst and are 
capable of continuous self-
renewal and differentiate 
into cells of any of the 3 
germ layers. 
Wei Cui’s lab. 
4 H7 Human 
embryonic stem 
cells 
These cells were derived 
from blastocyst and are 
capable of continuous self-
renewal and differentiate 
into cells of any of the 3 
germ layers. 
Wei Cui’s lab. 
5 NSC Neural stem cells  These cells were 
differentiated from human 
embryonic stem cells. 
Wei Cui’s lab. 
6 HeLa Cervical cancer 
cells 
These cells are remarkably 
durable and easy to 
transfect.  
Nick Dibb’s lab. 
7 HepG2 Liver cancer cells These cells were derived 
from human hepatoma.  
Nick Dibb’s lab. 
8 MCF7 Breast cancer 
cells 
These cells were derived 
from metastatic site 
(pleural effusion).  
Nick Dibb’s lab. 
9 PC3 Prostate cancer 
cells 
These cells do not response 
to androgen.  
Kindly donated by 
Alwyn Dart from 
Charlotte Bevan’s 
lab. 
10 DU145 Prostate cancer 
cells 
These cells were derived 
from brain metastasis and 
are not hormone sensitive.  
Kindly donated by 
Alwyn Dart from 
Charlotte Bevan’s 
lab. 
11 LNCaP Prostate cancer 
cells 
These cells were derived 
from left supraclavicular 
lymph node metastasis and 
are androgen sensitive.  
Kindly donated by 
Alwyn Dart from 
Charlotte Bevan’s 
lab. 
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2.25 Bioinformatics programs 
miRBase - http://microrna.sanger.ac.uk/sequences/ 
TargetScan - http://www.targetscan.org/ 
PicTar - http://pictar.mdc-berlin.de/ 
miRGen - http://www.diana.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets.cgi 
Diana Lab TarBase - http://diana.cslab.ece.ntua.gr/tarbase/ 
MicroRNAdb - 
http://bioinfo.au.tsinghua.edu.cn/micrornadb/browse_seq.php?ID=hsa-mir-23a 
UCSC Genome Browser - http://genome.cse.ucsc.edu/cgi-bin/hgBlat 
Ensembl Genome Browser - http://www.ensembl.org/index.html 
NCBI Blast - http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Primer3 - http://frodo.wi.mit.edu/ 
Venny - http://bioinfogp.cnb.csic.es/tools/venny/index.html 
NEB cutter V2.0 - http://tools.neb.com/NEBcutter2/ 
Hoodlab – Institute of System Biology - http://hood.systemsbiology.net/ 
OligoAnalyzer 3.1 - 
http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx 
MiRanda/ EMBL miRNA target prediction - http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/ 
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Chapter 3 Characterisation and evaluation of IsomiRs 
 
3.1 Introduction 
During her PhD, Elcie Chan generated miRNA libraries from human ESCs, NSCs and 
MSCs using Solexa or 454 technologies in collaboration with David Baulcombe and 
Attila Molnar. Human ESCs were derived from the inner cell mass of a blastocyst 
(Thomson et al., 1998; see Introduction). Neuronal stem cells (NSCs) were derived 
from hESCs by blocking the bone morphogenetic protein signalling using noggin 
(Gerrard et al., 2005) and human MSCs were derived from first trimester fetal bone 
marrow (Guillot et al., 2007). In general, MSCs have a fibroblast-like morphology 
and can differentiate into cells of the mesenchymal lineage, namely bone, cartilage 
and fat cells. In addition to their multipotent ability, MSCs have immunosuppressive 
properties and the ability to support the growth of other cell types (Uccelli et al., 
2008). MSCs can be isolated from bone marrow (Friedenstein et al., 1970), amniotic 
fluid (In't Anker et al., 2003a), placenta (Parolini et al., 2008), fetal tissues (In't Anker 
et al., 2003b) and umbilical cord blood (Bieback et al., 2004). 
 
It was observed from the sequencing data that the vast majority of miRNAs in all 3 
stem cell types are expressed as isomers (isomiRs) (see Introduction; Figure 3.1).  
Many other deep sequencing studies have discovered that mature miRNA consists of 
a group of isomiRs that differ in length (Morin et al., 2008; Lee et al., 2010; Cloonan 
et al., 2011). In principle, 5' isomiRs have different seed regions to their canonical 
miRNA and therefore could have a different subset of target genes. Here it is tested 
whether isomiRs are functional and more importantly whether 5' isomiRs can repress 
new mRNA subsets. 
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3.2 Results 
 
3.2.1The distribution of different categories of isomiRs in embryonic stem cells 
(ES), neural stem cells (NS) and mesenchymal stem cells (MS) 
Figure 3.1 is an analysis of a sequencing study by Elcie Chan (see above) which 
indicates that miRNA isomers are widely expressed by three different stem cell types 
(Table S3.1). Eight percent of the miRNAs in hESCs have 5' isomiRs, with 9.6% in 
NSCs and 20% in hMSCs. Meanwhile, 50% of miRNAs in hESCs have 3' isomiRs, 
with 72% in NSCs and 71% in hMSCs. The relatively small percentage of miRNA 
that have 5' isomiRs suggests that processing at the 5' end of the miRNA could be 
tightly regulated, perhaps because the 5' end harbours the seed sequence which is an 
important site for target recognition.  
 
The number of isomiRs with differences at the 5' end is small, representing about 10% 
of all miRNAs in hESCs and hNSCs and about 20% in hMSCs. However, the number 
of isomiRs with differences at the 3' end is huge, constituting about 50 to 60% of the 
miRNA (Figure 3.1). About 80% of the 5' isomiRs have additions or deletions of only 
1 nucleotide (Figure 3.1D). In contrast the variation in the size of deletions or 
additions is bigger at the 3' end (Figure 3.1E).  
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Figure 3.1 
The distribution of 5' and 3' isomiRs in embryonic stem cells (hESCs), neural 
stem cells (NSCs) and mesenchymal stem cells (MSCs). A) miR-302a as an 
example of a miRNA expressed by hESCs with variation at 5' and 3' ends giving rise 
to isomiRs, denoted as 5' or start site isomiRs and 3' or end site isomiRs. Purple texts 
represent the canonical miRNAs. B) A bar graph illustrating the percentage of each 
category of isomiRs in hESC, hNSC and hMSC. C, D, E) Bar graph and tables show 
the number of additions and deletions of bases at 5' and 3' isomiR ends. 
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3.2.2 IsomiRs are not sequencing artefacts 
IsomiRs are not sequencing artefacts because they were consistently detected by 
northern blotting (Figure 3.2). The intensity of the bands in the northern blots roughly 
corresponds to the sequencing numbers of miR/isomiRs (Figure 3.2). For miR-302a, 
the most highly sequenced miR length was 23 nts (sequencing number: 54), follow by 
22 nts (sequencing number: 34), which correspond to 2 bands in the northern blot, a 
darker band above and a lighter band below. In miR-367, the lengths of miR/isomiR 
are 20 nts (sequencing number: 11) and 22 nts (sequencing number: 34), which 
corresponds to the two bands. However, the intensity of both bands was almost the 
same - based on the sequencing number, the top band should be 3 times darker than 
the band below. For miR-9, there is a good overall correspondence between the 
sequencing and northern blot results, although we did not detect a band of 24 
nucleotides that was observed by sequencing (Figure 3.2). 
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Figure 3.2 IsomiRs are not sequencing artefacts 
IsomiRs observed in sequencing results were also detected by northern blotting. 
Figure shows comparison of northern blots and sequencing results of miR-302a, miR-
367 and miR-9. A) Northern blotting result of total RNA of NSC. 22-mer 
oligonucleotides were stained with ethidium bromide acted as ladder. B) Northern 
blotting of total RNA of either hESC or NSC hybridised with miR302a, miR-367 and 
miR-9 probes (with the predicted length of miR/isomiR) and C) sequencing results of 
corresponding miRNAs with the total sequencing number of each isomiRs based on 
their length. 
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3.2.3 Expression of miR/isomiRs varies in different human cell lines and mouse 
tissues 
IsomiRs of let-7a, miR-151-5p and miR-221 were readily detected in a variety of cell 
and tissue types confirming that isomiRs are commonly expressed in vivo (Figure 
3.3). Intriguingly, different cell lines and tissues express different ratios of isomiRs, as 
indicated by red arrows (Figure 3.3). For example, MRC5 cells and lung tissue have 
relatively more of the smallest isomer of miR-151-5p. In contrast, the middle band 
isomer of MCF7 is darkest while liver has the darkest uppermost band. This differing 
band intensity between cell types was also seen for miR-221 (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isomirs are not sequencing 
artefacts. The isomiRs bands 
seen by Northern blotting 
correspond in intensity to the 
sequencing results. The thickest 
band represents the canonical 
microRNA for miR-302a and miR-
9 (23 nucleotides in length). 
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Figure 3.3 
Expression of miR/isomiRs in different human cell lines and mouse tissues. 
Northern blots for the indicated miRNAs of total RNA prepared from A) Human cell 
lines: embryonic stem cells (hECS), neural stem cells (NSC), breast cancer cells 
(MCF7), lung fibroblasts (MRC5) and mesenchymals stem cells (hMSC) B) Mouse 
tissues: heart, kidney, liver, lung and spleen. Total RNA containing rRNA was stained 
with ethidium bromide as a loading control. 
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3.2.4 Detections of isomiRs by northern blotting in immunoprecipitated Ago1 
and Ago2 
In order to determine whether isomiRs in general are likely to be functional, we tested 
whether they associated with Argonaute (Ago) proteins in vivo by northern blot 
analysis of miRNAs that were first immunoprecipitated with antibodies against Ago1 
or Ago2 (Figure 3.4). Ago1 and Ago2 antibodies were kindly provided by Gunter 
Meister from University of Regensburg, Germany. The Ago immunoprecipitation (IP) 
results of hESC (Figure 3.4A) indicate that miR-302a and miR-367 and their isomiRs 
were immunoprecipitated with Ago1 and Ago2. Interestingly, the star strand of miR-
302a* and its isomiRs were also detected in Ago immunoprecipitations. MiR-9 
isomiRs that were associated with Ago were detected in NSCs (Figure 3.4B). As a 
control we show that miRNAs were not immunoprecipitated with antibodies against a 
target other than Ago (Figure 3.4C) and we have also shown that the mRNAs that are 
precipitated under these conditions are very distinctive and not simply reflective of 
the total mRNA (Chan, unpublished).   
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                       Lane 1   Lane 2       Lane 3   Lane 4 
 
 
Figure 3.4  
Detection of isomiRs by northern blotting following immunoprecipitation of 
Argonaute 1 (Ago1) or Argonaute 2 (Ago2) proteins of human embryonic stem 
cells (hESC) and neural stem cells (NSC).  A-B) Lanes 1 and 3 are northern blots of 
total RNA for the indicated miRNAs prior to immunoprecipitation (IP) with Ago 1 
(lane 2) or Ago2 (lane 4). C) Control showing that miRNAs were not precipitated 
with antibody against α-tubulin. Ribosomal RNA present in total RNA was stained 
with ethidium bromide as a loading control.  
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3.2.5 Changes of miRNA expression during hESC to NSC differentiation 
We next wanted to re-establish hESC to NSC differentiation that was previously used 
to obtain our miRNA sequencing libraries (Chan et al., unpublished). Using a protocol 
developed in Dr Wei Cui’s lab, hESCs were differentiated to NSCs by blocking the 
bone morphogenetic protein pathway (Gerrard et al., 2005) using noggin. At passage 
4 (approximately 4 weeks after differentiation), the cells started to disperse into single 
cell morphology, as expected (Figure 3.5A, Hook et al., 2011). Cells were collected at 
4 different stages of differention, i.e. hESCs (P0), a week after neural induction (P1), 
4 weeks after neural induction (P4) and NSC at passage 50 (NS50) and passage 60 
(NS60). Total RNAs were extracted for analysis by RT-PCR and northern blotting 
(Figure 3.5B,C).  
 
The RT-PCR and northern blot analysis presented here validated our previous 
sequencing and microarray results (Elcie Chan, unpublished, Figure 3.5).  As 
expected, pluripotency markers such as Oct4, Sox2, Nanog and lin28A were present 
in hESCs at the early stages of differentiation, while Nestin and Pax6 were seen after 
differentiation and continued to express into NSCs. Notably, CDH1 and DNMT3B 
were expressed in hESCs but were downregulated upon differentiation (Figure 3.5B). 
It should be noted that lane P1 of Figure 3.5B is overloaded.  MiR-302a and miR-367 
were confined to hESCs and disappeared after differentiation, and vice-versa for miR-
9 (Figure 3.5C). Although isomiRs of these two miRNAs were observed in cells 
undergoing differentiation, there was no clear change in their ratios during this 
process.  
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Figure 3.5 Changes of mRNA and microRNA expression during neural 
differentiation of human embryonic stem cells. A) Morphological changes during 
neural differentiation from human embryonic stem cells. B) RT-PCR and microarray 
analysis of mRNA expression of pluripotent and neural markers at different stages of 
neural differentiation. C) Northern blots for the indicated miRNAs during neural 
differentiation of hESCs. Total RNA containing the rRNA was stained with ethidium 
bromide as loading control. 
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3.2.6 5' isomiRs have different seed region from the canonical miRNA 
The 5' isomiRs that were identified in our miRNA sequencing databases are of 
particular interest as their seed sequences differ from the canonical or annotated 
miRNA. Table 3.1 shows some examples from miRNAs in hESCs of how additions 
or deletions of the 5' end of the microRNA alter its seed sequence. Table S3.2 shows 
this list in full.  
 
 
hESC 5' difference 5' end of miRNA Canonical seed IsomiR seed 
101 1 addition GUACAGUACU ACAGUAC UACAGUA 
183 1 deletion UAUGGCACUG AUGGCAC UGGCACU 
302a 1 deletion UAAGUGCUUC AAGUGCU AGUGCUU 
 
Table 3.1 Seed sequences of canonical miRNAs and isomiRs 
Examples of how deletions or additions to the 5' end of miRNAs alter their seed 
sequence. 
 
 
These differences in seed sequence should potentially alter their target selection or 
efficiency of target repression. I therefore investigated whether 5' isomiRs have 
different predicted targets to their canonical counterpart by using target prediction 
tools TargetScanHuman and TargetScan custom. I then cross-referenced the targets of 
canonical miRNA with the targets of 5' isomiR to determine which targets are in 
common and which are specific. Table S3.3A and B list the predicted targets of mir-9, 
miR-302a and their most common isomiRs that we sequenced. Bioinformatics 
analysis of all the miRNAs and isomiRs listed in Table S3.3 predicts that there are 
many specific targets of isomiRs and that the percentage of common targets is 
surprisingly low with an average value of about 22% (Table S3.4). This is illustrated 
in Figure 3.6. 
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A. Human embryonic stem cells                         B. Neural progenitor stem cells 
 
 
C. Mesenchymal stem cells 
 
 
Figure 3.6 Venn diagram: TargetScanHuman and TargetScan custom prediction 
of canonical microRNAs and their most common isomiRs (A) Human embryonic 
stem cells (ES), (B) neural progenitor stem cells (NS) and (C) mesenchymal stem 
cells (MS). These isomiRs have a subset of predicted targets that are not predicted 
targets of their canonical microRNAs, as well as targets that are similar. For example, 
miR-101 and isomiR-101 isomer have 109 and 158 specific targets respectively and 
414 common targets. Venn diagrams were generated by VENNY (Oliveros, 2007).  
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3.2.7  Predicting and testing targets of isomiRs 
Table 3.2 shows some predicted targets of miR-9, miR-302 and miR-367 and their 
isomiRs that were chosen on the basis of their possible biological interest. We chose 
these particular miRNA genes to study because they are amongst the most abundantly 
expressed in hESCs and NSCs and because they express a sizeable percentage of 
isomiRs (see Figures 3.7 and 3.8). Table S3.3 lists the full range of predicted targets 
for these miRNAs. Lefty1, PTEN and BTG2 are predicted targets of both canonical 
miRs and isomiRs but the remaining mRNAs are specific targets (Table 3.2). The 
predicted target sites are well conserved between species (see Figure 1.4), which is 
reflective of the prediction tools that were used (see Table S3.5).   
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Table 3.2 
Summary of luciferase assay tests of mRNAs that are predicted to be targeted by the 
indicated miRNAs. The shaded boxes highlight experimental results that do not agree 
with the predictions. √: Inhibition; X: no inhibition; nt: not tested; Luc: Luciferase. 
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3.2.8 IsomiRs with 5' or 3' end differences are capable of targeting mRNAs in 
vitro  
In order to find out whether isomiRs are functional, we constructed reporter vectors 
for the targets of miR-9, miR-302a, miR-367 and their isomiRs listed in Table 3.2., 
which also summarises the results presented in Figures 3.7-3.9. We first looked at 
isomiRs 302a and 367 as these have representative single nucleotide changes at the 5' 
and 3' ends respectively compared to their canonical miRNAs (Figure 3.7). Using 
targetscan and targetscan custom prediction databases, left-right determination factor 
(Lefty1) was predicted as a target for both miR-302a and isomiR-302a (Table 3.2), 
while phosphatase and tensin homolog (PTEN) is a target for both miR-367 and 
isomiR-367. Luciferase assays showed that both 5' and 3' isomiRs were able to target 
Lefty1 and PTEN 3' UTRs and therefore knockdown the expression of a luciferase 
reporter vector in HEK293 cells (Figure 3.7A and B). As expected, inhibition of 
luciferase expression was not seen if HEK293 cells were transfected with the control 
miRNA let-7d or with luciferase vectors with mutant seed target sites (Figure 3.7B).  
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A) 5' isomiR-302a is able to repress left-right determination factor 1 (Lefty1) 
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B) 3' isomiR-367 is able to repress phosphatase and tensin homolog (PTEN) 
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Figure 3.7 
Both 5' and 3' isomiRs are functional. The isomiR-302a has a one nucleotide 
deletion at the 5' end, while isomiR-367 has a 2 nucleotide deletion at the 3' end. A) 
Both miR-302a and isomiR-302a (5’ isomiR) were able to knockdown luciferase 
activity of Lefty1 reporter (pGL3-Lefty1), which has a 401 bp 3' UTR with a single 
target site.  B) Both miR-367 and isomiR-367 (3' isomiR) were able to knockdown 
luciferase activity of a PTEN reporter (pGL3-PTEN, 417 bp 3' UTR, single target site) 
(see Materials and Methods). Error bars represent the standard deviation obtained 
from three independent experiments (n=3). Renilla luciferase was used as internal 
control to standardise against all firefly luciferase activities.  
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3.2.9 IsomiRs target different subsets of mRNA from their canonical/ annotated 
miRNAs 
E-Cadherin (CDH1) and DNA methyltransferase 3 beta (DNMT3B) are predicted 
targets of miR-9 and isomiR-9 respectively (Table S3.3). Furthermore, these 2 genes 
are expressed in hESCs and downregulated upon differentiation, which corresponds 
with the appearance of miR-9 and isomiR-9 (Figure 3.5).  
 
Two reporter vectors, CDH1 and DNMT3B were constructed for miR-9 and isomiR-9, 
respectively. Luciferase assays confirmed that the 680 bp UTR of CDH1 is a target of 
miR-9 but isomiR-9 was not able to knockdown CDH1 as efficiently (Figure 3.8A), 
whereas the 470bp UTR of DNMT3B is a target of isomiR-9 but not miR-9 (Figure 
3.8B). Moreover, there was no repression, if these miRNAs were replaced with let-7d. 
Surprisingly, luciferase activity was increased when transfected with let-7d in CDH1 
assay (Figure 3.8A). In order to confirm that the seed sequence is important, 4 out of 
6 of the seed sequence were mutated to generate reporter vectors with mutated target 
sites within the 3' UTRs for CDH1 and DNMT3B. This markedly reduced the ability 
of miR-9 and isomiR-9 to repress their targets (Figure 3.8). 
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A) CDH1 is a target of miR-9 but not isomiR-9 
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B) DNMT3B is a target of isomiR-9 but not miR-9 
 
 
 
 
 
Figure 3.8  
Reporter assay: CDH1 is a target of miR-9 and DNMT3B is a target isomiR-9 
E-Cadherin (CDH1) and DNA methyltransferase 3 beta (DNMT3B) are predicted 
targets of miR-9 and isomiR-9, respectively. Relative activity of the firefly luciferase 
was plotted against increasing concentrations of miR-9 and isomiR-9 for A) CDH1 
and B) DNMT3B reporters. miRNA repression efficiency was attenuated in mutant 
reporter vectors, and the control miRNA let7d as expected. Error bars represent the 
standard deviation obtained from three independent experiments (n=3). * and ** 
represent statistical significance at the levels of p<0.05 and p<0.0001 respectively 
(statistical difference is between miR-9 and isomiR-9). Renilla luciferase was used as 
internal control to standardise against all firefly luciferase activities.  
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3.2.10 NCAM2 is another target of isomiR-9 but not miR-9 
Another predicted target of isomiR-9 but not miR-9, is the mRNA encoded by the 
gene for neural cell adhesion molecule 2 (NCAM2, Table S3.3, Figure 3.6). In 
luciferase assays, isomiR-9 was able to repress significantly the 307 bp 3' UTR of 
NCAM2 at 12 nM concentration only. However, miR-9 showed no repression at any 
concentration (Figure 3.9). 
 
 
Figure 3.9 
pMIR-NCAM2-3’UTR was co-transfected with either miR-9 or isomiR-9 miRNA 
mimic into HEK293 cells. Relative activity of the firefly luciferase for NCAM2 
reporter was plotted against increasing concentrations of miR-9 and isomiR-9. Error 
bars represent the standard deviation obtained from three independent experiments 
(n=3). All results were normalised by renilla luciferase. * represent statistical 
significance at the level of p<0.05 (statistical difference is between miR-9 and 
isomiR-9). 
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3.2.11 Confirmation that miR-9 and isomiR-9 miRNA mimics are of different 
lengths 
Total RNA was extracted from HEK293 cells transfected with miR-9 and isomiR-9 
miRNA mimics and probed with miR-9 locked nucleic acid (LNA) by northern 
blotting. Figure 3.10 shows that isomiR-9 was smaller by one nucleotide, as expected. 
The mimics appeared to run more slowly than miR-9 and isomiR-9 (Figure 3.10, lane 
1), for reasons that are not yet clear.   
 
 
Transfected miR-9 and isomiR-9 mimics were expressed at different length 
 
 
 
 
 
 
Figure 3.10  
Testing the miR-9 and isomiR-9 mimics. The expected difference in length of 
transfected miR-9 (23 nts) and isomiR-9 (22 nts) mimics was confirmed by northern 
blotting. Total RNA containing the rRNA was stained with ethidium bromide as 
loading control. 
 
 
 
 
 
 
102 
 
3.2.12 Detection of miR/ isomiR-9 expression in different cell lines and tissues 
Because miR-9 and isomiR-9 had generated our most interesting luciferase results, we 
decided to look in more detail at different cell types in order to characterise miR-9 
expression and to see if miR-9 isomers might be differentially expressed. Northern 
blotting using a miR-9 probe was performed on a range of mouse organs as well as 
the indicated human cell lines (Figure 3.11A). NSC and mouse kidney were the only 2 
cell/ tissue types that expressed miR-9, which largely confirms that miR-9 is a neural 
specific miRNA. Mouse cerebrum and cerebellum were collected subsequently and 
both expressed high levels of miR-9 compared to kidney tissue (Figure 3.11B). 
Interestingly, isomiR-9 expression was different between the mouse brain tissue and 
NSCs. NSCs showed darkest uppermost band and intensity reduces in the shorter 
isomiRs. In contrast, mouse cerebrum and cerebellum showed darker band at both the 
uppermost and lowermost bands than the middle band.  
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MiR-9/ isomiR-9 is differentially expressed in between NSC and mouse brain 
tissue 
 
A 
                      
 
 
B 
 
 
Figure 3.11 
MiR-9/ isomiR-9 is differentially expressed in neural related cells and tissues. A) 
A miR-9 LNA probe performed on mouse tissues (heart, kidney, liver, lung and 
spleen) and human cell lines (H1 hESCs, H7 hESCs, NSC, MRC5, HeLa, MCF7, 
LNCaP and DU145). B) MiR-9 LNA probe performed on hNSC and mouse 
cerebrum, cerebellum and kidney. Total RNA containing the rRNA was stained with 
ethidium bromide as loading control. 
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3.2.13 False positive and false negative target predictions 
Other predicted targets of miR-9, miR-302a and miR-367 that were tested included 
BTG1, BTG2, HMGA2 and Rock1 (Figure 3.12, Table 3.2). BTG1 is a predicted 
target of miR-302a but not isomiR-302a, but both were able to repress BTG1 (false 
negative target of isomiR-302a). Rock1 is a predicted target of isomiR-302a, 
however, it was not repressed (false positive target of isomiR-302a). BTG2 is a 
predicted target of miR-367 and isomiR-367 but neither were able to repress BTG2 
(false positive target of miR-367 and isomiR-367). HMGA2 is a predicted target of 
miR-9 but not isomiR-9. However, both were able to repress it (false negative target 
of isomiR-9). Table 3.2 summarises the results of the luciferase tests of predicted 
targets of miR-302a, 367 and 9 and their isomiRs. 
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Figure 3.12 
Other predicted targets that were tested. BTG1 and HMGA2 were false negative 
predicted targets of isomiR-302a and isomiR-9 respectively, while BTG2 was false 
positive predicted targets of miR-367 and isomiR-367, and Rock1 of isomiR-302a. 
Error bars represent the standard deviation obtained from three independent 
experiments (n=3). All results were normalised by renilla luciferase. * represent 
statistical significance at the level of p<0.05. 
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3.2.14 Validation of newly established seed target sites by seed mutation study 
To validate that the repression of NCAM2, HMGA2 and BTG1 were dependent on 
the seed target sites in the 3' UTR, mutant reporter vectors were generated with 
mismatches to the miRNA seed regions. Repression was reduced or totally abolished 
in all mutant 3' UTRs (Figure 3.13).  
 
 
 
Figure 3.13 
Novel miRNA target sites. Mutant NCAM2, HMGA2 and BTG1 seed target sites in 
the 3' UTR were made and tested by luciferase assays. In all experiments, miRNAs 
was transfected along with either reporter vectors with the original unmodified UTR 
or with a mutant UTR. Error bars represent the standard deviation obtained from three 
independent experiments (n=3). All results were normalised by renilla luciferase. * 
represent statistical significance at the level of p<0.05. 
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3.3 Discussion 
Here we report that over half of the miRNAs from our three stem cell libraries are 
isomers (isomiRs) that have 5' or 3' differences compared to the dominant canonical 
sequence (Figure 3.1B). The variation we detected is unlikely to be an artefact as we 
observed similar variation in all cases that were tested by northern blotting (Figures 
3.2 – 3.4). Previous miRNA sequencing projects have also reported the presence of 
isomiRs and similarly to our experiments demonstrated their association with Ago 
proteins (Morin et al., 2008; Lee et al., 2010; Cloonan et al., 2011; Figure 3.4).   
     
IsomiRs with 3' deletions or additions occurred with a frequency of over 50% across 
the ESC, NSC and MSC miRNA sequencing libraries (Figure 3.1B). This finding is 
consistent with previous studies that 3' isomiR variants are more common than 5' 
variants in mouse, human and Drosophila samples (Burroughs et al., 2010; Lee et al., 
2010; Cloonan et al., 2011; Wyman et al., 2011).   
 
The 5' variants we sequenced occurred at a frequency of only 5 to 15% but we show 
that such variation would be expected to have a major impact upon mRNA targeting 
(Figure 3.6). We wanted to test these predictions and chose to analyse isomiRs, miR-9, 
miR-302a and miR-367 because they represent the most abundantly expressed 
miRNAs in NSCs and hESCs. IsomiR-367 was able to repress PTEN, just like its 
canonical miRNA, but this was not a surprise given that they only differ by 2 
nucleotides at the 3' end (Figure 3.7) and is in agreement with the current opinion that 
the classical target selection depends on the seed region which is located at the 5' end 
of the miRNA.  
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Subsequently, bioinformatics analysis of target prediction was shifted to focus on 5' 
isomiRs. First, a target (Lefty1) for both miR-302a and isomiR-302a was chosen to 
investigate whether a 5' isomiR could function as efficiently as its canonical miRNA. 
Then, a target (DNMT3B) was chosen that is predicted to be targeted by a 5' isomiR 
but not its canonical miRNA.  Indeed, reporter assays indicated that 5' isomiRs are 
also functional and more importantly that they can have different targets to their 
canonical miRNA. Seed sequence mutation studies confirmed that the predicted seed 
target sites were crucial for the recognition of both miRs and isomiRs (Figures 3.8 
and 3.13). Two mRNAs (DNMT3B and NCAM2) were identified as targets of 
isomiR-9 but not the canonical miR-9 (Table 3.2, Figures 3.8 - 3.9) and we also found 
that isomiR-9 had lost the ability to repress CDH1.  Out of 17 new tests that we made 
of the bioinformatics predictions, only 5 (29.4%) were incorrect (Table 3.2) and in 
general our results support the bioinformatic prediction that single nucleotide changes 
at the 5' end of a miRNA are likely to generate new targets. Intriguingly, my 
experiment showed an upregulation of luciferase activity when let-7d was transfected 
with some of the reporter vectors (see figure 3.8A) for reasons that are not yet clear. 
One possibility is let-7d might saturate the RISC complex and interfere with the 
repression mechanism.  
 
Fukunaga et al., [25] described an in-vivo study where Dicer partner proteins may 
bind to Dicer and generate different isomiRs of a miRNA. Loquacious-PA generates a 
21-mer miR-307a and loquacious-PB generates a 23-mer miR-307a. Thus by altering 
the Dicer partner proteins changes the choice of the cleavage site, producing isomiRs 
with different target specificities. They went on to show glycerol kinase and taranis 
were targets of 23-mer miR-307a but not 21-mer miR-307a (Fukunaga et al., 2012). 
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Humphrey et al., (2012) have also presented preliminary evidence to indicate that 
miR-133a and an isomiR have different target specificities in murine cardiomyoctyes.  
 
We did not notice any obvious difference in the association of miRNAs with Ago1 
and Ago2 (Figure 3.4), although our analysis was not extensive.  Dueck et al., (2012) 
reported that human miRNAs are not differentially associated with Ago proteins, 
when analysed by northern blotting as opposed to sequencing.  However miRNAs that 
associate with Ago2 peak at 22 nt, whilst peaks of 23 or 24 nucleotides are observed 
for Ago 1 and 3 (Dueck et al., 2012).  This may be the reason why shorter isomiRs 
have a slight preference for binding to Ago2 (Dueck et al., 2012: Burroughs et al., 
2011).  
 
A number of groups have reported that isomiR expression patterns differ between cell 
lines or tissue types and in some cases the changes are as much as ten-fold 
(Fernandez-Valverde et al., 2010; Burroughs et al., 2010). These studies were based 
upon sequencing data, but it seems likely that they are essentially correct because our 
northern blotting results generally agreed with our sequencing data (Figure 3.2 -3.4).  
We also observed that the dominant isomiRs vary between cell and tissue types 
(Figure 3.3 and Table S3.1). 
 
MiR-9 has been shown to be upregulated in breast cancer cells and to repress CDH1, 
which promotes cancer cells motility and invasiveness. MiR-9 mediated 
downregulation of CDH1 is also associated with the activation of vascular endothelial 
growth factor through the upregulation of beta catenin signalling, which increases 
tumour angiogenesis. Inhibition of miR-9 by miRNA sponge reduces metastasis 
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formation (Ma et al., 2010). Here, CDH1 was again validated as a target of miR-9. 
DNMT3B was also found to be overexpressed in a subset of hypermethylated breast 
cancer cells. qPCR analysis showed miRs-29c, 148a, 148b, 26a, 26b, and 203 in 
hypermethylator cell lines was reduced 60%–85% compared to non-hypermethylator 
cell lines (Sandhu et al., 2012). Further investigations are required to determine 
whether a downregulation of miR-9/isomiR-9 is associated with the subset of 
hypermethylation breast cancer and upregulation with the non-methylated breast 
cancer.  
 
NCAM2 might be involved in neurological diseases such as Down’s syndrome and 
autism. In humans, NCAM2 is located on chromosome 21. Trisomy 21 is the cause of 
Down’s syndrome and excessive expression of NCAM2 has been suggested as a 
contributing factor to its development (Paoloni-Giacobino et al., 1997; Winther et al., 
2012). The expression pattern of NCAM2 suggests it may have a role in the 
development of olfactory sensory neurones (Hamlin et al., 2004). MiRNA array 
revealed extensive regulation of miRNAs during the development of the brain, two of 
them i.e., miR-9 and miR-131 were also dysregulated in presenilin-1 null mice that 
exhibited severe brain developmental defects (Krichevsky et al., 2003).  
 
It has been argued that isomiRs provide a new level of mRNA regulation (Neilsen et 
al., 2012) or that alternatively they are trivial variants produced by sloppy processing 
(Cummins et al., 2006a, b). One interesting proposal is that isomiR production might 
reduce the relative off target effect compared to a single miRNA (Cloonan et al., 
2011). It seems unlikely that isomiRs are trivial because although an individual 
isomiR is by definition a minority species, our sequencing numbers for isomiR-9 and 
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isomir-302a were higher than for many canonical miRNAs (Table S3.6A and S3.6B). 
The question of whether isomiRs have important biological roles is perhaps not clear 
as yet. However, two of our observations indicate the possible therapeutic and/ or 
experimental value of isomiRs. First, we observed that isomiR-9 is an equally 
effective inhibitor of DNMT3B as miR-9 is of CDH1 in vitro (Figure 3.8). Second, 
some of the predicted mRNA targets of isomiRs are not predicted targets of any other 
miRNA (Figure S3.1 and Table S3.7).   
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Chapter 4 Evaluation of miR-9 and isomiR-9 targets by 
RNA sponges 
 
4.1 Introduction 
Most miRNAs are predicted to target hundreds to thousands of mRNAs, however, 
30% of these predictions for human mRNAs are estimated to be false positives (Lewis 
et al., 2003). Experiments are therefore essential both to confirm targets and to 
explore the biological function of miRNAs and their isomiRs. Loss-of-function 
strategies are particularly informative and these include antisense oligonucleotide or 
antagomirs (Meister et al., 2004; Krützfeldt et al., 2005), miRNA sponges (Ebert et al., 
2007) and genetic knockout animals (Miska et al., 2007; Park et al., 2010). Sponges 
are potentially more efficient than antisense oligonucleotide (Ebert et al., 2007) and 
also seem more likely to be able to inhibit specific isomiRs. Here we describe the use 
of miRNA sponges as a mean to confirm and extend our isomiR results of Chapter 3. 
 
MicroRNA sponges, natural and synthetic were first described in 2007 (Ebert et al., 
2007; Franco-Zorrilla et al., 2007). These sponges express non-coding RNAs that 
have multiple miRNA target binding sites, and their expression is usually driven by a 
CMV promoter. They act as decoy mRNAs that compete with endogenous mRNA for 
base pairing with miRNAs.  
      
Sponges with binding sites containing a central bulge were reported to be more 
effective than sponges with perfect binding sites (Ebert et al., 2007). This may be due 
to degradation of the sponge transcripts by endonucleolytic cleavage activity of Ago2 
upon perfect binding of the miRNA with sponge. Otaegi et al., (2011) have tested 
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various constructs for their ability to repress their target gene. Sponge constructs with 
short 6 nts separation between miRNA binding sites worked better than constructs 
with 29 and 42 nts separations. Constructs that started with a coding gene followed by 
sponge RNA worked better than constructs without the coding gene. Lastly, 
constructs with 6 or 12 multiple binding sites were better than constructs with 24 
multiple binding sites (Otaegi et al., 2011). Ebert et al., (2007) has also described that 
sponges with >6 multiple binding sites repeats have only marginal increased 
efficiency, possibly due to saturation effects. Taking the above results as a guideline, 
the ingredients for a successful sponge design should be a sponge that has 6 multiple 
binding sites (MBS), a short separation between the MBS and that begins with a 
coding gene.  
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4.2 Results 
 
4.2.1 Using as a different reporter vector (pMIR-Report) to validate the targets 
of miR-9 and isomiR-9.  
We first wanted to confirm our results of Chapter 3 with a different vector. I therefore 
cloned the 3' UTRs of DNMT3B and CDH1 into the pMIR vector, which expresses 
luciferase from a CMV promoter. Figure 4.1 shows that isomiR-9 at a transfection 
concentration of 4 nM was able to repress luciferase activity (DNMT3B) but no 
inhibition was observed for miR-9. However, both miRNAs were unable to inhibit 
luciferase expression at 1 nM (Figure 4.1), probably because of the high luciferase 
expression driven by the CMV promoter. 
 
Figure 4.2 shows that miR-9 was a better inhibitor than isomiR-9 of luciferase joined 
to the 3' UTR of CDH1 (described in Chapter 3) in the pMIR reporter vector, however 
this was only clear cut at higher miRNA concentrations. (Figure 4.2 A and B). 
Overall, these results confirmed that that miR-9 was a more effective inhibitor of 
CDH1 than isomiR-9 in luciferase reporter vector.  
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Figure 4.1 
Luciferase assay of pMIR-DNMT3B-3'UTR transfected along with either miR-9 
or isomiR-9. The luciferase expression in this vector is driven by a CMV promoter. A 
segment of DNMT3B 3' UTR was inserted between SpeI and SacI sites. pMIR-
DNMT3B-3' UTR was co-transfected with either miR-9 or isomiR-9 at 1 nM and 4 
nM into HEK293 cells. All results were normalised by Renilla. Error bars represent 
the standard deviation obtained from three independent experiments (n=3). * indicate 
p value <0.05 (statistical difference is between miR-9 and isomiR-9). 
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A 
 
B 
 
 
Figure 4.2  
Luciferase assay of pMIR-CDH1-3'UTR, transfected along with either miR-9 or 
isomiR-9 at 8 and 16 nM (A). (B) 24, 32 and 40 nM.  
pMIR-CDH1 3'UTR luciferase vector was constructed by cloning a segment of CDH1 
3'UTR into pMIR-report vector. pMIR-CDH1-3'UTR was co-transfected with either 
miR-9 or isomiR-9 at 8 nM and 16 nM (A) into HEK293 cells. Then, repeated at 24 
nM, 32 nM and 40 nM (B). All results were normalised by Renilla. Error bars 
represent the standard deviation obtained from three independent experiments (n=3). 
* indicate p value <0.05 (statistical difference is between miR-9 and isomiR-9). 
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4.2.2 Design of CDH1/ miR-9 and DNMT3B/ isomiR-9 sponges  
After using a different reporter vector to validate the results of Chapter 3, the next 
question was whether it was possible to use sponges to specifically inhibit miR-9 and 
its isomiR in order to further strengthen my results. With the help of Leandro 
Castellano (Imperial College London), two sponges were designed and constructed 
with the intention to soak up either miR-9 or isomiR-9 separately. The 3' UTRs of 
CDH1 containing the target site of miR-9, and DNMT3B with the target site of 
isomiR-9 were used as the templates for the construction of these sponges. The initial 
sponges that were created contained 6 multiple miRNA binding sites (Figure 4.3). 
DNA sequences were synthesised by Eurogentec which were blunt end ligated into 
pUC57 at EcoRV (Position 431) within a multiple cloning site, which were 
subsequently validated by sequencing.  
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Selection of templates for the construction of sponges 
 
Description Sequences 
miR-9  
 
3’ AGTATGTCGATCTATTGGTTTCT 5’ 
CDH1/miR-9  
mRNA target site in 
3’UTR  
 
5’..AGTGCCTAAAGTGCTGCAGCCAAAGA..3’ 
Template 
 
AGTGCCTAAAGTGCTGCAGCCAAAGA 
CDH1/ miR-9 sponge 
with 6 MBS 
 
ACTAGTCGGAAGTGCCTAAAGTGCTGCAGCCAAAGACGATAGTGC
CTAAAGTGCTGCAGCCAAAGAACGCGTACGGAAGTGCCTAAAGTG
CTGCAGCCAAAGACGATAGTGCCTAAAGTGCTGCAGCCAAAGAAC
TAGTACGGAAGTGCCTAAAGTGCTGCAGCCAAAGACGATAGTGCC
TAAAGTGCTGCAGCCAAAGAAGCTT 
 
isomiR-9  
 
3’ AGTATGTCGATCTATTGGTTTC 5’ 
DNMT3B/isomiR-9  
mRNA target site in 
3’UTR       
 
5’..AGAAACAATGGCTAAGATACCAAAA..3’ 
Template 
 
AGAAACAATGGCTAAGATACCAAAA 
DNMT3B/ isomiR-9 
sponge with 6 MBS 
 
ACTAGTCGGAAGAAACAATGGCTAAGATACCAAAACGATAGAAAC
AATGGCTAAGATACCAAAAACGCGTACGGAAGAAACAATGGCTAA
GATACCAAAACGATAGAAACAATGGCTAAGATACCAAAAACTAGT
ACGGAAGAAACAATGGCTAAGATACCAAAACGATAGAAACAATGG
CTAAGATACCAAAAAGCTT 
 
 
Figure 4.3 
Selection of templates and generation of miRNA sponges. The target sites of miR-
9 in the 3' UTR of E-cadherin (CDH1) and target site of isomiR-9 in DNA 
methyltransferase 3b (DNMT3B) are shown (highlighted as green) and these were 
selected as templates for sponges. Sponges containing 6 templates or MBS for either 
miR-9 or isomiR-9 were constructed. The sequences of miR-9 and isomiR-9 are also 
shown.  Green shading highlights the seed sequences of miR-9 and isomiR-9 and their 
seed targets within the sponges. 
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4.2.3 pMIR-isomiR-9 sponge with 6 multiple binding sites 
In order to confirm that the sponge templates we designed were effective, they were 
first inserted as 3' UTRs downstream of the luciferase sequence in the pMIR-report 
vector. Figure 4.4 shows the results of experiments in which pMIR-isomiR-9 sponge 
with 6 MBS was co-transfected along with either miR-9, isomiR-9 or let-7d at 
increasing concentration from 4 to 16 nM. As expected the control miRNA let-7d was 
unable to inhibit luciferase activity but surprisingly both miR-9 and isomiR-9 were 
able to knockdown luciferase activity (Figure 4.4). The observation that both miR-9 
and isomiR-9 could repress luciferase activity might be because the multiple binding 
sites had somehow enhanced the ability of miR-9 to recognise the binding site for 
isomiR-9. To test this possibility the multiple binding sites were reduced to 2. This 
was performed by a simple digestion with SpeI which removed 4 of the 6 multiple 
binding sites. Using a pMIR-isomiR-9 sponge with 2 MBS, miR-9 and isomiR-9 were 
still able to knockdown luciferase activity. However, isomiR-9 appeared to be more 
effective at lower concentrations of 4 and 12 nM (Figure 4.5 A). The experiment was 
repeated at a lower miRNA concentration (1 – 4 nM) and at miRNA concentrations of 
1 nM, 2 nM, 4 nM and 12 nM and this confirmed that the differences in repression 
between miR-9 and isomiR-9 were significant at lower concentrations of miRNAs 
(Figure 4.5 A and B).  
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DNMT3B/isomiR-9 sponge template –  
       5’..AGAAACAATGGCTAAGATACCAAAA..3’ 
                     ||||    |||||| 
isomiR-9   3’ AGTATGTCGATCTATTGGTTTC  5’ 
                     ||||    ||||||| 
miR-9      3’ AGTATGTCGATCTATTGGTTTCT 5’ 
              ||| |||        |||||| 
let-7d     3’ TTGATACGTTGGATGATGGAGA  5’    
 
pMIR-isomiR-9 sponge (6MBS) 
 
Figure 4.4 
pMIR-isomiR-9 sponge with 6 MBS was co-transfected with either isomiR-9, 
miR-9 or let-7d. A fixed amount of 200 ng of this vector was transfected along with 
isomiR-9, miR-9 and let-7d at increasing miRNA concentration (4 nM, 8 nM, 12 nM 
and 16 nM). All results were normalised by renilla luciferase. Error bars represent the 
standard deviation obtained from three independent experiments (n=3). * indicate p 
value <0.05 (statistical difference is between miR-9 and isomiR-9). 
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pMIR-isomiR-9 sponge (2MBS) 
A 
 
B 
 
 
Figure 4.5 
pMIR-isomiR-9 sponge with 2 MBS was co-transfected with either miR-9 or 
isomiR-9. A fixed amount of 200 ng of vector was transfected along with isomiR-9 
and miR-9 at increasing concentrations (A) 4 nM, 12 nM and 20 nM and (B) 1 nM, 2 
nM and 4 nM.  All results were normalised by renilla luciferase. Error bars represent 
the standard deviation obtained from three independent experiments (n=3). * indicate 
p value <0.05 (statistical difference is between miR-9 and isomiR-9). 
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4.2.4 pMIR-miR-9 sponge with 6 multiple binding sites 
Subsequently, pMIR-miR-9 sponge with 6 MBS was co-transfected with either miR-
9, isomiR-9 or let-7d at increasing concentration from 4 nM to 20 nM (Figure 4.6). 
Overall miR-9 was better inhibitor of expression than isomiR-9, however, the results 
were not as convincing as previous results using vector with a single miR-9 binding 
site (Figure 3.8A).   
 
CDH1/miR9 mRNA target site in 3’UTR –  
      5’ AGTGCCTAAAGTGCTGCAG--CCAAAGA 3’ 
                     |||      |||||| 
miR-9      3’ AGTATGTCGATCTATTGGTTTCT 5’ 
                     |||      ||||| 
isomiR-9   3’ AGTATGTCGATCTATTGGTTTC  5’ 
                    |||       |||||| 
let-7d     3’  TTGATACGTTGGATGATGGAGA 5’ 
 
pMIR-miR-9 sponge (6MBS) 
 
Figure 4.6  
pMIR-miR-9 sponge with 6 MBS was co-transfected with either miR-9, isomiR-9 
or let-7d. Increasing concentration of miRNA (4, 8, 12, 16 and 20 nM) was 
transfected along with a fixed concentration of the pMIR-miR-9 sponge reporter 
vector (200ng). All results were normalised by renilla luciferase. Error bars represent 
the standard deviation obtained from three independent experiments (n=3). * indicate 
p value <0.05 (statistical difference is between miR-9 and isomiR-9). 
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4.2.5 pcDNA3.1(+) -miR-9 and –isomiR-9 sponges selectively absorb miR-9 and 
isomiR-9 respectively 
The multiple binding sites on the sponges described above may have compromised 
the ability of luciferase vectors to distinguish between miR-9 and isomiR-9 effects. 
Next, these RNA sponges were used for their intended purpose and were first 
introduced into expression vectors and then co-transfected along with a reporter 
vector and miRNA (Figure 4.7). 
 
MiR-9 sponge and isomiR-9 sponge regions (Figure 4.3) were excised from pUC57 
and ligated into pcDNA3.1(+) at EcoRI (Position 952)/ApaI (Position 1001) and 
HindIII (Position 911)/XbaI (Position 991) respectively. These pcDNA-miR-9 and 
pcDNA-isomiR-9 sponges expression vectors produce RNA sponges that have 6 
multiple binding sites and their expression are driven by a CMV promoter (Figure 
4.7A). Fixed amounts of pGL3-DNMT3B-3'UTR (400ng) and isomiR-9 (12 nM) 
were transfected together with either pcDNA-miR-9 sponge or pcDNA-isomiR-9 
sponge at different concentrations into HEK293 cells (Figure 4.7B). The experiment 
was repeated using pGL3-CDH1-3'UTR and miR-9 (Figure 4.7C). The control 
columns report pGL3 transfections only. The 0 ng columns show the results for the 
inhibition of the pGL3 vector by miR-9 (Figure 4.7B) or by isomiR-9 (Figure 4.7C). 
Figure 4.7B shows that the repression caused by miR-9 was alleviated by the 
introduction of 100 ng of miR-9 sponge but not by the isomiR-9 sponge. By contrast, 
isomiR-9 sponge partially alleviated the repression of isomiR-9 on DNMT3B-3’UTR 
but sponge miR-9 did not (Figure 4.7C). NCAM2 was also tested by these sponges 
(Figure 4.7D). Similarly, isomiR-9 sponge partially rescued the repression by isomiR-
9 on NCAM2-3'UTR whereas miR-9 sponge did not. 
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A) 
 
 
 
B)    pGL3-CDH1-3'UTR (400ng) and miR-9 (12 nM) 
 
 
C)    pGL3-DNMT3B-3'UTR (400ng) and isomiR-9 (12 nM) 
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D) pMIR-NCAM2-3'UTR (200ng) and isomiR-9 (12 nM) 
 
 
Figure 4.7   
Sponge inhibitors of miR-9 and isomiR-9. A) Structure of sponge constructs 
pcDNA-miR-9 sponge and pcDNA-isomiR-9 sponge. HEK293 cells were transfected 
with the indicated concentrations of sponge vectors and either B) pGL3-CDH1-3'UTR 
(400ng) and miR-9, C) pGL3-DNMT3B-3'UTR (400ng) and isomiR-9 or D) pMIR-
NCAM2-3'UTR (200ng) and isomiR-9. Control: Reporter vectors only. 0 ng: 
Indicates reporter vector and miR-9 or isomiR-9 (12 nM).  25 ng, 100 ng, 150 ng and 
200 ng are the amount of sponge DNA that was introduced. D) All results were 
normalised by renilla luciferase. Error bars represent the standard deviation obtained 
from three independent experiments (n=3). * indicate p value <0.05 (statistical 
difference is between miR-9 sponge and isomiR-9 sponge). 
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4.2.6 In search of a cell line that expresses DNMT3B or NCAM2 
To further test whether isomiR-9 could repress DNMT3B in an endogenous system, a 
cell line that expressed DNMT3B is required. Western blotting was performed to look 
for cell lines that express DNMT3B. Based on the limited number of cell lines that 
were tested, hESC was the only cell line that expresses DNMT3B protein (Figure 
4.8). As hESC is a hard to transfect cells, I screened for the presence of an alternate 
target of isomiR-9 NCAM2 and recently found LNCaP cell line (a human prostate 
adenocarcinoma derived from metastatic supraclavicular lymph node)(a gift from 
Alwyn Dart, member of Charlotte Bevan group) expresses NCAM2 protein (Figure 
4.8).    
 
 
Figure 4.8 
DNMT3B and NCAM2 protein expressions. 
A) Western blotting results of DNMT3B antibody (Santa Cruz, 97kDa) on the 
indicated cell lines. Ponceau staining of the western blot membrane was used as 
loading control. Orange band of the ColorPlus prestained protein ladder (NEB UK) 
represents 80kDa. B) NCAM2 western blotting on different cell lines. α-tubulin was 
used as loading control.  
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4.2.7 Infection is the preferred method of introducing miRNA into hESCs 
 
This experiment was designed to compare the efficiency of transfection and infection 
of hESCs. A red fluorescent tag miRNA mimic (Dharmacon) was used in the 
transfection and lentiviral infection was performed using PLVTHM, a lentiviral 
vector that expresses GFP. As expected, only an average of 5% of hESCs was 
transfected compared to 60% in HEK293 cells. In contrast, an average of 50% of 
hESCs was infected (Figure 4.9A) compared to 70% in HEK293 cells. There was 
therefore a 10-fold difference in efficiency between transfection and transduction of 
hESCs (Figure 4.9B).  
 
To be certain that hESCs were the actual cells that were infected, rather than just 
stromal or differentiated cells, pRRL-cPPT-PGK-dsred lentiviral vector that expresses 
red fluorescent protein was used to infect T5-Oct4 GFP transgenic hESCs. The 
rationale was that if the green cells also express red fluorescent protein then infection 
has occurred in the hESCs. In this experiment, 42% of the cells were infected were 
both red and green fluorescent, indicating that 42% of the infected cells were hESCs. 
This constitutes about 2/3 of the stem cell population (Figure 4.9C). This was 
confirmed by direct visualisation of cells expressing green and red fluorescent 
proteins with a fluorescent microscope (Figure 4.9E). This result shows miRNA 
sponges can be effectively introduced into hESCs by lentiviruses.    
 
It is important to note that lentivirus might not be a good way of introducing isomiR-9 
ectopic expression as they will be expressed in their primary or precursor form and 
therefore be subjected to the usual processing that will generate all other isomiRs 
including the canonical miRNA.  
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Figure 4.9 
Transfection and viral infection efficiency in HEK293 and hESCs. A) PLVTHM-
infected hESCs express GFP. B) Transfection was performed using red fluorescent 
tag miRNA mimic and infection using lentiviral vector that expresses GFP. Bar graph 
showed the percentage of cells that were transfected or infected. C) T5 Oct4-GFP 
transgenic hESCs were infected by PGK-RFP lentivirus. Bar graph showed the 
percentage of infected and non-infected hESCs and stromal cells. D) FACS analysis 
shows red and green compensation was performed before the evaluation of percentage 
of cells that have red and green colours. E) Red & green cells represent infected 
hESCs, red only cells represent infected stromal/ differentiated cells, green only cells 
represent uninfected hESCs and non-green/non-red cells represent uninfected stromal/ 
differentiated cells. Error bars represent the standard deviation obtained from two 
independent experiments (n=2). 
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4.2.8 Construction of a DNMT3B expressing vector 
Returning to the DNMT3B study, as hESCs are hard to transfect, in order to evaluate 
whether isomiR-9 can knockdown DNMT3B, I constructed a vector that expresses 
DNMT3B along with its 3' UTR. A plasmid containing the full length coding region 
of DNMT3B (2562bp) was obtained from addgene (Plasmid 35522: pcDNA3/Myc-
DNMT3B1) (Chen et al., 2005). The 3' UTR of DNMT3B was amplified from human 
genomic DNA (1560bp) by PCR and a full length DNMT3B with its 3' UTR was then 
constructed (see Materials and methods).  This gene was first ligated into pGEM-T 
easy vector and sequenced. Then DNMT3B 3' UTR was cloned into pcDNA3.1(+) 
between BamHI and XbaI sites. DNMT3B expression was confirmed by transfection 
of pcDNA-DNMT3B into HEK293 cells using HiPerfect (Figure 4.10). 
 
 
 
 
Figure 4.10 
Ectopic expression of DNMT3B in HEK293 cells. 400 ng of pcDNA-DNMT3B 
was transfected into HEK293 cells (lane 3) and protein was extracted using RIPA 
buffer after 48 hours. hESCs control and HEK cells control were in lane 1 and 2 
respectively. α-tubulin was used as loading control.  
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4.3 Discussion 
Here we show that it is possible to make sponge vectors that can distinguish between 
miR-9 and isomiR-9 (Figure 4.7), which adds further assurance that isomiRs can 
recognise different targets to canonical/ annotated miRNAs. In principle, this advance 
will allow us to test the biological significance of isomiR production by selective 
sequestration of isomiRs in appropriate model systems.   
 
As expected, miR-9 and isomiR-9 showed different targeting of the UTRs of CDH1 
and DNMT3B when these were cloned into a different luciferase vector (Figures 4.1 
and 4.2). However, it was more difficult to show selective targeting by the sponge 
regions with 6 target sites for CDH1 or DNMT3B (Figure 4.4 and 4.6), when these 
were cloned into a luciferase vector (Figures 4.4 to 4.6). Our analysis indicates that 
specificity can be lost by increases in the number of MBS and by the use of high 
concentrations of miRNAs (Figure 4.5).   
 
The sponge regions worked better when they were used as decoy mRNAs that 
sequestered miRNAs from the co-transfected luciferase vectors (Figure 4.7).  
Nevertheless, the results of Figures 4.4 to 4.6 indicate that the effectiveness of 
sponges in general is likely to be dependent upon the relative concentration of 
endogenous miRNA and sponge expression level (Figure 4.11). For sponges that are 
trying to distinguish between very similar miRNAs and isomiRs, it would seem 
particularly important not to express an excessive amount of decoy mRNA relative to 
miRNA levels.   
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Figure 4.11  
Sponges compete with target mRNA for binding with miRNA and the various 
outcomes as a result of the concentration differences between the miRNA and 
sponge. Long blue bar – target mRNA; short black bar – miRNA binding site; orange 
oval – protein; green pentAgon – endogenous miRNA; red cross – protein not 
produced; arrow – protein translation. In an environment where there is high level of 
miRNA concentration but low sponge expression, the most likely outcome is protein 
will not be produced. Conversely, if there is high sponge expression coupled with a 
low miRNA concentration, most invariably protein will be produced. The situation 
becomes unpredictable when there is either high level of both miRNA and sponge or 
low level of both miRNA and sponge. 
 
 
A miR-9 sponge can repress genes such as CDH1 in breast cancer (Ma et al., 2010) 
and FoxP1 in chick spinal cord (Otaegi et al., 2011). Sponges therefore might have 
therapeutic potential for cancer treatment. MiR-21 and miR-221, which target PTEN, 
are also overexpressed in a variety of tumours (Garofalo et al., 2011).  
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Our results show that an “isomiR-9 sponge” could specifically sequester isomiR-9 at a 
better efficiency than the canonical miR-9 with one base difference at the 5' end, and 
vice-versa. This shows that miRNA sponge could potentially be used to knockdown 
specific isomiRs. It would be interesting to investigate whether isomiR-9 or its sponge 
could be of therapeutic important in breast cancer cells that overexpress DNMT3B 
(Sandhu et al., 2012). 
 
In future, my plan is to investigate the biological effect of miR-9/isomiR-9 
knockdown in neural stem cells. This could be achieved by either introducing 
miR/isomiR-9 sponges directly into NSC or by first establishing stable transgene 
expression of a sponge in hESCs by lentiviral infection (Figure 4.9) and then 
proceeding to neural differentiation. Our results show that hESCs are hard to transfect, 
indicating that a lentiviral system will be the best way for sponge delivery. A previous 
study also showed that a lentiviral system gave better gene delivery, in comparison 
with transfection. Nucleofection is another alternative but it was associated with low 
survival rate (Cao et al. 2010). 
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Chapter 5 MicroRNA 302 cluster and somatic cell 
reprogramming 
 
5.1 Introduction 
The polycistronic miR-302 cluster encodes five miRNA genes that have an important 
role in the regulation of embryonic stem function. These five miRNA genes include 
miR-302a, b, c and d, and miR-367.  The cluster is located on chromosome 4 (Figure 
5.1) within an intron of and in the opposite orientation to the gene LARP7, which 
unlike the miR-302 cluster is ubiquitously expressed. Most functional studies have 
been of miR-302a as this is generally consider as the functional guide strand and has a 
common seed region with other members of this cluster, namely miR-302b, c and d 
(Rosa et al., 2009; Rosa et al., 2011; Barroso-delJesus et al., 2011). Inhibition of miR-
302 in stem cells resulted in the downregulation of pluripotency markers and vice 
versa (Rosa et al., 2009). Furthermore, global loss of miRNA in DGCR8 deficient 
stem cells resulted in defects in proliferation and differentiation (Gangaraju et al., 
2009).  
 
Figure 5.1 
The polycistronic miR-302 cluster is conserved. Image was taken from UCSC 
Genome Browser website (http://genome.ucsc.edu/cgi-bin/hgTracks? 
hgsid=280340015). 
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Table 5.1 lists a collection of sequencing data of members of the miR-302 cluster 
from 5 different sources, including ours (Suh et al., 2004; Bar et al., 2008; Morin et 
al., 2008; Lipchina et al., 2011; Chan, unpublished). The differences in expression 
levels of miRNAs such as miR-302a to d and miR-367 that are transcribed from the 
same promoter is an interesting feature of many miRNA clusters (Table 5.1).   
 
Source 
Suh et al., 
2004 
Bar et al., 
2008 
Morin et al.,  
2008 
Lipchina et al., 
2011 
Chan 
unpublished 
Species/ 
Methods 
Human 
Human 
454 
Human 
Illumina 
Human 
454 
Human 
Solexa 
Human 
Solexa 
302a 0.219 0.045 0.519 0.406 0.062 0.037 
302a* 0.057 0 0.074 0 0.330 0.838 
302b 0.429 0.402 0.214 0.015 0.255 0.041 
302b* 0.019 0 0.005 0 0.007 0.002 
302c 0.095 0.120 0.055 0.059 0.087 0.024 
302c* 0.009 0 0.008 0 0.012 0 
302d 0.124 0.433 0.121 0.244 0.080 0.027 
302d* 0.048 0 0.004 0 0.002 0.016 
367 0 0 0 0.276 0.164 0.015 
367* 0 0 0 0 0.001 0 
 
Table 5.1 
Comparison of the fraction between members of miR-302 cluster (302a, 302a*, 302b, 
302b*, 302c, 302c*, 302d, 302d*, 367 and 367*) in human embryonic stem cells of 
selected publications. Numbers that are highlighted in grey denote the most highly 
sequenced miRNA in the cluster. The numbers are expressed as fractions of the total 
sequencing reads. 454, Illumina and Solexa represent the sequencing platforms that 
were used in the deep sequencing.  
 
 
MiRNA* is derived from the opposite arm to the guide strand in the precursor 
miRNA, and is usually detected at lower frequency than the guide stand miRNAs 
(Bartel, 2004; Lagos-Quintana et al., 2002; Aravin et al., 2003; Lim et al., 2003). 
Interestingly, our sequencing results revealed that miR-302a* was the most highly 
sequenced miRNA in human embryonic stem cells from the miR-302 cluster, some 20 
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fold more than the guide strand of miR-302, Lipchina et al., (2011) also reported that 
miR-302a* was the most highly sequence miRNA (Table 5.1).   
 
Overall, we found that miRNA* strands were, as expected, expressed at much lower 
frequencies in all 3 stem cell lines (Figure 5.2). Across the three cell types, on average 
5.8% of miRNA genes expressed only the star strand and 16.6% expressed both 
miRNA/miRNA* (Figure 5.2 and Table 5.2). Intriguingly, there were cell lines that 
expressed only the opposite strands, for example hESCs expressed miR-30e* only, 
while NSCs expressed miR-30e only (Table S5.1).  
 
 
 
Cell types Star only (%) Guide and Star (%) Guide only (%) 
hESC 4.8 15.8 79.4 
NSC 5.3 6.7 88 
MSC 7.4 27.3 65.3 
Average 5.8 16.6 77.6 
 
Figure 5.2 and Table 5.2  
Figure and table illustrate the percentage of miRNA genes that encode only guide, star 
or both miRNA strands in the deep sequencing results of combined human embryonic 
stem cells, neural stem cells and mesenchymal stem cells. The deep sequencing 
experiment was performed by Elcie Chan (unpublished). hESC – Human embryonic 
stem cells; NSC – Neural stem cells; MSC – Mesenchymal stem cells.  
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Recently, miRNA* was reported to be associated with Ago protein (Okamura et al., 
2008), which is consistent with my northern blotting results where miR-302a* was 
detected in Ago 1 and 2 immunoprecipitations (Figure 3.4). Similarly to our deep 
sequencing data, Jagadeeswaran et al., (2010) observed that some miRNA* were 
expressed at a higher level than the corresponding guide strands (Table S5.1). 
Consequently, miRBase has replaced the star sign with either miR-5p or -3p. As 
expected, target prediction studies showed that the mRNA targets of  opposite arms 
differ significantly (Griffiths-Jones et al., 2011). The star sequence of miR-367 has 
only been detected at a low level in all sequencing studies (Table 5.1), indicating that 
it is far less likely to have a biological function compared to miR-302a* or miR-
302d*. 
 
Forced expression of the miR-302 cluster can reprogram somatic cells to pluripotent 
stem cells or can enhance the production of stem cells by OSKM factors. Table 5.3 
lists the various strategies that have been used to generate iPSCs through the use of 
miRNAs, and also shows the estimated efficiencies, where available. Some of the 
efficiency levels that are reported are orders of magnitude greater than the the OSKM 
method (Anokye-Danso et al., 2011). Induced pluripotent stem cells (IPSCs) could 
potentially be used as: disease models, for example, spinal muscular atrophy (Ebert et 
al., 2009) and LEOPARD syndrome (Carvajal-Vergara et al., 2010); drug testing and 
regenerative medicine (Wu et al., 2011). The mechanism by which stem cells can be 
reprogrammed from somatic cells is an area of great interest. For the miR-302 cluster 
it would appear that the expression of miR-302a and miR-367 is important (Anokye-
Danso et al., 2011) but the potential contribution of the miR-302a* has not been 
addressed.  
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Recently, in addition to IPSCs, there were reports of miRNA-mediated conversion of 
fibroblasts to neurones (miR-9/9*, miR-124 and NeuroD2; Yoo et al., 2011) and 
cardiomyocytes (miR-1, miR-133, miR-208 and miR-499; Jayawardena et al., 2012). 
Here, a miR-302 cluster lentivirus was constructed in order to test the reproducibility 
of somatic cell reprogramming and then to use this technology to investigate the 
mechanism of reprogramming by the miR-302 cluster. We also wanted to find out 
whether the star/ passenger strand of miR-302a is important for somatic cell 
reprogramming 
 
 
 
Table 5.3 
List of publications in somatic cell reprogramming using miRNAs (Taken from Tan et 
al., 2012) 
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5.2 Results 
 
5.2.1 Characteristics of miR-302 cluster  
Table 5.4 shows that miR-302a to d have a common seed region, which is different to 
the conserved seed regions of the star miRNAs. MiR-367 has a distinctive seed region 
that is conserved with other species (Figure 5.1).   
Mature miRNA sequence MiRNA name 
UAAGUGCUUCCAUGUUUUGGUGA hsa-miR-302a-3p MIMAT0000684 
UAAGUGCUUCCAUGUUUUAGUAG hsa-miR-302b-3p MIMAT0000715 
UAAGUGCUUCCAUGUUUCAGUGG hsa-miR-302c-3p MIMAT0000717 
UAAGUGCUUCCAUGUUUGAGUGU hsa-miR-302d-3p MIMAT0000718 
  
ACUUAAACGUGGAUGUACUUGCU hsa-miR-302a-5p/ 302a* 
MIMAT0000683 
ACUUUAACAUGGAAGUGCUUUC hsa-miR-302b-5p/ 302b* 
MIMAT0000714 
UUUAACAUGGGGGUACCUGCUG hsa-miR-302c-5p/ 302c* 
MIMAT0000716 
ACUUUAACAUGGAGGCACUUGC hsa-miR-302d-5p/ 302d* 
MIMAT0004685 
  
AAUUGCACUUUAGCAAUGGUGA hsa-miR-367-3p MIMAT0000719 
ACUGUUGCUAAUAUGCAACUCU hsa-miR-367-5p/ 367* 
MIMAT0004686 
 
Table 5.4 
Table lists the members of miR-302 cluster with emphasis on the seed sequence 
difference between the guide and star strands. Highlighted sequences denote seed 
region. Yellow represents the common seeds for miR-302a/b/c/d. Light blue 
represents the common seed for miR-302a*/b*/c*/d* and miR367*. Green represents 
the seed region of miR-367. Grey areas represent variation of sequences between 
miRNAs.  
 
Table 5.5 lists the numbers of predicted targets of each member of the miR-302 
cluster and Figure 5.3 shows which of these targets are in common. The SP3 
transcriptional factor is a predicted target of five miRNAs including miR-302a* and 
was selected for further investigation, largely because studies suggest that SP3 binds 
to the promoter region of Oct4 and Nanog genes and might regulate their expression 
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(Pesce et al., 1999; Wu et al., 2006). ZNF148 gene was of interest as there are 
miRNA binding sites in its UTR for miR-302a/b/c/d, miR-302a* and miR-367 
(Figure 5.3 and Table S5.2). In figure 5.3, the Venn diagram shows target predictions 
of miR-302a/b/c/d (similar seed region – see table 5.4), miR-302a*, miR-302b*/d* 
and miR-367. MiR-302c* and miR-367 were not analysed because the deep 
sequencing reads for these two miRNAs were zero (see table 5.1). These miRNAs 
represent 3 of the most abundantly express miRNAs in the cluster. In addition, 3 
different databases independently predicted that SP3 is a target of miR-302a* (Figure 
S5.1). 
MiRNA Number of targets 
302a=302b=302c=302d 445 
302b*=302d* 405 
302a* 361 
302c* 483 
367  567 
367* 125 
 
Table 5.5  
Table shows the total number of predicted targets of members of the miR-302 cluster. 
Target prediction was performed using Targetscan Custom Human 4.1. 
 
 
Figure 5.3 
Venn diagram shows the number of predicted targets that are either shared by or 
unique to the members of the miR-302 cluster. SP3 is a target common to miR-
302a/b/c/d and miR-302a*. ZNF148 is a target common to miR-302a/b/c/d, miR-
302a* and miR-367. BCL11B is a target that is common to all 4 groups of miR-302 
cluster. Targets that are in common are listed in Table S5.2. 
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5.2.2 Target evaluation of SP3 and ZNF148 reporters by luciferase assays  
To test whether miR-302a* can repress its predicted targets, SP3 and ZNF148 
luciferase reporters were constructed. A segment of SP3 and ZNF148 3'UTRs were 
amplified and ligated to pGEM-T easy vector and sequence verified. Finally, SP3-
3'UTR (795bp) was cloned into Xba I and Fse I sites at positions 1934 and 1953 of 
pGL3 control vector (Figure 5.4A and Figure S2.2). While ZNF148-3'UTR (429bp) 
was cloned into Spe I and Sac I sites at positions 525 and 519 of pMIR report vector 
(Figure 5.5A and Figure S5.2).  
 
MiR-302a* was unable to consistently repress SP3, even at different miRNA 
concentrations (Figure 5.4B). Again, as seen earlier in figure 3.8A, the luciferase 
activity increased after transfection with let-7d (Figure 5.4). In ZNF148, at 4 nM the 
repression was slight >10% but the difference from let-7d was only marginally 
significant (p value = 0.049). There was no statistical difference between miR-302a* 
and let-7d at 12 nM and 20 nM (Figure 5.5B).  
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A 
 
 
B 
5’.CCUGUUGAAAAGCCAUGUUUAAGAU..3’ SP3-3’UTR 
                ||o||||||| 
3’  UCGUUCAUGUAGGUGCAAAUUCA   5’ miR-302a* /302a-5p 
                   |||o||| 
3’   UUGAUACGUUGGAUGAUGGAGA   5’ let-7d      
 
   
 
 
 
Figure 5.4 SP3 3'UTR reporter assay 
A) In pGL3 vector, the luciferase expression is driven by SV40 promoter. SP3 3' UTR 
was inserted downstream to the luciferase sequence. B) pGL3-SP3-3'UTR was co-
transfected with miR-302a* or let-7d into HEK293 cells. Relative activity of the 
firefly luciferase for SP3 reporter was plotted against increasing concentrations of 
miR-302a*. Control denotes transfection of reporter vector only. Error bars represent 
the standard deviation obtained from six independent experiments (n=6) for SP3 and 
three independent experiments (n=3) for let-7d. All results were normalised by renilla 
luciferase. 
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A 
 
 
B 
5’..GUUUUUACAGCUUGUUUUUAAGAAU..3’ ZNF148-3’UTR 
                    |||||| 
3’  UCGUUCAUGUAGGUGCAAAUUCA    5’ miR-302a* /302a-5p 
                    ||o||| 
3’   UUGAUACGUUGGAUGAUGGAGA    5’ let-7d      
 
 
 
 
Figure 5.5 ZNF148 3'UTR reporter assay 
A) In pMIR vector, the luciferase expression is driven by CMV promoter. ZNF148 3' 
UTR was inserted downstream to the luciferase sequence. B) pMIR-ZNF148-3'UTR 
was co-transfected with either miR-302a* and let-7d into HEK293 cells. Relative 
activity of the firefly luciferase for ZNF148 reporter was plotted against increasing 
concentration of miRNAs. Control denotes transfection of reporter vector only. Error 
bars represent the standard deviation obtained from three independent experiments 
(n=3). All results were normalised by renilla luciferase. * indicate p value is <0.05 
(statistical difference is between miR-302a* and let-7d). 
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5.2.3 Construction of a lentiviral vector that expresses miR-302 cluster 
MiR-302 cluster comprising of miR-302b, miR-302c, miR-302a, miR-302d and miR-
367, accompanied by 120bp upstream and 150bp downstream of the cluster (975bp) 
was amplified by PCR from human genomic DNA (Figure S5.3). The amplified 
fragment was ligated into pGEM-T easy vector and verified by sequencing. Finally, it 
was cloned into XhoI and MluI sites at position 3806 and 4064 of pTRIPz inducible 
lentiviral vector (Figure 5.6 and Figure S5.4).  
 
As this vector has a red fluorescent protein (RFP) marker, the pTRIPz-302 cluster 
lentivirus was first tested by infecting HEK293 (human embryonic kidney) and 
MRC5 (human lung fibroblasts) cells to observe for RFP. Doxycycline induced, 
lentiviral infected HEK293 and MRC5 cells expressed RFP (Figure 5.7A). 
Subsequently, northern blots of total RNAs collected from the infected HEK293 and 
MRC5 cells showed miRNA expressions from members of the miR-302 cluster, i.e., 
miR-302a, miR-302a* and miR-367 (Figure 5.7B).  
 
 
Figure 5.6 
MiR-302 cluster in the pTRIPz-miR-302 cluster lentiviral vector is driven by minimal 
CMV with tetracycline response element. Its expression can be monitored by turbo 
red fluorescent protein expression. 120 and 150 represent the length of nts extended 
upstream and downstream from the miR-302 cluster gene. MinCMV – Minimal 
cytomegalovirus promoter; tRFP – turbo red fluorescent protein; miR-302cl – miR-
302 cluster; UBC – Ubiquitin promoter; rtTA3 – Reverse transactivator; IRES – 
Internal ribosome entry site; PURO – Puromycin.  
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Figure 5.7  
MiR-302 cluster expression in HEK and MRC5 cells 
A) HEK and MRC5-infected cells expressed RFP after induction with doxycycline.  
B) Northern blots of infected HEK and MRC5 cells were probed for miR-302a, miR-
367 and miR-302a*. rRNA stained with ethidium bromide was used as loading 
control. hESCs- human embryonic stem cells; NSCs- neural stem cells; HEK- human 
embryonic kidney cells; 302cl- miR-302 cluster; Ctr-Control. 
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5.2.4 Evaluation of miR-302 cluster in the reprogramming of human lung 
fibroblasts 
To test the potential of miR-302 cluster in somatic cell reprogramming, MRC5 cells 
were infected with the pTRIPz-302 cluster lentivirus and cultured in hESC conditions 
(matrigel coated plate and MEF-conditioned media). Cell colonies started to appear 6 
to 8 weeks after infection (Figure 5.8A). This was seen in 2 out of 5 attempts.  
 
These cells expressed RFP (Figure 5.8B), formed colonies (Figure 5.8C) and were 
faintly positive toward alkaline phosphatase (Figure 5.8D). In addition, RT-PCR 
showed these cells expressed low level of DNMT3B and Nanog, equivocal Oct4 and 
Lin28, but they did not express Sox2 (Figure 5.9), suggesting that they were not fully 
reprogrammed. This might be due to the low level of miR-302 cluster expression by 
pTRIPz-302 cluster in MRC5 cells.  
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Figure 5.8  
pTRIPz-302 custer lentivirus infection in MRC5 cells 
MRC5 cells were infected with pTRIPz-302 cluster lentivirus, cultured in hESCs 
condition. Cell colonies appeared approximately 6-8 weeks after infection. A) Cell 
colonies at day 1, day 3 and day 5 from the day of appearance. Black arrows show 
cells forming colony. B) These cells expressed red fluorescent protein indicates that 
they were infected. C) Comparison of the morphology between the colony and hESCs 
colony. D) Alkaline phosphatase staining of the cell colonies and hESCs. 
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Figure 5.9  
Comparison of pluripotency gene expressions between hESCs and infected 
MRC5 
Total RNAs were extracted from wild type/ control and pTRIPz-302 cluster virus 
infected MRC5 cells with and without reverse transcription. The pluripotency genes 
were compared between the MRC5 cells and hESCs. Ctr- Control; 302cl- 302 cluster; 
RT- reverse transcription. 
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5.3 Discussion 
For some miRNA genes, strand switching occurs during development so that the star 
strand becomes the dominant miRNA (Griffith-Jones et al., 2011), which is 
presumably reflective of our observation that about 6% of the miRNAs that we 
sequenced expressed the star strand rather than the guide strand listed in miRBase 
(Figure 5.2). We only sequenced miRNA from three cell types, which raises the 
possibility that the star strand of other miRNA genes might be more expressed in a 
different cell background. Our sequencing data also shows that some 15% of miRNA 
genes that are expressed in our libraries make substantial amounts of both the guide 
and star strand. Overall we suspect that star strand production is currently 
underestimated.  
 
Several star strands have been established to be functional (Okamura et al., 2008; Qu 
et al, 2012), however, as yet there have been no publications as to the function of 
miR-302a*. The high level of expression of miR-302a* (Table 5.1) suggests that it is 
likely to have an important function in stem cells and it may also be important for the 
induction of stem from somatic cells, as our results indicate that miR-302a* is likely 
to have been produced by vectors previously used in iPSC studies (Figure 5.7B and 
Table 5.3).   
 
I found that miR-302a* was able to repress ZNF148 at 4 nM, although the repression 
was not that convincing because the repression was inconsistent at higher miRNA 
concentrations (Figure 5.5). For this reason we did not undertake a mutational 
analysis in order to validate target specificity. It might be of interest to test whether 
the guide strands of miR-302a can repress the expression of ZNF148, alone or in 
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combination with miR-302a*, as there are target sites for miR-302a and 302a*. The 
mRNA encoded by SP3 was also not clearly inhibited by miR-302a*, despite 
predictions to the contrary (Figure 5.4).   
 
To date, three groups have successfully reprogrammed somatic cells to a pluripotent 
state by using miRNA alone (Lin et al., 2008; Anokye-Danso et al., 2011; Miyoshi et 
al., 2012). Other groups have shown that miRNAs can enhance reprogramming by 
OSKM factors (Oct4, Sox2, Klf4 and Myc) (Liao et al., 2011; Subramanyam et al., 
2011). Anokye-Danso et al., (2011) reported that they have achieved a 
reprogramming efficiency with miR-302 cluster alone that was 2 orders of magnitude 
higher than conventional reprogramming using OSKM factors. In addition, somatic 
cell reprogramming was successfully performed using mature miRNA by simple 
transfection (Myoshi et al., 2011).  
 
Our data shows that pTRIPz-302 cluster did not fully reprogram the human lung 
fibroblasts to a pluripotent state, probably due to low miRNA expression. In the Lin et 
al., (2011) paper, the authors show that reprogramming of human hair follicle cells 
would only take place above a certain level of miRNA expression, approximately 1.5 
fold of the miRNA expression in hESCs. Although we achieved a high level of 
expression of the miR-302 cluster in HEK293 cells, expression in MRC5 cells was 
relatively low (Figure 5.7). A high expression constitutive vector is perhaps a better 
choice to use in this study.  
 
Relatively little is known about the regulation of pluripotency and differentiation of 
stem cells by the mir-302a cluster. Rosa et al., (2011) reported that NR2F2, an 
inhibitor of Oct4 was a target of miR-302a. They showed that both Oct4 and miR-
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302a directly repress NR2F2, and regulate the maintenance of pluripotency and 
differentiation of ES cells. Notably, NR2F2 was a predicted target of miR-302a as 
well as miR-302a* by TargetScan Human (Table S5.2). SP3 is a possible inhibitor of 
Oct-4 and Nanog transcription factors (Pesce et al., 1999; Wu et al., 2006). Although 
SP3 is a predicted target of miR-302a* we were unable to confirm this.   
 
Lin et al., (2011) attributed reprogramming by the miR-302a cluster to was global 
demethylation due to the repression of epigenetic regulators such as AOF1, AOF2, 
MECP1-p66 and MECP2. They found that expression of the miR-302 cluster 
repressed the above mentioned proteins, accompanied by the appearance of 
pluripotency associated proteins and global demethylation. Other targets of the miR-
302 cluster that might be involved in the maintenance of pluripotency and 
differentiation include lefty1 and lefty2 (Rosa et al., 2009), CDKN1A; p21, Cyclin D1, 
BTG1, BTG2 and BTG3 (Wang et al., 2008; Card et al., 2008), RHOC and TGFb 
(Subramanyam et al., 2011), and PTEN (Sun et al., 1999; Lipchina et al., 2011).  
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Chapter 6 General Discussion 
 
6.1 Star strands and isomiRs 
The advent of deep sequencing has resulted in the discovery of large numbers of new 
miRNAs (Suh et al., 2004; Morin et al., 2008; Lipchina et al., 2011) with over 1600 
entries for human miRNA genes in the most recent version of miRBase (Griffith-
Jones., 2004). In parallel, the development of bioinformatics programs (Table 1.2) 
allows genome wide prediction of the mRNA targets of miRNAs (Lewis et al., 2005). 
Although the prediction programs are not entirely accurate (Ritchie et al., 2009), it is 
becoming increasingly feasible to test such predictions experimentally through the use 
of new technologies such as PAR-CLIP (Lipchina et al., 2011). These developments 
have opened up the ability to undertake genome scale investigation of miRNA 
regulation.   
 
Star strands and isomiRs are emerging features of miRNAs that may in future become 
incorporated into the predictive and functional studies described above. Until recently 
the star strand has been considered to be a by-product that is degraded (Schwarz et al., 
2003). However, it is now clear that miRNA* sequences are often highly expressed 
and associated with RISC proteins (Okamura et al., 2008). Indeed we found that miR-
302a* and miR-9* were amongst the most highly expressed miRNAs in our database. 
Several papers have reported functional roles for miRNA star strands (Okamura et al., 
2008; Yoo et al., 2011). The overall importance of star strands is strongly supported 
by the observation of arm-switching between cell types, where particular tissues 
switch to making more of the star strand than the guide miRNA (Ro et al., 2007; Ruby 
et al., 2007; de Wit et al., 2009; Chiang et al., 2009; Griffiths-Jones et al., 2011). 
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Arm-switching also occurs during evolution, where certain species switch to making 
the star strand of a miRNA (Griffith-Jones et al., 2011). These observations strongly 
indicate that the expression of some star strands have been selected during evolution, 
strongly indicating that they are functionally important.  
      
I observed that about 5.8% of the miRNAs we sequenced were star strands rather than 
guide strands, which is comparable with other studies (Lagos-Quintana et al., 2002; 
Aravin et al., 2003; Lim et al., 2003; Bartel, 2004). However this is probably an 
underestimate of star strand importance because it does not take into account possible 
star strand production by different tissues or the evolutionary possibility that some 
guide strands were originally star strands.   
 
6.2 IsomiRs and evolution 
IsomiRs can also be highly expressed and are associated with the RISC complex 
(Cloonan et al., 2011; see Chapter 3). The publication by Fukunaga et al., (2012) is 
perhaps the only publication to experimentally establish the functional importance of 
two isomiRs of Drosphila, which show tissue specific expression. However, the 
identification of arm switching is an alternative approach that has contributed strongly 
to the evidence of the functional importance of star strands (see above). I suggest that 
the same approach can be adapted for isomiRs, essentially by looking for changes in 
isomiR production between closely related miRNA genes, tissue types or species. For 
example, Figure 6.1 illustrates that the dominant miRNA for hsa-miR-500a is 
AUGCACCUGGGCAAGGAUUCUG, whereas the dominant miRNA for hsa-miR-
502 looks like a 5’/3’ isomiR with the sequence 
AAUGCACCUGGGCAAGGAUUCA. These are the sequences for the two miRNA 
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genes that are listed in miRBase. Figure 6.1 illustrates that hsa-miR-500a and 502 are 
within the same cluster and encode very similar miRNAs, indicating that they most 
probably arose by duplication during evolution. It can be seen that both genes make 
many similar isomiRs but express different isomiRs at the highest level. The most 
straightforward explanation of Figure 6.1 is that all of the isomiRs are functional and 
that the two genes have evolved in order to express two isomiRs in particular, 
suggesting that both isomiRs are selectively advantageous and therefore biologically 
important. The example in Figure 6.1 was identified by using miRBase to look at the 
sequencing details of a list of 31 miRNA clusters (Yu et al., 2006). In addition I found 
two other clusters from the total of 31 that were screened that showed evidence of 
isomiR switching (Figure S6.1 and S6.2).   
 
Similarly, I noted that the dominant isomiR of 9-1 that is expressed by 
megakaryoblasts has the sequence UCUUUGGUUAUCUAGCUGUAUGA, whereas 
the dominant isomiR expressed by a brain sample has the sequence 
UUGGUUAUCUAGCUGUAUGA (miRGator database, samples 1 and 5; Cho et al., 
2012). It should be noted that I have not confirmed this sequencing data by an 
independent experimental approach. Nevertheless, the bioinformatics analyses I have 
done so far illustrate that this is a promising approach towards testing whether 
isomiRs are of biological and evolutionary importance.   
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hsa-miR-500a 
 
 
 hsa-miR-502 
 
 
 
 
Figure 6.1  
miR-500a and miR-502 are located in the same cluster and have mature sequence that 
are almost similar to each other with one or two bases different in the 5' and 3' ends. 
Deep sequencing results were taken from miRBase (August 2012, Griffith-Jones et al., 
2004) and human genome map was taken from UCSC genome browser. 
155 
 
6.3 IsomiR expression 
My northern blots findings were similar to the deep sequencing results of others in 
that the most dominant isomiRs varies between tissue types (Figure 3.3) (Fernandez-
Valverde et al., 2010) and were able to associate with Argonaute proteins (Figure 3.4) 
(Burrough et al., 2011). My results that cross-referenced the predicted targets of 
isomiRs and canonical/ annotated miRNAs show only a small fraction of them have 
common targets (22%, see Figure 3.6 and Table S3.4). This reveals that large number 
of miRNA targets might have been missed as isomiRs were not included in the 
prediction of a miRNA, because only the annotated mature sequence is used in the 
prediction (TargetScan Human, Lewis et al., 2005).  
 
My experimental studies did not establish whether the inhibition of DMNT3B or 
NCAM2 by isomiR-9 is of biological significance. They do however support the 
prediction that minor changes at the 5' end of miRNAs can have a major impact upon 
mRNA targeting. It remains to be seen whether natural selection is more likely to 
select conservative 5' isomiRs that target a similar set of mRNAs to the canonical 
miRNA, as suggested by Cloonan et al., 2011. Alternatively, tissue specific 
expression of isomiRs might allow a very different set of mRNAs to be targeted 
(Fukunaga et al., 2012).  
 
In future, it might be interesting to observe the effect of isomiR-9 knockdown. As 
neural stem cells express high level of miR-9 and isomiR-9 (Table S3.1, Figure 3.5C), 
it is a good candidate to investigate the biological effect of isomiR-9 knockdown. This 
could be achieved by loss-of-function study using RNA sponge that we have 
developed (Figure 4.3). A lentiviral isomiR-9 sponge expression vector could be used 
156 
 
to introduce a sponge vector into NSCs or I could first establish stable transgene 
expression of a sponge in hESCs prior to neural differentiation. In addition, the effect 
of isomiR-9 knockdown could also be tested in a transgenic animal. Further studies 
are needed to test the function of miR-302a* in hESCs, where this miRNA is very 
abundant (Table S3.1).  
 
6.4 NCAM2 and Prostate Cancer 
NCAM2 is highly expressed in the brain and at low levels in various adult tissues 
including prostate, ovary, liver, kidney, pancreas and spleen (Paoloni-Giacobino et al., 
1997). My finding of NCAM2 expression in androgen-dependent LNCaP but not in 
androgen-independent PC3 and DU145 prostate cancer cell lines (Figure 4.8) are 
consistent with a previous study (Takahashi et al., 2011). In future, it would be 
interesting to further investigate the interaction between isomiR-9 and NCAM2.  
 
6.5 Conclusion 
Overall my results support the bioinformatics prediction that single nucleotide 
changes at the 5' end of a miRNA are likely to generate functionally significant new 
targets, which was again supported by the RNA sponge experiment. Out of 17 
miRNA target tests that I made based upon the bioinformatics predictions, 5 were 
incorrect, giving a 29.4% false positive or negative predictions, suggesting the target 
prediction is fairly reliable. This project supports the observation that isomiRs are 
functionally significant and more importantly may have very different targets to the 
canonical/ annotated miRNA. This suggests that the regulation of cellular processes 
by miRNA is far more complex than previously thought. This project also provides a 
good platform for future studies into the biological significant of isomiRs.
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Appendix 
 
 
 
 hESC NSC MSC 
hsa-miR- Sequence SN Sequence SN Sequence SN 
7 
  
TGGAAGACTAGTGATTTTGTTGTT 112 
  
   
TGGAAGACTAGTGATTTTGTTGT 31 
    
      9    TCTTTGGTTATCTAGCTGTATGA 587    
   
CTTTGGTTATCTAGCTGTATGA 116 
  
   
TCTTTGGTTATCTAGCTGTATG 49 
  
   
TCTTTGGTTATCTAGCTGTATGAA 37 
  
   
CTTTGGTTATCTAGCTGTATGAA 15 
  
   
TCTTTGGTTATCTAGCTGTAT 13 
  
   
TCTTTGGTTATCTAGC 13 
  
   
TTTGGTTATCTAGCTGTATGA 10 
     
     9*     ATAAAGCTAGATAACCGAAAGT 643    
   
TAAAGCTAGATAACCGAAAGTA 216 
  
   
ATAAAGCTAGATAACCGAAAGTA 145 
  
   
TAAAGCTAGATAACCGAAAGT 71 
  
   
TAAAGCTAGATAACCGAAAGTAT 66 
  
   
TAAAGCTAGATAACCGAAAGTAA 53 
  
   
ATAAAGCTAGATAACCGAAAGTAT 28 
  
   
ATAAAGCTAGATAACCGAAAG 19 
  
   
ATAAAGCTAGATAACCGAAAGTAA 14 
  
   
ATAAAGCTAGATAACCGAAA 10 
    
      10a    TACCCTGTAGATCCGAATTTGT 14 TACCCTGTAGATCCGAATTTGT 13 
  
  
TACCCTGTAGATCCGAATTTGTG 
 
ACCCTGTAGATCCGAATTTGTG 8 
  
    
ACCCTGTAGATCCGAATTTGT 4 
  
    
TACCCTGTAGATCCGAAT  3 
  
    
TACCCTGTAGATCCGAATTTGTG 3 
  
    
ACCCTGTAGATCCGAATTTG 1 
  
    
ACCCTGTAGATCCGAATT  1 
  
    
TACCCTGTAGATCCGAATT  1 
  
    
CCCTGTAGATCCGAATTTGTG  1 
  
      10a*       CAAATTCGTATCTAGGGGAAT  2 
    
   
CAAATTCGTATCTAGGGGAATA 
    
15a     TAGCAGCACATAATGGTTTGTG 12 TAGCAGCACATAATGGTTTGTG 24 
  
  
TAGCAGCACATAATGGTTTGT 12 TAGCAGCACATAATGGTTTGT  4 
  
      15b       TAGCAGCACATCATGGTTTACA  101 
  
    
TAGCAGCACATCATGGTTTAC  31 
  
    
TAGCAGCACATCATGGTTTACAT  4 
  
    
TAGCAGCACATCATGGTT  2 
  
    
TAGCAGCACATCATGGTTTA  2 
  
    
TAGCAGCACATCATGGT  1 
  
      16-2*       ACCAATATTACTGTGCTGCTTTA 4 
  
    
CCAATATTACTGTGCTGCTTTA 2 
  
    
ACCAATATTACTGTGCTGCTTT  1 
  
    
CCAATATTACTGTGCTGCTTT  1 
  
    
ACCAATATTACTGTGCTG  1 
  
      16 TAGCAGCACGTAAATATTGGCG 19 TAGCAGCACGTAAATATTGGCG 107 TAGCAGCACGTAAATATTGGCG  47 
  TAGCAGCACGTAAATATTGGCGT 11 TAGCAGCACGTAAATATTGGCGT 43 TAGCAGCACGTAAATATTGGCGT  32 
  
    
TAGCAGCACGTAAATATTGGC  25 
  
    
TAGCAGCACGT 3 
  
    
TAGCAGCACGTAAATATTG  1 
  
    
TAGCAGCACGTAAATATT  1 
  
    
TAGCAGCACGTAAA  1 
  
    
TAGCAGCACGTA 1 
  
    
AGCAGCACGTAAATATTGGCGT  1 
  
      17 CAAAGTGCTTACAGTGCAGGTAG 39 CAAAGTGCTTACAGTGCAGGTAG 41 CAAAGTGCTTACAGTGCAGGTAG 111 
  CAAAGTGCTTACAGTGCAGGT 19 
  
CAAAGTGCTTACAGTGCAGGTA  8 
  
    
CAAAGTGCTTACAGTGCAGGTAGT  3 
  
    
TCAAAGTGCTTACAGTGCAGGT  3 
  
    
CAAAGTGCTTACAGTGCAGGT 1 
  
    
TCAAAGTGCTTACAGTGCAGGTA  1 
  
      18a       TAAGGTGCATCTAGTGCAGATAG  11 
  
    
TAAGGTGCATCTAGTGCAGAT  4 
  
      19b TGTGCAAATCCATGCAAAACTGA 10 TGTGCAAATCCATGCAAAACTGA 11 TGTGCAAATCCATGCAAAACTGA  14 
  
    
TGTGCAAATCCATGCAAAACTG  1 
  
    
GTGCAAATCCATGCAAAACTGA  1 
  
      20a    TAAAGTGCTTATAGTGCAGGTAG 10 TAAAGTGCTTATAGTGCAGGTAG  2 
  
    
TAAAGTGCTTATAGTGCAGG  1 
  
      20a*       ACTGCATTATGAGCACTTAAAGT 1 
  
    
ACTGCATTATGAGCACTTAAAG  
   
      20b CAAAGTGCTCATAGTGCAGGTAG 33       
  
      21 TAGCTTATCAGACTGATGTTGAC 324 TAGCTTATCAGACTGATGTTGAC 2452 TAGCTTATCAGACTGATGTTGAC  496 
  TAGCTTATCAGACTGATGTTGA 80 TAGCTTATCAGACTGATGTTGA 462 TAGCTTATCAGACTGATGTTGA  337 
  TAGCTTATCAGACTGATGTTGACA 16 TAGCTTATCAGACTGATGTTGACA 112 TAGCTTATCAGACTGATGTTG 22 
  TAGCTTATCAGACTGATGTTGAA 10 TAGCTTATCAGACTGATGTTGACT 49 TAGCTTATCAGACTGATGT  9 
  
  
AGCTTATCAGACTGATGTTGAC 21 TAGCTTATCAGACTGATGTTGACT  7 
  
  
TAGCTTATCAGACTGATGTTGAA 20 TAGCTTATCAGACTGATGTT  4 
  
  
TTATCAGACTGATGTTGACTAGC 11 TAGCTTATCAGAC   1 
  
    
TAGCTTATCAGA  1 
176 
 
  
    
AGCTTATCAGACTGATGTTGA  1 
  
    
TAGCTTATCAGACTGATG  1 
  
    
TAGCTTATCAGACTGA 1 
  
      21*       CAACACCAGTCGATGGGCTGTC  3 
  
    
CAACACCAGTCGATGGGCTGT 
   
      22       AAGCTGCCAGTTGAAGAACTGT  400 
  
    
AAGCTGCCAGTTGAAGAACTG  16 
  
    
AGCTGCCAGTTGAAGAACTGT 5 
  
    
AAGCTGCCAGTTGAAGAACT  3 
  
    
AAGCTGCCAGTTGAAGAAC  2 
  
    
AAGCTGCCAGTTGAAGAA  1 
  
    
AAAGCTGCCAGTTGAAGAACTGT  1 
  
    
AAGCTGCCAGTTGAAGAACTGTT  1 
  
      22*       AGTTCTTCAGTGGCAAGCTTTA  4 
  
    
AGTTCTTCAGTGGCAAGCTTT  2 
  
      23a    ATCACATTGCCAGGGATTTCCA 21 ATCACATTGCCAGGGATTTCCA  712 
  
  
ATCACATTGCCAGGGATTTCC 13 ATCACATTGCCAGGGATTTCC 601 
  
  
ATCACATTGCCAGGGATTTCCAA 12 ATCACATTGCCAGGGATTTCCAA  278 
  
    
TCACATTGCCAGGGATTTCCAAC  105 
  
    
ATCACATTGCCAGGGATTTC  88 
  
    
TCACATTGCCAGGGATTTCCA  64 
  
    
TCACATTGCCAGGGATTTCC  33 
  
    
ATCACATTGCCAGGGATTTCCAAC 31 
  
    
TCACATTGCCAGGGATTTCCAA 28 
  
    
TCACATTGCCAGGGATTTC  12 
  
    
ATCACATTGCCAGGGATTT  7 
  
    
AATCACATTGCCAGGGATTTCCA  6 
  
    
CAAATCACATTGCCAGGGATTTC  1 
  
    
CACATTGCCAGGGATTTCCAA 1 
  
      23b    ATCACATTGCCAGGGATTACCACT 13 ATCACATTGCCAGGGATTACCAC  50 
  
  
ATCACATTGCCAGGGATTACC 
 
TCACATTGCCAGGGATTACCAC  10 
  
    
ATCACATTGCCAGGGATTACCA  6 
  
    
ATCACATTGCCAGGGATTACC 4 
  
    
ATCACATTGCCAGGGATTAC 3 
  
    
AATCACATTGCCAGGGATTACCAC 1 
  
    
TCACATTGCCAGGGATTAC  1 
  
      23b*       TGGGTTCCTGGCATGCTGATTT  1 
  
      24 TGGCTCAGTTCAGCAGGAACAG 11 TGGCTCAGTTCAGCAGGAACAGT 187 TGGCTCAGTTCAGCAGGAACAG 86 
  
  
TGGCTCAGTTCAGCAGGAACAG 66 TGGCTCAGTTCAGCAGGAAC  24 
  
  
TGGCTCAGTTCAGCAGGAAC 10 TGGCTCAGTTCAGCAGGAACA  5 
  
    
TGGCTCAGTTCAGCAGGA  2 
  
    
TGGCTCAGTTCAGCAGGAA  1 
  
      25 CATTGCACTTGTCTCGGTCTGA 98 CATTGCACTTGTCTCGGTCTGA 139 CATTGCACTTGTCTCGGTCTGA  2 
  
    
CATTGCACTTGTC   1 
  
      25* AGGCGGAGACTTGGGCAATTGCT 23 AGGCGGAGACTTGGGCAATTGCT 14    
  AGGCGGAGACTTGGGCAATTGC 10 AGGCGGAGACTTGGGCAATTGC 10 
    AGGCGGAGACUUGGGCAAUUG 
 
AGGCGGAGACUUGGGCAAUUG 
     
      26a TTCAAGTAATCCAGGATAGGCT 38 TTCAAGTAATCCAGGATAGGCT 289 TTCAAGTAATCCAGGATAGGCT  619 
  
  
TTCAAGTAATCCAGGATAGGCTAT 29 TTCAAGTAATCCAGGATAGGC  94 
  
  
TTCAAGTAATCCAGGATAGGCTA 26 TTCAAGTAATCCAGGATAGG  14 
  
  
TTCAAGTAATCCAGGATAGGCTT 23 TTCAAGTAATCCAGGATAG 5 
  
  
TTCAAGTAATCCAGGATAGGC 14 TTCAAGTAATCCAGGATA  3 
  
    
TCAAGTAATCCAGGATAGGCT  2 
  
    
ATTCAAGTAATCCAGGATAGGCT  1 
  
    
TTCAAGTAATCCAGGAT   1 
  
    
TTCAAGTAATCCAGGA  1 
  
      26b    TTCAAGTAATTCAGGATAGGTT 28 TTCAAGTAATTCAGGATAGGTT 3 
  
  
TTCAAGTAATTCAGGATAGGT 
 
TTCAAGTAATTCAGGATAG   2 
  
    
TTCAAGTAATTCAGGATAGG 1 
  
    
TTCAAGTAATTCAGGATAGGT 
   
27a     TTCACAGTGGCTAAGTTCCG 25 TTCACAGTGGCTAAGTTCCGC   28 
  
  
TTCACAGTGGCTAAGTTCCGC 13 TTCACAGTGGCTAAGTTCCG 2 
  
      27b    TTCACAGTGGCTAAGTTCTGC 110 TTCACAGTGGCTAAGTTCTG  2 
  
  
TTCACAGTGGCTAAGTTCTG 20 TTCACAGTGGCTAAGTTCTGC  1 
  
  
TTCACAGTGGCTAAGTTCTGCA 10 
    
      27b*       AGAGCTTAGCTGATTGGTGAACA   1 
  
    
AGAGCTTAGCTGATTGGTGAAC 
 28-5p       AAGGAGCTCACAGTCTATTGAG  19 
  
    
AAGGAGCTCACAGTCTATTGA  18 
  
    
AAGGAGCTCACAGTCTATTG  2 
  
    
CAAGGAGCTCACAGTCTATTGA  1 
  
    
AGGAGCTCACAGTCTATTGAG  1 
  
      28-3p CACTAGATTGTGAGCTCCTGGA 37 CACTAGATTGTGAGCTCCTGGA 39 CACTAGATTGTGAGCTCCTGGA  28 
  CACTAGATTGTGAGCTCCTGGAA 10 CACTAGATTGTGAGCTCCTGGAA 13 CTAGATTGTGAGCTCCTGGAG  2 
  
    
CACTAGATTGTGAGCTCCTGG  2 
  
      28-5p AAGGAGCTCACAGTCTATTGA 13       
  AAGGAGCTCACAGTCTATTGAG 
       
      29a TAGCACCATCTGAAATCGGTTA 30 TAGCACCATCTGAAATCGGTTA 511 TAGCACCATCTGAAATCGGTTA  116 
  
  
TAGCACCATCTGAAATCGGTT 24 TAGCACCATCTGAAATCGGTT  24 
  
  
TAGCACCATCTGAAATCGGTTAT 11 TAGCACCATCTGAAATCGGT  18 
  
    
TAGCACCATCTGAAATCGG  6 
  
    
TAGCACCATCTGAA  5 
  
    
TAGCACCATCTGAAATCGGTTAT  3 
  
    
CTAGCACCATCTGAAATCGGTTA  3 
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CTAGCACCATCTGAAATCGGTT  2 
  
    
TAGCACCATCTGAAA  1 
  
    
TAGCACCATCTGAAATCG 1 
  
      29a*       ACTGATTTCTTTTGGTGTTCAG  3 
  
    
ACTGATTTCTTTTGGTGTTCAGA 1 
  
      29b       TAGCACCATTTGAAATCAGTGTT  18 
  
    
TAGCACCATTTGAAATCAGTGT  5 
  
    
TAGCACCATTTGAAATCAGT  4 
  
    
TAGCACCATTTGAAATCAGTGTTT 3 
  
    
TAGCACCATTTGAAATCAGTG   1 
  
    
TAGCACCATTTGAAATCAG 1 
  
      29c    TAGCACCATTTGAAATCGGTTA 15    
  
      30a TGTAAACATCCTCGACTGGAAGC 22 TGTAAACATCCTCGACTGGAAGCT 71 TGTAAACATCCTCGACTGGAAGC  22 
  TGTAAACATCCTCGACTGGAAGCT 22 TGTAAACATCCTCGACTGGAAGC 39 TGTAAACATCCTCGACTGGAAGCT 4 
  TGTAAACATCCTCGACTGGAAG 
 
TGTAAACATCCTCGACTGGAAG 
 
TGTAAACATCCTCGACTGGAA  1 
  
    
TGTAAACATCCTCGACTGGAAG 
   
30a* CTTTCAGTCGGATGTTTGCAGC 50 CTTTCAGTCGGATGTTTGCAGC 83 CTTTCAGTCGGATGTTTGCAGC  16 
  CTTTCAGTCGGATGTTTGCAGT 38 CTTTCAGTCGGATGTTTGCAGT 23 CTTTCAGTCGGATGTTTGCAG  3 
  
  
TTTCAGTCGGATGTTTGCAGC 13 CTTTCAGTCGGATGTTTGCAGCT 1 
  
      30b       TGTAAACATCCTACACTCAGC   1 
  
    
TGTAAACATCCTACACTCAGCT 
   
30b*         CTGGGAGGTGGATGTTTACTTC   1 
  
    
CTGGGAGGTGGATGTTTAC  1 
  
      30c-2* CTGGGAGAAGGCTGTTTACTCT 16 CTGGGAGAAGGCTGTTTACTCT 14 TGTAAACATCCTACACTCTCAGC   7 
  
    
TGTAAACATCCTACACTCTCAGCT 2 
  
      30d TGTAAACATCCCCGACTGGAAGCT 22 TGTAAACATCCCCGACTGGAAGCT 140 TGTAAACATCCCCGACTGGAAG  9 
  UGUAAACAUCCCCGACUGGAAG 
 
TGTAAACATCCCCGACTGGAAGC 36 TGTAAACATCCCCGACTGGAAGCT  9 
  
  
TGTAAACATCCCCGACTGGAAGCTT 11 TGTAAACATCCCCGACTGGAAGC  6 
  
  
TGTAAACATCCCCGACTGGAAG 10 
    
      30e    
  
TGTAAACATCCTTGACTGGAAGCT 3 
  
    
TGTAAACATCCTTGACTGGAAGC  2 
  
    
TGTAAACATCCTTGACTGGAAG 
   
      30e* CTTTCAGTCGGATGTTTACAGT 82 CTTTCAGTCGGATGTTTACAGC 117 CTTTCAGTCGGATGTTTACAG   4 
  CTTTCAGTCGGATGTTTACAGC 55 CTTTCAGTCGGATGTTTACAGT 84 CTTTCAGTCGGATGTTTACA  3 
  CTTTCAGTCGGATGTTTACAG 14 CTTTCAGTCGGATGTTTACAG 14 CTTTCAGTCGGATGTTTACAGC  1 
  
      31 AGGCAAGATGCTGGCATAGCTG 31    AGGCAAGATGCTGGCATAGCTGT  30 
  AGGCAAGATGCTGGCATAGCT 27 
  
AGGCAAGATGCTGGCATAGCTG   29 
  AGGCAAGATGCTGGCATAGCTGT 19 
  
AGGCAAGATGCTGGCATAGCT  19 
  
    
AGGCAAGATGCTGGCATAGC  5 
  
    
GGCAAGATGCTGGCATAGCTG  3 
  
    
GGCAAGATGCTGGCATAGC  1 
  
    
GGCAAGATGCTGGCATAGCT  1 
  
    
GGCAAGATGCTGGC 1 
            
92a TATTGCACTTGTCCCGGCCTGT 18 TATTGCACTTGTCCCGGCCTGT 34 TATTGCACTTGTCCCGGCCTGT  5 
  
    
TATTGCACTTGTCCCGGCC   1 
  
    
ATTGCACTTGTCCCGGCCTGT  1 
  
      92b TATTGCACTCGTCCCGGCCTCC 19 TATTGCACTCGTCCCGGCCTCC 530    
  
  
TATTGCACTCGTCCCGGCCTC 96 
    
  
TATTGCACTCGTCCCGGCCTCCT 35 
    
  
TATTGCACTCGTCCCGGCCT 29 
    
  
TATTGCACTCGTCCCGGCCTCA 28 
    
  
TATTGCACTCGTCCCGGCCTCT 23 
    
  
TATTGCACTCGTCCCGGCCTCCAT 22 
    
  
TATTGCACTCGTCCCGGCCTCCTAT 22 
    
  
TATTGCACTCGTCCCGGCCTCCA 17 
    
  
TATTGCACTCGTCCCGGCCTCCATC 17 
    
  
TATTGCACTCGTCCCGGCC 12 
    
      92b* AGGGACGGGACGCGGTGCAGTGTT 12 AGGGACGGGACGCGGTGCAGTGT 77    
  AGGGACGGGACGCGGTGCAGTGT 10 AGGGACGGGACGCGGTGCAGTGTT 60 
    AGGGACGGGACGCGGUGCAGUG 
 
AGGGACGGGACGCGGTGCAGT 18 
    
  
AGGGACGGGACGCGGTGCAGTGTTT 18 
    
  
AGGGACGGGACGCGGUGCAGUG 
     
      93 CAAAGTGCTGTTCGTGCAGGTAG 81 CAAAGTGCTGTTCGTGCAGGTAG 66 CAAAGTGCTGTTCGTGCAGGTAG  4 
  
    
CAAAGTGCTGTTCGTGCAGGT  1 
  
    
CAAAGTGCTGTTCGTGCAG  1 
  
      98    TGAGGTAGTAAGTTGTATTGTT 18 TGAGGTAGTAAGTTGTATTGT  11 
  
    
TGAGGTAGTAAGTTGTATTGTT  10 
  
    
TGAGGTAGTAAG  2 
  
    
TGAGGTAGTAA  2 
  
    
TGAGGTAGTAAGTTGTATTG  1 
  
      99a    AACCCGTAGATCCGATCTTGTG 30    
  
  
AACCCGTAGATCCGATCTTGT 14 
    
      99b CACCCGTAGAACCGACCTTGC 25 CACCCGTAGAACCGACCTTGC 63    
  CACCCGTAGAACCGACCTTGCG 22 CACCCGTAGAACCGACCTTGCG 54 
    
      100    AACCCGTAGATCCGAACTTGTG 91 AACCCGTAGATCCGAACTTGTG  36 
  
  
AACCCGTAGATCCGAACTTGT 45 AACCCGTAGATCCGAACTTGT 15 
  
  
AACCCGTAGATCCGAACTTGTGA 16 AACCCGTAGATCCGAACTT  3 
  
  
AACCCGTAGATCCGAAC 10 ACCCGTAGATCCGAACTTGTG  2 
  
  
AACCCGTAGATCCGAACTTGTGT 10 AACCCGTAGATCCGAACTTG  2 
  
    
AAACCCGTAGATCCGAACTTGTG  1 
  
    
AAACCCGTAGATCCGAACT  1 
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AACCCGTAGATCCGAACT  1 
  
      101 TACAGTACTGTGATAACTGAAG 165 TACAGTACTGTGATAACTGAAG 334 TACAGTACTGTGATAACTGAA  2 
  GTACAGTACTGTGATAACTGAA 80 TACAGTACTGTGATAACTGAAT 112 GTACAGTACTGTGATAACTGAA 1 
  GTACAGTACTGTGATAACTGAAA 32 GTACAGTACTGTGATAACTGAA 102 TACAGTACTGTGATAACTGA  1 
  TACAGTACTGTGATAACTGAA 30 TACAGTACTGTGATAACTGAA 63 
    TACAGTACTGTGATAACTGAAT 29 TACAGTACTGTGATAACTGAAA 53 
    GTACAGTACTGTGATAACTGA 23 GTACAGTACTGTGATAACTGAAA 25 
    TACAGTACTGTGATAACTGAAA 20 GTACAGTACTGTGATAACTGA 22 
    
  
TACAGTACTGTGATAACTGAAGT 22 
    
  
TACAGTACTGTGATAACTGAAGA 13 
    
      103 AGCAGCATTGTACAGGGCTATGA 393 AGCAGCATTGTACAGGGCTATGA 196 AGCAGCATTGTACAGGGCTATGA  24 
  AGCAGCATTGTACAGGGCTAT 104 AGCAGCATTGTACAGGGCTAT 178 AGCAGCATTGTACAGGGCTATG  3 
  AGCAGCATTGTACAGGGCTATG 26 AGCAGCATTGTACAGGGCTATGAT 18 AGCAGCATTGTACAGGGCTATGAA 3 
  AGCAGCATTGTACAGGGCTATGAT 11 AGCAGCATTGTACAGGGCTATG 17 GCAGCATTGTACAGGGCTATGA  1 
  
      106b TAAAGTGCTGACAGTGCAGATA 38 TAAAGTGCTGACAGTGCAGATA 36 TAAAGTGCTGACAGTGCAGAT  8 
  TAAAGTGCTGACAGTGCAGAT 33 TAAAGTGCTGACAGTGCAGAT 35 TAAAGTGCTGACAGTGCAGA 4 
  
  
TAAAGTGCTGACAGTGCAGA 11 TAAAGTGCTGACAGTGCAGATA  4 
  
    
TAAAGTGCTGACAGTGCAG  1 
  
    
TAAAGTGCTGACAGTGCAGATAGT 1 
  
      106b* CCGCACTGTGGGTACTTGCTGC 10       
  
      107 AGCAGCATTGTACAGGGCTATCA 10    AGCAGCATTGTACAGGGCT  3 
  
    
AGCAGCATTGTACAGGGC  2 
  
    
AGCAGCATTGTACAGGGCTAT 1 
  
    
AGCAGCATTGTACAGGGCTA  1 
  
    
AGCAGCATTGTACAGGGCTATCA 
   
124 TAAGGCACGCGGTGAATGCCAA 25 TAAGGCACGCGGTGAATGCCAA 23     
  TAAGGCACGCGGTGAATGCC 
 
TAAGGCACGCGGTGAATGCC 
     
      125a-5p       TCCCTGAGACCCTTTAACCTGTGA 3 
  
      125a-3p       ACAGGTGAGGTTCTTGGGAGC  2 
  
    
 ACAGGTGAGGTTCTTGGGAGCC 1 
  
      125b-1*       ACGGGTTAGGCTCTTGGGAGCT 7 
  
    
ACGGGTTAGGCTCTTGGGAGC  3 
  
    
ACGGGTTAGGCTCTTGGGAG  2 
   
     125b     TCCCTGAGACCCTAACTTGTGA 246 TCCCTGAGACCCTAACTTGTGA  78 
  
  
TCCCTGAGACCCTAACTTGTG 17 TCCCTGAGACCCTAACTTGTG  7 
  
  
TCCCTGAGACCCTAAC 10 TCCCTGAGACCCTAACTTGT  6 
  
    
TCCCTGAGACCCTAACTTGTGAT  2 
  
    
TCCCTGAGACCCTAAC  2 
  
    
CCCTGAGACCCTAACTTGTGAT  1 
  
    
TCCCTGAGACCCTAACTTG  1 
  
      127-3p       TCGGATCCGTCTGAGCTTGGCT  6 
  
    
TCGGATCCGTCTGAGCTTGGC  3 
  
    
CGGATCCGTCTGAGCTTGGCT  1 
  
      128 TCACAGTGAACCGGTCTCTTT 12 TCACAGTGAACCGGTCTCTTT 40    
  
      130a CAGTGCAATGTTAAAAGGGCAT 888 CAGTGCAATGTTAAAAGGGCAT 509 CAGTGCAATGTTAAAAGGGCAT  116 
  CAGTGCAATGTTAAAAGGGCATA 52 CAGTGCAATGTTAAAAGGGCAC 81 CAGTGCAATGTTAAAAGGGCA 13 
  CAGTGCAATGTTAAAAGGGCATT 20 CAGTGCAATGTTAAAAGGGCATT 35 CAGTGCAATGTTAAAAGGGCATT 10 
  CAGTGCAATGTTAAAAGGGC 14 CAGTGCAATGTTAAAAGGGCA 25 CAGTGCAATGTTAAAAGGGC  9 
  CAGTGCAATGTTAAAAGGGCA 12 CAGTGCAATGTTAAAAGGGCATA 18 CAGTGCAATGTTAAAAG 1 
  
  
CAGTGCAATGTTAAAAGGGC 13 CAGTGCAATGTTAAAAGGG  1 
  
    
CAGTGCAATGTTAAAA  1 
  
      130b CAGTGCAATGATGAAAGGGCAT 257 CAGTGCAATGATGAAAGGGCAT 208 CAGTGCAATGATGAAAGGGCAT  79 
  CAGTGCAATGATGAAAGGGCATT 26 CAGTGCAATGATGAAAGGGCATT 20 CAGTGCAATGATGAAAGGGC  7 
  CAGTGCAATGATGAAAGGGCATA 18 CAGTGCAATGATGAAAGGGCA 12 CAGTGCAATGATGAAAGGGCA  5 
  CAGTGCAATGATGAAAGGGCA 15 CAGTGCAATGATGAAAGGGCATA 10 CAGTGCAATGATGAAAGGG 1 
  
    
AGTGCAATGATGAAAGGGCAT  1 
  
      132       TAACAGTCTACAGCCATGGTCG  14 
  
    
GTAACAGTCTACAGCCATGGTC  1 
  
    
TAACAGTCTACAGCCATGGT  1 
  
      134       TGTGACTGGTTGACCAGAGGGG  2 
  
    
TGTGACTGGTTGACCAGAGGG  1 
  
      135b    TATGGCTTTTCATTCCTATGTGA 20    
  
      138    AGCTGGTGTTGTGAATCAGGCCG 11 AGCTGGTGTTGTGAATCAGGCCG  1 
  
    
AGCTGGTGTTGTGAATCAGGCCGTT 1 
  
      140 ACCACAGGGTAGAACCACGGAC 62 ACCACAGGGTAGAACCACGGAC 110 TACCACAGGGTAGAACCACGGA 3 
  TACCACAGGGTAGAACCACGG 
 
TACCACAGGGTAGAACCACGGAC 24 TACCACAGGGTAGAACCACGGAC  2 
  
  
CCACAGGGTAGAACCACGGAC 12 ACCACAGGGTAGAACCACGGAC 2 
  
  
ACCACAGGGTAGAACCACGGA 11 ACCACAGGGTAGAACCACGGA  1 
  
  
TACCACAGGGTAGAACCACGG 
 
TACCACAGGGTAGAACCACGGACA 1 
  
    
TACCACAGGGTAGAACCACGG 
   
140-5p         CAGTGGTTTTACCCTATGGTAG  3 
  
      141 TAACACTGTCTGGTAAAGATGGC 25       
  UAACACUGUCUGGUAAAGAUGG 
       
      143       TGAGATGAAGCACTGTAGCTC  68 
  
    
TGAGATGAAGCACTGTAGCT  14 
  
    
TGAGATGAAGCACTGTAGC  12 
  
    
TGAGATGAAGC  2 
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145         GTCCAGTTTTCCCAGGAATCCC  28 
  
    
GTCCAGTTTTCCCAGGAATCCCT  24 
  
    
GTCCAGTTTTCCCAGGAAT  20 
  
    
GTCCAGTTTTCCCAGGAA  13 
  
    
GTCCAGTTTTCCCAGGAATCCCTT  12 
  
    
GTCCAGTTTTCCCAGGAATCC  5 
  
    
GTCCAGTTTTCCCAGGAATC  4 
  
    
GTCCAGTTTTCCC  3 
  
    
GTCCAGTTTTCCCAGGA  2 
  
    
GTCCAGTTTTCCCAGG  1 
  
    
GTCCAGTTTTCCCAGGAATCCCTTA 1 
  
      146a       TGAGAACTGAATTCCATGGGTT  7 
  
    
TGAGAACTGAATTCCATGGGTTG  1 
  
      146b    TGAGAACTGAATTCCATAGGCTGT 57    
  
  
TGAGAACTGAATTCCATAGGCTGG 31 
  
  
  
UGAGAACUGAAUUCCAUAGGCU 
 
   148a TCAGTGCACTACAGAACTTTGT 110 TCAGTGCACTACAGAACTTTGT 79    
  TCAGTGCACTACAGAACTTTGTC 16 
      
      148b    TCAGTGCATCACAGAACTTTGT 12    
  
      151-3p CTAGACTGAAGCTCCTTGAGG 290 CTAGACTGAAGCTCCTTGAGG 294 CTAGACTGAAGCTCCTTGAGGA  18 
  CTAGACTGAAGCTCCTTGAGGA 162 CTAGACTGAAGCTCCTTGAGGA 178 CTAGACTGAAGCTCCTTGAGG  6 
  CTAGACTGAAGCTCCTTGAGGAA 64 CTAGACTGAAGCTCCTTGAG 58 TACTAGACTGAAGCTCCTTGAG  1 
  CTAGACTGAAGCTCCTTGAG 49 CTAGACTGAAGCTCCTTGAGGT 54 
    CTAGACTGAAGCTCCTTGAGGT 25 CTAGACTGAAGCTCCTTGAGGAA 43 
    CTAGACTGAAGCTCCTTGAGGAAA 18 CTAGACTGAAGCTCCTTGAGT 25 
    CTAGACTGAAGCTCCTTGAGA 13 CTAGACTGAAGCTCCTTGAGGAT 14 
    
  
CTAGACTGAAGCTCCTTGAGA 13 
    
  
TACTAGACTGAAGCTCCTTGAGG 13 
    
  
TACTAGACTGAAGCTCCTTGAG 12 
    
  
CTAGACTGAAGCTCCTTGA 11 
    
  
CTAGACTGAAGCTCCTTGAGGAAA 10 
    
      151-5p TCGAGGAGCTCACAGTCTAGT 12 TCGAGGAGCTCACAGTCTAGT 37 TCGAGGAGCTCACAGTCTAGT 1304 
  
  
TCGAGGAGCTCACAGTCTAGTA 20 TCGAGGAGCTCACAGTCTAGTA 1135 
  
    
TCGAGGAGCTCACAGTCTAG  91 
  
    
TCGAGGAGCTCACAGTCTAGTAT  79 
  
    
CTCGAGGAGCTCACAGTCTAGT  25 
  
    
CTCGAGGAGCTCACAGTCTAGTA 19 
  
    
TCGAGGAGCTCACAGTCTAGTATG 12 
  
    
CTCGAGGAGCTCACAGTCTAGTAT 6 
  
    
TCGAGGAGCTCACAGTCT  3 
  
    
TCGAGGAGCTCACAGTCTA  3 
  
    
TCGAGGAGCTCACAGT  2 
  
    
TCGAGGAGCTCACAG  2 
  
    
CTCGAGGAGCTCACAGTCTAG  1 
  
    
CTCGAGGAGCTCACAGTCT  1 
  
    
CGAGGAGCTCACAGTCTAGTATGT  1 
  
    
CGAGGAGCTCACAGTCTAGTATG 1 
  
    
CGAGGAGCTCACAGTCTAGTAT  1 
  
      152       TCAGTGCATGACAGAACTTGG  21 
  
    
TCAGTGCATGACAGAACTTGGG  8 
  
    
TCAGTGCATGAC  1 
  
    
CAGTGCATGACAGAACTTGGG  1 
  
      154*       AATCATACACGGTTGACCTAT  1 
  
    
AATCATACACGGTTGACCTATT 
   
154         TAGGTTATCCGTGTTGCCTTCG  1 
  
      155       TTAATGCTAATCGTGATAGGGGTTT  1 
  
    
TTAATGCTAATCGTGATAGGGGTT  1 
  
    
TTAATGCTAATCGTGATAGGGGT  1 
  
      181a    AACATTCAACGCTGTCGGTGAGTTT 104 AACATTCAACGCTGTCGGTGAGT  1 
  
  
AACATTCAACGCTGTCGGTGAGTT 32 AACATTCAACGCTGTCGGTGAGTTT 1 
  
  
AACATTCAACGCTGTCGGTGAGT 17 AACATTCAACGCTGTCGGTGAG 1 
  
      181b    AACATTCATTGCTGTCGGTGGGTT 10 AACATTCATTGCTGTCGGTGGGTT  6 
  
  
AACATTCATTGCTGTCGGTGGGT 
 
AACATTCATTGCTGTCGGTGGGT  3 
  
    
AACATTCATTGCTGTCGGTGGG  2 
  
    
AACATTCATTGCTGTCGGTGGGTTT 1 
  
      182 TTTGGCAATGGTAGAACTCACACT 432       
  TTTGGCAATGGTAGAACTCACACTGG 166 
      TTTGGCAATGGTAGAACTCACAC 148 
      TTTGGCAATGGTAGAACTCACACTG 95 
      TTTGGCAATGGTAGAACTCACACTGGT 20 
      TTTGGCAATGGTAGAACTCACA 13 
      TTTGGCAATGGTAGAACTCACACTGGA 12 
      TTTGGCAATGGTAGAACTCACACTGT 11 
      
      183 ATGGCACTGGTAGAATTCACTG 133       
  ATGGCACTGGTAGAATTCACT 69 
      TATGGCACTGGTAGAATTCACT 66 
      TATGGCACTGGTAGAATTCACTG 45 
      ATGGCACTGGTAGAATTCACTGT 20 
      ATGGCACTGGTAGAATTCACTGA 11 
      
      185 TGGAGAGAAAGGCAGTTCCTGA 29 TGGAGAGAAAGGCAGTTCCTGA 54    
  
      186    CAAAGAATTCTCCTTTTGGGCTT 11 CAAAGAATTCTCCTTTTGGGC  3 
  
  
CAAAGAATTCTCCTTTTGGGCT 
 
CAAAGAATTCTCCTTTTGGGCTT  1 
  
    
CAAAGAATTCTCCTTTTGGGCT 
   
186*         GCCCAAAGGTGAATTTTTTGGG  1 
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      191 CAACGGAATCCCAAAAGCAGCTG 76 CAACGGAATCCCAAAAGCAGCTG 49 CAACGGAATCCCAAAAGCAGCTG  275 
  CAACGGAATCCCAAAAGCAGCTGT 25 CAACGGAATCCCAAAAGCAGCTGT 40 CAACGGAATCCCAAAAGCAGCT   117 
  CAACGGAATCCCAAAAGCAGCT 23 CAACGGAATCCCAAAAGCAGCT 13 CAACGGAATCCCAAAAGCAGCTGT 115 
  CAACGGAATCCCAAAAGCAGCTGA 11 CAACGGAATCCCAAAAGCAGCTGA 12 CAACGGAATCCCAAAAGCAGC  95 
  
    
CAACGGAATCCCAAAAGCAG  17 
  
    
AACGGAATCCCAAAAGCAGCTG 11 
  
    
CAACGGAATCCCAAAAGC  3 
  
    
CAACGGAATCCCAAAAGCA  1 
  
    
AACGGAATCCCAAAAGCAGC  1 
  
    
CAACGGAATCC 1 
  
    
AACGGAATCCCAAAAGCAGCTGT 1 
  
      193a-5p       TGGGTCTTTGCGGGCGAGATGA   2 
  
      193a AACTGGCCTACAAAGTCCCAGT 15    AACTGGCCTACAAAGTCCCAGT  98 
  
    
AACTGGCCTACAAAGTCCCAG  4 
  
    
AACTGGCCTACAAAGTCCCAGTT  3 
  
    
CAACTGGCCTACAAAGTCCCAGT  1 
  
    
ACTGGCCTACAAAGTCCCAGT  1 
  
      194       TGTAACAGCAACTCCATGTGGAA 2 
  
    
TGTAACAGCAACTCCATGTGGA   1 
  
      195    TAGCAGCACAGAAATATTGGCA 17    
  
  
UAGCAGCACAGAAAUAUUGGC 
 
   199a-5p        CCCAGTGTTCAGACTACCTGTTC   10 
  
    
CCCAGTGTTCAGACTACCTGTT  2 
  
    
CCCAGTGTTCAGAC  1 
  
      199b-5p       CCCAGTGTTTAGACTATCTGTTC   3 
  
      199b-3p       ACAGTAGTCTGCACATTGGTTA  11 
  
    
ACAGTAGTCTGCACATTGGTT  3 
  
    
TACAGTAGTCTGCACATTGGTT  2 
  
    
TACAGTAGTCTGCACATTGGT  2 
  
    
CAGTAGTCTGCACATTGGTTA   1 
  
    
CAGTAGTCTGCACATTG  1 
  
    
CAGTAGTCTGCACATTGGT  1 
  
      210 CTGTGCGTGTGACAGCGGCTGA 10 CTGTGCGTGTGACAGCGGCTGA 199    
  
      214       ACAGCAGGCACAGACAGGCAGT  13 
  
    
ACAGCAGGCACAGACAGGCAG  8 
  
    
TACAGCAGGCACAGACAGGCAG  3 
  
    
TACAGCAGGCACAGACAGGCAGT  3 
  
    
TACAGCAGGCACAGACAGGC   1 
  
    
ACAGCAGGCACAGACAGGCA  1 
  
    
CAGCAGGCACAGACAGGCAG  1 
  
    
TACAGCAGGCACAGACAGGCA  1 
  
      219-2-3p AGAATTGTGGCTGGACATCTGT 20       
  
      221 AGCTACATTGTCTGCTGGGTTTC 15    AGCTACATTGTCTGCTGGGTTTC  16 
  
    
AGCTACATTGTCTGCTGGGT  6 
  
    
AGCTACATTGTCTGCTGGGTTT  6 
  
    
AGCTACATTGTCTGCTGGGTTTCA  2 
  
    
GCTACATTGTCTGCTGGGTTT  1 
  
    
GCTACATTGTCTGCTGGGT  1 
  
    
AGCTACATTGTCTGCTGG  1 
  
    
GCTACATTGTCTGCTGGGTTTC  1 
  
    
AGCTACATTGTCTGCTGGGTT  1 
  
    
AGCTACATTGTCTGCTG  1 
  
      221* ACCTGGCATACAATGTAGATTTCTGT 72 ACCTGGCATACAATGTAGATTTCTGT 93 ACCTGGCATACAATGTAGATTT  1 
  ACCTGGCATACAATGTAGATTTCT 17 ACCTGGCATACAATGTAGATTTCT 22 
    ACCTGGCATACAATGTAGATTTC 10 ACCTGGCATACAATGTAGATTTCTG 14 
    ACCTGGCATACAATGTAGATTT 
 
ACCTGGCATACAATGTAGATTT 
      
222 AGCTACATCTGGCTACTGGGTCT 21 AGCTACATCTGGCTACTGGGTCT 35 AGCTACATCTGGCTACTGGGTCTC 18 
  AGCTACATCTGGCTACTGGGT 
 
AGCTACATCTGGCTACTGGGT 
 
AGCTACATCTGGCTACTGGGTCT  11 
  
    
AGCTACATCTGGCTACTGGGT  5 
  
    
AGCTACATCTGGCTACTGGGTC  5 
  
    
GCTACATCTGGCTACTGGGTCTC  3 
  
    
AGCTACATCTGGCTACTGGGTCTCT 3 
  
    
CTACATCTGGCTACTGGGTCT  1 
  
    
TACATCTGGCTACTGGGTCTC  1 
  
    
AGCTACATCTGGCTACTGGG  1 
  
    
AGCTACATCTGGCTACTGG  1 
  
    
GCTACATCTGGCTACTGGGTCTCT  1 
  
      222*       GGCTCAGTAGCCAGTGTAGATCC  1 
  
    
CTCAGTAGCCAGTGTAGATCCT 
   
      299-3p       TATGTGGGATGGTAAACCGCT   2 
  
    
TATGTGGGATGGTAAACCGCTT  1 
  
      302a TAAGTGCTTCCATGTTTTGGTGA 54       
  TAAGTGCTTCCATGTTTTGGTG 18 
      AAGTGCTTCCATGTTTTGGTGA 16 
      
      302a* TAAACGTGGATGTACTTGCTTT 1113       
  TAAACGTGGATGTACTTGCTT 491 
      CTTAAACGTGGATGTACTTGCTT 132 
      CTTAAACGTGGATGTACTTGCT 109 
      ACTTAAACGTGGATGTACTTGCT 96 
      TAAACGTGGATGTACTTGCTTTGA 86 
      ACTTAAACGTGGATGTACTTGC 80 
      TAAACGTGGATGTACTTGCT 67 
      TAAACGTGGATGTACTTGCTTTG 24 
    
181 
 
  TAAACGTGGATGTACTTGCTTTGAAACT 23 
      TAAACGTGGATGTACTTGCTTTA 22 
      TAAACGTGGATGTACTTGCTTTGAAAC 20 
      TAAACGTGGATGGACTTGCTTT 16 
      TTAAACGTGGATGTACTTGCTT 15 
      TAAACGTGGATGTACTTGCTTTGAA 12 
      
      302b TAAGTGCTTCCATGTTTTAGTAG 60       
  TAAGTGCTTCCATGTTTTAGTA 26 
      TAAGTGCTTCCATGTTTTAGT 12 
      TAAGTGCTTCCATGTTTTAGTAGT 12 
      
      302c AAGTGCTTCCATGTTTCAGTGGT 51       
  AAGTGCTTCCATGTTTCAGTGG 11 
      TAAGTGCTTCCATGTTTCAGTGG 
       
      302d TAAGTGCTTCCATGTTTGAGTGT 63       
  AAGTGCTTCCATGTTTGAGTGT 12 
      
      302d* ACTTTAACATGGAGGCACTTGCT 18       
  ACTTTAACATGGAGGCACTTGC 15 
      ACTTTAACATGGAGGCACTTG 13 
      
      320a AAAAGCTGGGTTGAGAGGGCGA 221 AAAAGCTGGGTTGAGAGGGCGA 190 AAAAGCTGGGTTGAGAGGGCGA  3 
  AAAAGCTGGGTTGAGAGGGCGAA 62 AAAAGCTGGGTTGAGAGGGCGAT 89 AAGCTGGGTTGAGAGGGCGAAA   1 
  AAAAGCTGGGTTGAGAGGGCGAT 54 AAAAGCTGGGTTGAGAGGGCGAA 63 AAAAGCTGGGTTGAGAGGGCGAA 1 
  AAAAGCTGGGTTGAGAGGGCGT 24 AAAAGCTGGGTTGAGAGGGCGAAT 20 AAAGCTGGGTTGAGAGGGCGA  1 
  AAAAGCTGGGTTGAGAGGGCGAAT 10 AAAAGCTGGGTTGAGAGGGCGT 18 AAAAGCTGGGTTGAGAGGGCGAAA 1 
  
  
AAAGCTGGGTTGAGAGGGCGA 13 
    
      324-5p       CGCATCCCCTAGGGCATTGGTGT   2 
  
    
CGCATCCCCTAGGGCATTGGTG  1 
  
      329       AACACACCTGGTTAACCTCTT   6 
  
    
ACACACCTGGTTAACCTCTT  2 
  
    
AACACACCTGGTTAACCTCTTT 
   
335 TCAAGAGCAATAACGAAAAATG 65 TCAAGAGCAATAACGAAAAATG 51 TCAAGAGCAATAACGAAAAATGT   3 
  TCAAGAGCAATAACGAAAAAT 58 TCAAGAGCAATAACGAAAAAT 25 TCAAGAGCAATAACGAAA  2 
  TCAAGAGCAATAACGAAAAATGT 33 TCAAGAGCAATAACGAAAAATGT 25 TCAAGAGCAATAACGAAAAAT 2 
  
    
TCAAGAGCAATAACGAAAAATG  1 
  
      335*       TTTTTCATTATTGCTCCTGACC  8 
  
    
TTTTTCATTATTGCTCCTGAC  2 
  
      337-3p       TCCTATATGATGCCTTTCTTC  63 
  
    
CTCCTATATGATGCCTTTCTTC  30 
  
    
CTCCTATATGATGCCTTTCTT  7 
  
    
TCCTATATGATGCCTTTCTT  6 
  
    
TCCTATATGATGCCTTTCTTCA   1 
  
    
CTCCTATATGATGCCTTTCT  1 
  
    
TCCTATATGATGCCTTTCT  1 
  
      339-5p       TCCCTGTCCTCCAGGAGCTCA   1 
  
    
TCCCTGTCCTCCAGGAGCTCAC  1 
  
    
TCCCTGTCCTCCAGGAGCTCACG  1 
  
      340 TTATAAAGCAATGAGACTGATT 381 TTATAAAGCAATGAGACTGATT 487    
  TTATAAAGCAATGAGACTGAT 72 TTATAAAGCAATGAGACTGAT 149 
    TTATAAAGCAATGAGACTGA 15 TTATAAAGCAATGAGACTGA 32 
    
      345       GCTGACTCCTAGTCCAGGGCTC   4 
  
    
GCTGACTCCTAGTCCAGGGC  1 
  
    
GCTGACTCCTAGTCCAGGGCT  1 
  
      361-5p       TTATCAGAATCTCCAGGGGTAC  8 
  
    
TTATCAGAATCTCCAGGGGTA  1 
  
    
TTATCAGAATCTCCAGGGGTACT  1 
  
      363 AATTGCACGGTATCCATCTGTA 12       
  
      365       TAATGCCCCTAAAAATCC  1 
  
    
TAATGCCCCTAAAAATCCT  1 
  
    
TAATGCCCCTAAAAATCCTTA  1 
  
    
TAATGCCCCTAAAAATCCTTAT 
   
      367 AATTGCACTTTAGCAATGGTGA 34       
  AATTGCACTTTAGCAATGGT 11 
      
      369-3p       AATAATACATGGTTGATCTTT  18 
  
    
AATAATACATGGTTGATCTT   6 
  
    
AATAATACATGGTTGATCTTTT  4 
  
    
AATAATACATGGTTGATC  1 
  
    
ATAATACATGGTTGATCTTT  1 
  
      374a TTATAATACAACCTGATAAGT 24 TTATAATACAACCTGATAAGT 35 TTATAATACAACCTGATAAGT  2 
  TTATAATACAACCTGATAAGTG 
 
TTATAATACAACCTGATAAGTG 
 
TTATAATACAACCTGATAAGTG 1 
  
      374b ATATAATACAACCTGCTAAGTG 24 ATATAATACAACCTGCTAAGTG 31    
  
      376a       ATCATAGAGGAAAATCCACGT 207 
  
    
AATCATAGAGGAAAATCCACGT  17 
  
    
TCATAGAGGAAAATCCACGT 7 
  
    
ATCATAGAGGAAAATCCAC   5 
  
    
ATCATAGAGGAAAATCCACGTT  4 
  
    
ATCATAGAGGAAAATCCACG  4 
  
      376b       ATCATAGAGGAAAATCCATGT  116 
  
    
ATCATAGAGGAAAATCCATGTT 27 
  
    
ATCATAGAGGAAAATCCATGTTT  8 
  
    
TCATAGAGGAAAATCCATGT 6 
182 
 
  
    
TCATAGAGGAAAATCCATGTTT   5 
  
    
ATCATAGAGGAAAATCCAT  2 
  
    
ATCATAGAGGAAAATCCATG  1 
  
    
ATCATAGAGGAAAATCCATGTTTT  1 
  
    
TCATAGAGGAAAATCCATGTT 1 
  
      376c       AACATAGAGGAAATTCCACGT  384 
  
    
ACATAGAGGAAATTCCACGT  25 
  
    
AACATAGAGGAAATTCCACGTT   19 
  
    
AACATAGAGGAAATTCCACG  5 
  
    
AACATAGAGGAAA  4 
  
    
AACATAGAGGAAATTCCAC  3 
  
    
AAACATAGAGGAAATTCCACGT  3 
  
    
AAACATAGAGGAAATTCCACG  2 
  
    
AACATAGAGGAAATTCCACGTTT  2 
  
    
AACATAGAGGA  2 
  
    
ACATAGAGGAAATTCCACGTT  1 
  
    
ACATAGAGGAAATTCCAC 1 
  
    
AACATAGAGGAAATTCC  1 
  
    
TAAACATAGAGGAAATTCCACG  1 
  
    
AACATAGAGGAAAT  1 
  
      377*       AGAGGTTGCCCTTGGTGAATTC  6 
  
    
AGAGGTTGCCCTTGGTGAAT  2 
  
    
AGAGGTTGCCCTTGGTGAATTCG  1 
  
    
AGAGGTTGCCCTTGGTGAATT  1 
  
      378 ACTGGACTTGGAGTCAGAAGGC 214 ACTGGACTTGGAGTCAGAAGGC 114 ACTGGACTTGGAGTCAGAAGG  14 
  ACTGGACTTGGAGTCAGAAGGCA 86 ACTGGACTTGGAGTCAGAAGGCA 39 ACTGGACTTGGAGTCAGAAGGC   2 
  ACTGGACTTGGAGTCAGAAGG 47 ACTGGACTTGGAGTCAGAAGG 37 
    CTGGACTTGGAGTCAGAAGGC 32 CTGGACTTGGAGTCAGAAGGC 27 
    ACTGGACTTGGAGTCAGAAGGCAT 21 ACTGGACTTGGAGTCAGAAGGCAT 21 
    ACTGGACTTGGAGTCAGAAG 19 CTGGACTTGGAGTCAGAAGGCT 13 
    ACTGGACTTGGAGTCAGAAGGCAA 12 ACTGGACTTGGAGTCAGAAG 11 
    CTGGACTTGGAGTCAGAAGGCA 11 
      
      379    TGGTAGACTATGGAACGTAGG 21 TGGTAGACTATGGAACGTAGG  4 
  
    
ATGGTAGACTATGGAACGTAGG   1 
  
    
TGGTAGACTATGGAACGTAG  1 
  
      379*       TATGTAACATGGTCCACTAAC  12 
  
    
ATGTAACATGGTCCACTAACT   2 
  
    
TATGTAACATGGTCCACTAA  2 
  
    
TATGTAACATGGTCCACTAACT  
   
382         GAAGTTGTTCGTGGTGGATTCG  15 
  
    
GAAGTTGTTCGTGGTGGATTC  7 
  
    
GAAGTTGTTCGTGGTGGATT  5 
  
    
GAAGTTGTTCGTGGTGGAT  4 
  
    
AGTTGTTCGTGGTGGATTC  2 
  
    
AGTTGTTCGTGGTGGATTCGCT  1 
  
    
AAGTTGTTCGTGGTGGAT  1 
  
    
AAGTTGTTCGTGGTGGATTC 1 
  
      409-3p       CGAATGTTGCTCGGTGAACCCCT  2 
  
    
GAATGTTGCTCGGTGAACCCCT  2 
  
    
CGAATGTTGCTCGGTGAACCCC 1 
  
    
CGAATGTTGCTCGGTGAACCC  1 
  
      409-5p       GGTTACCCGAGCAAC 1 
  
    
AGGTTACCCGAGCAACTTTGCAT 
   
411         TAGTAGACCGTATAGCGTACG  1 
  
      411*        TATGTAACACGGTCCACTAAC  14 
  
    
TATGTAACACGGTCCACTAA 12 
  
    
TATGTAACACGGTCCACTAACC 
   
423 TGAGGGGCAGAGAGCGAGACTTT 529 TGAGGGGCAGAGAGCGAGACTTT 1512 AGCTCGGTCTGAGGCCCCTCAGT   5 
  TGAGGGGCAGAGAGCGAGACTTTT 85 TGAGGGGCAGAGAGCGAGACTTTT 328 
    TGAGGGGCAGAGAGCGAGACTT 38 TGAGGGGCAGAGAGCGAGACTT 203 
    TGAGGGGCAGAGAGCGAGACT 31 TGAGGGGCAGAGAGCGAGACT 140    
  TGAGGGGCAGAGAGCGAGACTTTA 19 TGAGGGGCAGAGAGCGAGAC 42 TGAGGGGCAGAGAGCGAGAC   2 
  
  
TGAGGGGCAGAGAGCGAGACTTTA 38 TGAGGGGCAGAGAGCGAGACTTT  2 
  
  
TGAGGGGCAGAGAGCGAGA 31 TGAGGGGCAGAGAGCGAGACT  2 
  
  
TGAGGGGCAGAGAGCGAGACTTTTT 27 TGAGGGGCAGAGAGCGAGA  1 
  
  
TGAGGGGCAGAGAGCGAGACTTA 16 TGAGGGGCAGAGAGCGAGACTT  1 
  
  
TGAGGGGCAGAGAGCGAGACA 13 TGAGGGGCAGAGAGCGAGACTTTT  1 
  
  
TGAGGGGCAGAGAGCGAGAAA 11 TGAGGGGCAGAGA  1 
  
      424*       CAAAACGTGAGGCGCTGCTATA   2 
  
    
CAAAACGTGAGGCGCTGCTAT  1 
  
      424       CAGCAGCAATTCATGTTTTGAA  51 
  
    
CAGCAGCAATTCATGTTTTGA  20 
  
    
CAGCAGCAATTCATGTTTTG 1 
  
      425       AATGACACGATCACTCCCGTTGAGT 6 
  
    
ATGACACGATCACTCCCGTTGAGT 1 
  
    
AATGACACGATCACTCCCGTTGAG  1 
  
    
AATGACACGATCACTCCCGTTGA 
   
      425*       TCGGGAATGTCGTGTCCGCCC  1 
  
    
TCGGGAATGTCGTGTCCGCC  1 
  
    
CATCGGGAATGTCGTGTCCGCC  1 
  
    
ATCGGGAATGTCGTGTCCGCCC 
   
432         TCTTGGAGTAGGTCATTGGGTGG 9 
  
    
TCTTGGAGTAGGTCATTGGGTG   2 
  
    
TTGGAGTAGGTCATTGGGTGG  1 
  
      
183 
 
433         ATCATGATGGGCTCCTCGGTGT  3 
  
    
ATCATGATGGGCTCCTCGGTG 1 
  
    
ATCATGATGGGCTCCTCGGT  1 
  
      450b    TTTTGCAATATGTTCCTGAAT 12    
  
  
TTTTGCAATATGTTCCTGAATA 
     
      542-3p    TGTGACAGATTGATAACTGAAA 16    
  
      548f AAAACTGTAATTACTTTTGGAC 11       
  AAAAACTGTAATTACTTTT 
       
      455-3p       GCAGTCCATGGGCATATACAC 4 
  
    
ATGCAGTCCATGGGCATAT 3 
  
    
GCAGTCCATGGGCATATACA 2 
  
    
ATGCAGTCCATGGGCATATACAC 1 
  
    
TGCAGTCCATGGGCATATACAC  1 
  
    
GCAGTCCATGGGCATATACACT  1 
  
    
ATGCAGTCCATGGGCATATAC  1 
  
      483-5p       AGACGGGAGGAAAGAAGGGAGT  1 
  
    
AAGACGGGAGGAAAGAAGGGAG  1 
  
      484       TCAGGCTCAGTCCCCTCCCGAT 4 
  
    
TCAGGCTCAGTCCCCTCCCGA   2 
  
      485-5p       AGAGGCTGGCCGTGATGAATTCG   2 
  
    
AGAGGCTGGCCGTGATGAATT  2 
  
    
AGAGGCTGGCCGTGATGAATTC 
   
      487b       AATCGTACAGGGTCATCCACTT  2 
  
    
ATCGTACAGGGTCATCCACTTT   1 
  
      490-5p       CCATGGATCTCCAGGTGGGT  3 
  
    
CCATGGATCTCCAGGTGGGTCA   1 
  
    
CCATGGATCTCCAGGTGGG  1 
  
      491-5p       AGTGGGGAACCCTTCCATGAGGA 26 
  
    
AGTGGGGAACCCTTCCATGAGG  2 
  
    
TGGGGAACCCTTCCATGAGGA   1 
  
    
TGGGGAACCCTTCCATGAGGAGT  1 
  
    
AGTGGGGAACCCTTCCATGA 1 
  
    
AGTGGGGAACCCTTCCATG  1 
  
      493*       TTGTACATGGTAGGCTTTCATT  91 
  
    
TTGTACATGGTAGGCTTTCAT 20 
  
    
TTGTACATGGTAGGCTTTCA  5 
  
    
TTGTACATGGTAGGCTTTC  3 
  
      494       TGAAACATACACGGGAAACCTCT   4 
  
    
TGAAACATACACGGGAAAC  2 
  
    
TGAAACATACACGGGAAACC  1 
  
    
TGAAACATACACGGGAAACCTC 
 495       AAACAAACATGGTGCACTTCTT  90 
  
    
AAACAAACATGGTGCACTTCTTT  71 
  
    
AACAAACATGGTGCACTTCTT  21 
  
    
AAACAAACATGGTGCACTTCTTTT  16 
  
    
AACAAACATGGTGCACTTCTTT   13 
  
    
AAACAAACATGGTGCACTTCT  13 
  
    
AAACAAACATGGTGCACTT  4 
  
    
AACAAACATGGTGCACTTCTTTT  3 
  
    
AAACAAACATGGTGCACTTC  2 
  
    
ACAAACATGGTGCACTTCTTTTT  1 
  
    
AACAAACATGGTGCACTTCTTTTT  1 
  
    
ACAAACATGGTGCACTTCTTTT  1 
  
    
AACAAACATGGTGCACTTC  1 
  
    
AACAAACATGGTGCACTTCT  1 
  
      501-3p       ATGCACCCGGGCAAGGATTCT   1 
  
    
AATGCACCCGGGCAAGGATTCT  
 501-5p       AATCCTTTGTCCCTGGGTGAGAGT  1 
  
    
AATCCTTTGTCCCTGGGTGAGA 
   
      503 TAGCAGCGGGAACAGTTCTGAAA 13    TAGCAGCGGGAACAGTTCTGCA  5 
  TAGCAGCGGGAACAGTTCTGCAG 
   
TAGCAGCGGGAACAGTTCTGCAG  3 
  
    
TAGCAGCGGGAACAGTTCT  1 
  
    
TAGCAGCGGGAACAGTTCTGCAGT  1 
  
      532 CATGCCTTGAGTGTAGGACCGT 42 CATGCCTTGAGTGTAGGACCGT 68    
  
        
      539       AGAAATTATCCTTGGTGTGTTC   1 
  
    
GGAGAAATTATCCTTGGTGTGT  1 
  
    
GGAGAAATTATCCTTGGTGTGTT  1 
  
      542-3p       TGTGACAGATTGATAACTGAAA   3 
  
    
TGTGACAGATTGATAACTGAAAG  1 
  
      652       AATGGCGCCACTAGGGTTGTGC   1 
  
    
ATGGCGCCACTAGGGTTGTG 1 
  
    
AATGGCGCCACTAGGGTTGTG 
   
        
      654-5p       TGGTGGGCCGCAGAACATGTGC  3 
  
    
TGGTGGGCCGCAGAACATGTGCT   1 
  
    
TGGTGGGCCGCAGAACATGT  1 
  
      654-3p       TATGTCTGCTGACCATCACC   2 
  
    
CATATGTCTGCTGACCATCACC  1 
  
    
TATGTCTGCTGACCATCAC  1 
184 
 
  
    
TATGTCTGCTGACCATCACCTT 
   
      708 AAGGAGCTTACAATCTAGCTGGG 23    AAGGAGCTTACAATCTAGCTGGG  2 
  
      708* AACTAGACTGTGAGCTTCTAGA 11       
  CAACUAGACUGUGAGCUUCUAG 
       
      744 TGCGGGGCTAGGGCTAACAGCA 21 TGCGGGGCTAGGGCTAACAGCA 74 TGCGGGGCTAGGGCTAACAGCA   2 
  
  
TGCGGGGCTAGGGCTAACAGC 40 TGCGGGGCTAGGGCTAACAGC  1 
  
  
TGCGGGGCTAGGGCTAACAGCAA 12 
    
      769 TGAGACCTCTGGGTTCTGAGCT 11 TGAGACCTCTGGGTTCTGAGCT 29    
  
      769-3p       TGGGATCTCCGGGGTCTTGGTT   1 
  
    
CTGGGATCTCCGGGGTCTTGGTT 
   
      1180       TTTCCGGCTCGCGTGGGTGTGT   11 
  
    
TTTCCGGCTCGCGTGGGTGTGTAG  1 
  
      1185       AGAGGATACCCTTTGTATGTTCA   2 
  
    
AGAGGATACCCTTTGTATGTTC  7 
  
    
AGAGGATACCCTTTGTATGTT 
   
      1255b       CGGATGAGCAAAGAAAGTGGTT   1 
  
      1260 ATCCCACCGCTGCCACCA 10 ATCCCACCGCTGCCACCA 18    
  
      1270 CTGGAGATATGGAAGAGCTGTGT 27       
  
      1275 GTGGGGGAGAGGCTGT 13 GTGGGGGAGAGGCTGT 12    
  GTGGGGGAGAGGCTGTC 
 
GTGGGGGAGAGGCTGTC 
     
      1286       TCTGGGCAACAAAGTGAGA   1 
  
    
TCTGGGCAACAAAGTGAGACCT 
   
      1296       TTAGGGCCCTGGCTCCATC   1 
  
    
TTAGGGCCCTGGCTCCATCT  1 
  
    
TTAGGGCCCTGGCTCCATCTCC 
   
      1301       TGCAGCTGCCTGGGAGTGAC   1 
  
    
TTGCAGCTGCCTGGGAGTGACTTC  
   
      1305       TTTCAACTCTAATGGGAGAGAC  1 
  
    
TTTTCAACTCTAATGGGAGAGA 
   
      1323 TCAAAACTGAGGGGCATTTTCT 53       
  
      2110       TTGGGGAAACGGCCGCTGAGTGAG 1 
  
    
TTGGGGAAACGGCCGCTGAGTG 
             
let-7a TGAGGTAGTAGGTTGTATAGTT 20 TGAGGTAGTAGGTTGTATAGTT 2798 TGAGGTAGTAGGTTGTATAGTT 1222 
   
TGAGGTAGTAGGTTGTATAGT 525 TGAGGTAGTAGGTTGTATAGT 712 
   
TGAGGTAGTAGGTTGTATAGTTA 146 TGAGGTAGTAGGTTGTATAG 55 
   
TGAGGTAGTAGGTTGTATAGTTT 100 TGAGGTAGTAGGTTGTATAGTTT 37 
   
TGAGGTAGTAGGTTGTATAG 29 TGAGGTAGTAGGTTGTATA 15 
   
TGAGGTAGTAGGTTGTATAGTTAA 12 GTGAGGTAGTAGGTTGTATAGT 4 
   
TGAGGTAGTAGGTTGTAT 11 TGAGGTAGTAGGTTGTATAGTTTT 3 
   
TGAGGTAGTAGGGTGTATAGTT 10 ATGAGGTAGTAGGTTGTATAGTT 2 
     
TTGAGGTAGTAGGTTGTATAGT 1 
     
TTGAGGTAGTAGGTTGTATAGTT 1 
            
let-7b 
  
TGAGGTAGTAGGTTGTGTGGTT 253 TGAGGTAGTAGGTTGTGTGGTT 90 
   
TGAGGTAGTAGGTTGTGTGGT 50 TGAGGTAGTAGGTTGTGTGGT 58 
   
TGAGGTAGTAGGTTGTGTGGTTT 38 TGAGGTAGTAGGTTGTGTGGTTT 41 
   
TGAGGTAGTAGGTTGTGTGGTTA 24 TGAGGTAGTAGGTTGTGTGG 15 
     
TGAGGTAGTAGGTTGTGTG 3 
     
TGAGGTAGTAGGTTGTGT 3 
     
GAGGTAGTAGGTTGTGTGGTT 1 
            
let-7c 
  
TGAGGTAGTAGGTTGTATGGTT 399 TGAGGTAGTAGGTTGTATGGTT 12 
   
TGAGGTAGTAGGTTGTATGGTTA 35 TGAGGTAGTAGGTTGTATGGT 1 
   
TGAGGTAGTAGGTTGTATGGT 23 
  
   
TGAGGTAGTAGGTTGTATGGTTT 18 
              
let-7d 
  
AGAGGTAGTAGGTTGCATAGTT 156 AGAGGTAGTAGGTTGCATAGTT 1072 
   
AGAGGTAGTAGGTTGCATAGTTT 15 AGAGGTAGTAGGTTGCATAGT 99 
   
AGAGGTAGTAGGTTGCATAGT 12 AGAGGTAGTAGGTTGCATAGTTT  72 
     
GAGGTAGTAGGTTGCATAGTT  34 
     
AGAGGTAGTAGGTTGCATAG 30 
     
GAGGTAGTAGGTTGCATAGT  5 
     
AAGAGGTAGTAGGTTGCATAGTT 3 
     
AGAGGTAGTAGG 3 
     
AGAGGTAGTAGGTTGCATAGTTTT 2 
     
AAGAGGTAGTAGGTTGCATAG  1 
     
AGAGGTAGTAGGTTGCATA  1 
     
GAGGTAGTAGGTTGCATAGTTT  1 
            
let-7d* 
    
TATACGACCTGCTGCCTTTCT 1 
        CTATACGACCTGCTGCCTTTCT    
       
let-7e 
  
TGAGGTAGGAGGTTGTATAGTT 198 
  
   
TGAGGTAGGAGGTTGTATAGT 44 
  
   
TGAGGTAGGAGGTTGTATAGTTT 38 
  
   
TGAGGTAGGAGGTTGTATAGTTA 31 
       
 
     
let-7f 
  
TGAGGTAGTAGATTGTATAGTT 3135 TGAGGTAGTAGATTGTATAGTT 131 
   
TGAGGTAGTAGATTGTATAGT 649 TGAGGTAGTAGATTGTATAGT 101 
   
TGAGGTAGTAGATTGTATAGTTA 261 TGAGGTAGTAGA 19 
   
TGAGGTAGTAGATTGTATAGTTT 150 TGAGGTAGTAGATTGTATAG 14 
   
TGAGGTAGTAGATTGTATAG 37 TGAGGTAGTAGATTGTATA  10 
185 
 
   
TGAGGTAGTAGATTGTAT 19 ATGAGGTAGTAGATTGTATAGT 4 
   
TGAGGTAGTAGATTGTATAGTTATC 17 TGAGGTAGTAGATTGTATAGTTT 2 
   
TGAGGTAGTAGATTGTATA 17 ATGAGGTAGTAGATTGTATAGTT  2 
   
TGAGGTAGTAGATTGTATAGTTC 12 TGAGGTAGTAGATTGTAT 2 
   
TGAGGTAGTAGATTGTATAGTTG 11 TGAGGTAGTAGAT 1 
     
TGAGGTAGTAGATT 1 
            
let-7g 
  
TGAGGTAGTAGTTTGTACAGTT 146 TGAGGTAGTAGTTTGTACAGTT  91 
   
TGAGGTAGTAGTTTGTACAGT 40 TGAGGTAGTAGTTTGTACAGT  65 
     
TGAGGTAGTAGTTTGTACAG  8 
     
TGAGGTAGTAGTTTGTAC  4 
     
TGAGGTAGTAGTTTGTACAGTTT  3 
            
let-7i 
  
TGAGGTAGTAGTTTGTGCTGTT 95 TGAGGTAGTAGTTTGTGCTGTT  26 
   
TGAGGTAGTAGTTTGTGCTGT 16 TGAGGTAGTAGTTTGTGCTGT  7 
   
TGAGGTAGTAGTTTGTGCTGTTT 16 TGAGGTAGTAGTTTGTGC  5 
   
TGAGGTAGTAGTTTGTGCTGTTA 10 TGAGGTAGTAGTTTGTGCT  2 
             
let-7i* 
    
CTGCGCAAGCTACTGCCTTGCT  1 
            
 
Table S3.1  
Sequencing number of canonical microRNAs and their isomiRs in human 
embryonic stem cells (hESC) and neuronal stem cells (NSC) and mesenchymal 
stem cells (MSC). Canonical/ annotated (highlighted in yellow) and isomiRs were 
detected by Solexa (hESC and NSC) and 454 (MSC) sequencing. Sequencing 
frequency of microRNA was listed. SN - sequencing number. Cloning and sequencing 
was performed by Elcie Chan. 
 
 
 
 
ES 5' different 5' end of miRNA Canonical seed IsomiR seed 
101 1 addition GUACAGUACU ACAGUAC UACAGUA 
183 1 deletion UAUGGCACUG AUGGCAC UGGCACU 
302a 1 deletion UAAGUGCUUC AAGUGCU AGUGCUU 
302a* 1-3 deletion ACUUAAACGUG CUUAAAC AAACGUG 
302d 1 deletion UAAGUGCUUC AAGUGCU AGUGCUU 
378 1 deletion ACUGGACUUG CUGGACU UGGACUU 
     NS 5' different Seed sequence Canonical seed IsomiR seed 
9 1-2 deletion UCUUUGGUUA CUUUGGU UUUGGUU 
9* 1 deletion AUAAAGCUAG UAAAGCU AAAGCUA 
21 1,4 deletion UAGCUUAUCA AGCUUAU GCUUAUC 
30a* 1 deletion CUUUCAGUCG UUUCAGU UUCAGUC 
101 1 addition GUACAGUACU ACAGUAC UACAGUA 
140 1-2 deletion UACCACAGGG ACCACAG CCACAGG 
151-3p 2 addition UACUAGACUGA UAGACUG ACUAGAC 
320a 1 deletion AAAAGCUGGGU AAAGCUG AAGCUGG 
378 1 deletion ACUGGACUUG CUGGACU UGGACUU 
     MS 5' different Seed sequence Canonical seed IsomiR seed 
10a 1 deletion UACCCUGUAG ACCCUGU CCCUGUA 
16* 1 addition ACCAAUAUUA CAAUAUU CCAAUAU 
17 1 addition UCAAAGUGCU AAAGUGC CAAAGUG 
23a 1 deletion AUCACAUUGC UCACAUU CACAUUG 
186 
 
23b 1 deletion AUCACAUUGC UCACAUU CACAUUG 
26a 1 deletion UUCAAGUAAU UCAAGUA CAAGUAA 
28-3p 2 deletion CACUAGAUUGU ACUAGAU UAGAUUG 
29a 1 addition CUAGCACCAU AGCACCA UAGCACC 
31 1 deletion AGGCAAGAUG GGCAAGA GCAAGAU 
100 1 deletion AACCCGUAGA ACCCGUA CCCGUAG 
140-3p 1 deletion UACCACAGGG ACCACAG CCACAGG 
151-5p 1 addition CUCGAGGAGC CGAGGAG UCGAGGA 
191 1 deletion CAACGGAAUC AACGGAA ACGGAAU 
199b-3p 1 addition UACAGUAGUC CAGUAGU ACAGUAG 
214 1 addition UACAGCAGGC CAGCAGG ACAGCAG 
222 1 deletion AGCUACAUCU GCUACAU CUACAUC 
337-3p 1 deletion CUCCUAUAUG UCCUAUA CCUAUAU 
376a 1-2 deletion AAUCAUAGAGG AUCAUAG CAUAGAG 
376b 1 deletion AUCAUAGAGGA UCAUAGA CAUAGAG 
376c 1 deletion AACAUAGAGG ACAUAGA CAUAGAG 
379* 1 deletion UAUGUAACAU AUGUAAC UGUAACA 
382 2 deletion GAAGUUGUUCG AAGUUGU GUUGUUC 
409-3p 1 deletion CGAAUGUUGC GAAUGUU AAUGUUG 
455-3p 2 addition AUGCAGUCCAU CAGUCCA UGCAGUC 
495 1 deletion AAACAAACAU AACAAAC ACAAACA 
let7a 1 addition AUGAGGUAGUA GAGGUAG UGAGGUA 
let7d 1 deletion AGAGGUAGUAG GAGGUAG AGGUAGU 
let7f 1 addition AUGAGGUAGUA GAGGUAG UGAGGUA 
 
Table S3.2  
The commonest isomiRs that show 5' differences. Analysis was based on the deep 
sequencing results, generated from hESC, NSC and MSC (see Table S3.1). The listed 
canonical and isomiR seed regions were used to generate target predictions (See 
Figure 3.6) 
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miR-9  
CUUUGGU 
    
Common targets 
  
IsomiR-9  
UUUGGUU 
 ABCA1 
 
FNDC3B 
 
PTMA 
 
ACVR1B 
 
SLC8A1 
 
A2BP1 
 
LOC51136 
ABCD1 
 
FOXF2 
 
PXDN 
 
ADAM11 
 
SLC9A1 
 
AAK1 
 
LPGAT1 
ACCN2 
 
FOXG1B 
 
PYGO2 
 
ADAMTS6 SMARCD2          ABHD3    LRIG3 
ACOT7 
 
FOXN2 
 
QKI 
 
ALCAM 
 
SMURF2 
 
ACSL1 
 
LRP8 
ACTR1A 
 
FOXO1A 
 
RAB34 
 
AP1S2 
 
SNIP1 
 
ACSL4 
 
LRRC41 
ACVR2B 
 
FOXO3A 
 
RAB38 
 
AP3B1 
 
SNRK 
 
ADCY1 
 
LRRN3 
ADAM10 
 
FRMD4A 
 
RAB40B 
 
ARHGAP24 SOCS5 
 
ADRA2C 
 
LRRTM3 
ADAMTS3 FRY 
 
RAB5B 
 
ARID1A 
 
SORT1 
 
ADSS 
 
LYSMD2 
ADAMTS5 FURIN 
 
RAG1AP1 
 
ARID1B 
 
STARD13 
 
AKAP2 
 
MAFB 
ADCY9 
 
FXR1 
 
RAI14 
 
ARL4C 
 
STK3 
 
ALKBH5 
 
MAFG 
ADPGK 
 
FYCO1 
 
RALB 
 
ARNT 
 
STS-1 
 
ANKRD40 
 
MAGI2 
AEBP2 
 
FYTTD1 
 
RALGDS 
 
ATBF1 
 
SYT9 
 
ANKRD50 
 
MAML1 
AFAP1 
 
FZD8 
 
RAP1B 
 
ATP1B1 
 
TESK2 
 
AP3S1 
 
MAP2K4 
AFF1 
 
GAB2 
 
RAP2A 
 
ATP7A 
 
TGFBI 
 
ARHGAP5 
 
MAP3K2 
AK3L1 
 
GABBR2 
 
RASD2 
 
BACE1 
 
TLK1 
 
ARHGEF12  MAP3K5 
AKAP7 
 
GAD1 
 
RBM24 
 
BAHD1 
 
TMCC1 
 
ARHGEF9 
 
MAP4K4 
ALS2CR13 
 
GALNT1 
 
RBM5 
 
BCL6 
 
TMEM16A 
 
ARID4B      MAP9 
AMMECR1L GALNT17 
 
RBM9 
 
BCLAF1 
 
TNKS 
 
ARPC5 
 
MAPK9 
AMOTL1 
 
GALNT3 
 
RBMS3 
 
C14orf129 TNRC6A 
 
ARPP-21 
 
MAX 
AMOTL2 
 
GCH1 
 
REEP4 
 
C18orf25 
 
TNRC6B 
 
ATF7 
 
MEF2D 
ANK2 
 
GIT2 
 
RERE 
 
C3orf58 
 
TRAM1 
 
ATG5 
 
METAP2 
ANP32B 
 
GOLPH3 
 
RFX1 
 
C9orf150 
 
TRIM2 
 
ATP10A 
 
MGC4655 
ANXA2 
 
GOPC 
 
RFXDC2 
 
CACNB2 
 
TRPM7 
 
ATP2B1 
 
MITF 
AP2M1 
 
GOSR1 
 
RHOJ 
 
CAMTA1 
 
TSC22D2 
 
ATP2B2 
 
MLL3 
AP4E1 
 
GOT1 
 
RIMS2 
 
CAPZA1 
 
UBE2H 
 
ATRX 
 
MLLT3 
APPBP2 
 
GPAM 
 
RIMS3 
 
CARM1 
 
UBE2R2 
 
AUTS2 
 
MLSTD2 
ARCN1 
 
GPATCH8 
 
RIMS4 
 
CBFA2T2 
 
UBE3C 
 
AVPR1A 
 
MTF1 
ARFGEF1 
 
GPBP1L1 
 
RIPK5 
 
CCNG1 
 
UTRN 
 
B3GNT2 
 
MTMR10 
ARFIP2 
 
GPC6 
 
RNF11 
 
CELSR2 
 
VANGL1 
 
BAAT 
 
MTMR4 
ARHGDIA 
 
GPR124 
 
RNF128 
 
ChGn 
 
VCL 
 
BACE2 
 
MTUS1 
ARHGEF17 GPR158 
 
RNF144 
 
CLOCK 
 
XYLT1 
 
BAZ2A 
 
MTX2 
ARHGEF2 
 
GPR85 
 
RNF150 
 
CNNM1 
 
YPEL2 
 
BAZ2B 
 
MXD1 
ARID3B 
 
GPRASP2 
 
RNF19 
 
CNNM2 
 
ZBTB39 
 
BCL9 
 
MXI1 
ARL1 
 
GRSF1 
 
RNF44 
 
CNOT6L 
 
ZBTB41 
 
BDNF 
 
N4BP3 
ARMCX2 
 
GZF1 
 
RPS6KA2 
 
CNTN3 
 
ZFHX4 
 
BICD2 
 
NAGS 
ARPC1A 
 
HCN2 
 
RPS6KA4 
 
COL15A1 
 
ZKSCAN1 
 
BRD1 
 
NARG1 
ASXL1 
 
HDAC4 
 
RTN4RL1 
 
CPEB1 
 
ZNF236 
 
C10orf12 
 
NCAM2 
ATF1 
 
HECW2 
 
RUNX1 
 
CPEB2 
 
ZNF319 
 
C17orf63 
 
NDST3 
ATOH8 
 
HIAT1 
 
RUTBC2 
 
CPEB4 
 
ZNF354A 
 
C19orf22 
 
NEDD9 
ATP11A 
 
HISPPD1 
 
RXRA 
 
CREB3L2 
 
ZNF618 
 
C20orf23 
 
NEGR1 
ATP11C 
 
HISPPD2A S100PBP 
 
CREB5 
   
C20orf77 
 
NEUROG2 
ATP8B2 
 
HMGA2 
 
SCN2B 
 
CREBZF 
   
C5orf5 
 
NFATC1 
ATXN1 
 
HN1L 
 
SCUBE3 
 
CRIM1 
   
C9orf25 
 
NIPA1 
ATXN3 
 
HNRPA3 
 
SCYL3 
 
CSDA 
   
C9orf58 
 
NLK 
ATXN7 
 
HOXC13 
 
SDC2 
 
CSNK1A1 
   
CACNB1 
 
NR2F6 
AUH 
 
HRB 
 
SEC31A 
 
CXCR4 
   
CACNG3 
 
NR3C2 
AXL 
 
HRBL 
 
SEMA6D 
 
DCUN1D4 
   
CALD1 
 
NRBF2 
B4GALNT1 ICMT 
 
SENP1 
 
DCX 
   
CALM1 
 
NRK 
BAG4 
 
IGF2BP1 
 
SERTAD2 
 
DDX17 
   
CAP1 
 
NUP153 
BAIAP2 
 
IKZF2 
 
SEZ6 
 
DDX3X 
   
CAPN5 
 
NUP160 
BAZ2B 
 
IKZF5 
 
SFRS10 
 
DEDD 
   
CAST 
 
OTUD5 
BCAT2 
 
IPO11 
 
SFRS6 
 
DHX40 
   
CBLN2 
 
OTX2 
BCL11A 
 
IPO13 
 
SFXN2 
 
DIAPH2 
   
CCNC 
 
PALLD 
BCL2L11 
 
IPO4 
 
SGCD 
 
DIO2 
   
CCND1 
 
PALM2-AKAP2 
BICC1 
 
ISL1 
 
SGMS1 
 
DLX3 
   
CCNJ 
 
PCDH9 
BIN1 
 
ITGA6 
 
SH2B3 
 
DOCK9 
   
CDC14A 
 
PCGF2 
BMPER 
 
ITPKC 
 
SH3BP4 
 
DTNA 
   
CDC2L6 
 
PDZRN3 
BRPF3 
 
JAKMIP2 
 
SH3GLB1 
 
DYNC1LI2 
   
CDH2 
 
PER2 
188 
 
BRUNOL4 
 
JMJD2C 
 
SHB 
 
DYRK1A 
   
CDYL 
 
PER3 
BRUNOL6 
 
JUB 
 
SHC1 
 
EDEM3 
   
CGI-09 
 
PFN2 
BSN 
 
JUP 
 
SHC2 
 
EIF4E 
   
CHD4 
 
PHF16 
BTBD10 
 
KCNK4 
 
SHROOM3 ERBB2IP 
   
CHD6 
 
PHF17 
BTBD14B 
 
KCNMB2 
 
SIN3A 
 
ERC2 
   
CHIC1 
 
PHF6 
BTBD7 
 
KIAA0174 
 
SIRT1 
 
ESR1 
   
CITED4 
 
PHYHIPL 
BTG2 
 
KIAA0284 
 
SIX5 
 
EVI5L 
   
CKAP4 
 
PLCB1 
C11orf58 
 
KIAA0323 
 
SLC10A3 
 
FAM107B 
   
CLCN5 
 
PLEC1 
C11orf9 
 
KIAA0423 
 
SLC16A2 
 
FAM19A4 
   
CLINT1 
 
POU2F3 
C14orf101 KIAA0562 
 
SLC19A2 
 
FAM46C 
   
CLIP3 
 
POU3F1 
C14orf147 KIAA0738 
 
SLC1A1 
 
FAM55C 
   
CLP1 
 
POU4F1 
C16orf70 
 
KIAA0831 
 
SLC20A2 
 
FBN1 
   
CNOT6 
 
PPARBP 
C17orf85 
 
KIAA1217 
 
SLC22A17 
 
FBXW2 
   
COL1A1 
 
PPAT 
C1QL1 
 
KIAA1219 
 
SLC26A7 
 
FGF12 
   
COPS2 
 
PPP2CA 
C1QL3 
 
KIAA1468 
 
SLC27A4 
 
FLJ11171 
   
CPLX2 
 
PPP2R2D 
C20orf39 
 
KIAA1539 
 
SLC30A3 
 
FLRT3 
   
CPNE8 
 
PPP2R5A 
C21orf25 
 
KIAA1553 
 
SLC30A8 
 
FNIP1 
   
CPT1A 
 
PPP2R5E 
C21orf91 
 
KIAA1913 
 
SLC33A1 
 
FOXP1 
   
CSMD2 
 
PRKACB 
C22orf9 
 
KIF13B 
 
SLC39A13 
 
FOXP4 
   
CSN3 
 
PRKG1 
C3orf57 
 
KIF21A 
 
SLC39A14 
 
FREM2 
   
CSNK1A1L PSMF1 
C5orf30 
 
KITLG 
 
SLC5A3 
 
FRMD6 
   
CSNK1G1 
 
PTPN9 
C6orf106 
 
KLF12 
 
SLC6A6 
 
FRYL 
   
CSNK2A2 
 
PURB 
C7orf42 
 
KLF13 
 
SLC7A8 
 
FSTL1 
   
CTDSPL 
 
PWWP2 
C8ORFK32 KLHDC5 
 
SLITRK2 
 
GABRB2 
   
CTGF 
 
RAB11FIP2 
CA7 
 
KLHL1 
 
SMARCE1 
 
GALNAC4S-6ST 
  
CTTNBP2NL RAB30 
CAMK2N1 KLHL24 
 
SMC1A 
 
GLCCI1 
   
CUL4B 
 
RAB31 
CAMKK2 
 
KLHL3 
 
SMEK1 
 
GMEB2 
   
CXXC5 
 
RAB8B 
CBL 
 
KSR1 
 
SMPD3 
 
GNPNAT1 
  
CYP2U1 
 
RAD23B 
CBLN4 
 
LAMP1 
 
SNAP23 
 
GRHL1 
   
DCUN1D1 
 
RALBP1 
CBX1 
 
LDLRAD3 
 
SNF1LK 
 
HDAC5 
   
DDHD1 
 
RANBP9 
CBX6 
 
LEPRE1 
 
SNX16 
 
HIC2 
   
DDX3Y 
 
RAPH1 
CC2D1A 
 
LHFP 
 
SNX25 
 
HIPK1 
   
DDX50 
 
RARG 
CC2D1B 
 
LIFR 
 
SNX7 
 
HIST1H4A 
   
DICER1 
 
RASAL2 
CCDC126 
 
LIN7C 
 
SOAT1 
 
HLCS 
   
DLG2 
 
RBPMS2 
CCDC43 
 
LMBRD2 
 
SON 
 
HMG20A 
   
DLG3 
 
RFFL 
CCDC6 
 
LMX1A 
 
SORBS3 
 
HOXA11 
   
DMXL1 
 
RFT1 
CCNE1 
 
LOC153222 SP4 
 
HUNK 
   
DMXL2 
 
RHOA 
CCNE2 
 
LOC162073 SP7 
 
ID4 
   
DNAJA5 
 
RICS 
CD47 
 
LOC201725 SPECC1L 
 
IGF2BP2 
   
DNAJC6 
 
RICTOR 
CDC73 
 
LOC401720 SPG20 
 
IGF2BP3 
   
DNAL4 
 
RNF2 
CDH1 
 
LPHN1 
 
SPIN1 
 
IKZF4 
   
DNMT3B 
 
RNF6 
CENTG2 
 
LPP 
 
SPTLC2 
 
INSIG1 
   
DSCAML1 
 
ROCK1 
CEP350 
 
LRCH4 
 
SRC 
 
ITM2B 
   
DST 
 
RP11-493K23.2 
CHMP2B 
 
LSM14A 
 
SRCAP 
 
ITM2C 
   
DUSP10 
 
RP11-493K23.3 
CHSY1 
 
LUC7L2 
 
SRF 
 
KALRN 
   
DUSP5 
 
RP2 
CLCN5 
 
LZTS2 
 
SRGAP3 
 
KCNA1 
   
DYNLL2 
 
RPIA 
CLCN6 
 
MAEA 
 
SRPK1 
 
KCNJ2 
   
EDG3 
 
RRBP1 
CLDN2 
 
MAP1B 
 
SSX2IP 
 
KCTD12 
   
EEF1A1 
 
RUTBC3 
CMTM6 
 
MAP2K3 
 
ST8SIA4 
 
KIAA0240 
   
EFCBP1 
 
SATB2 
CNNM4 
 
MAP2K7 
 
STAM 
 
KIAA1128 
   
EHF 
 
SCN1A 
CNOT1 
 
MAP3K3 
 
STC1 
 
KIAA1598 
   
EIF3S1 
 
SCN2A 
CNOT7 
 
MAPKAPK2 STCH 
 
KIAA1967 
   
EIF4G3 
 
SCN8A 
CNTFR 
 
MAR06/ 
 
STK38L 
 
KIF1C 
   
EIF5A2 
 
SCOC 
CNTN4 
 
MDGA1 
 
STMN1 
 
KLF5 
   
EML5 
 
SEC61B 
COL12A1 
 
MESDC1 
 
STX1A 
 
KLHL18 
   
ENOX2 
 
SEP15/ 
COL18A1 
 
MGA 
 
SYAP1 
 
KPNB1 
   
ENTPD7 
 
SETBP1 
COL4A2 
 
MGC13057 SYNJ1 
 
LARP1 
   
EPHB1 
 
SETD7 
COL5A1 
 
MKNK2 
 
SYNJ2BP 
 
LDLRAP1 
   
ERF 
 
SETD8 
COL9A1 
 
MLXIP 
 
SYNPR 
 
LIN28 
   
EYA1 
 
SF3A3 
COLEC12 
 
MME 
 
SYT10 
 
LIN28B 
   
FAM13A1 
 
SLC12A2 
CPEB3 
 
MMP15 
 
SYT4 
 
LMNA 
   
FAM63B 
 
SLC17A6 
189 
 
CSNK1G2 
 
MMP16 
 
T,brachuury 
 
LOC196463 
  
FAM80A 
 
SLC25A26 
CTDP1 
 
MNT 
 
TARDBP 
 
LRRC1 
   
FBXL3 
 
SLC30A7 
CTDSP2 
 
MRFAP1 
 
TBC1D22A 
 
LRRTM4 
   
FBXO10 
 
SLC38A2 
CTHRC1 
 
MTHFD1L 
 
TBC1D4 
 
M6PR 
   
FBXO11 
 
SLC39A10 
CTLA4 
 
MTMR2 
 
TBL1XR1 
 
MAF 
   
FGL2 
 
SLC6A8 
CUL4A 
 
MTPN 
 
TBPL1 
 
MAMDC1 
   
FJX1 
 
SLITRK5 
D4ST1 
 
MYH1 
 
tcag7.1017 
 
MAN1A2 
   
FLJ20366 
 
SLMAP 
DACT3 
 
MYH9 
 
TCF2 
 
MAP1A 
   
FLJ39378 
 
SMAD2 
DBNL 
 
MYO1C 
 
TCF7 
 
MAP3K7IP3 
  
FLJ45557 
 
SMARCC1 
DBT 
 
MYO1D 
 
TES 
 
MAP7 
   
FMNL2 
 
SMPD4 
DCBLD2 
 
MYOHD1 
 
TFRC 
 
MBNL1 
   
FRMPD4 
 
SNIP 
DCC 
 
NAGPA 
 
TGFBR2 
 
MIER3 
   
G3BP2 
 
SNX7 
DENND1A NCOA3 
 
TGOLN2 
 
MTHFD2 
   
GABARAPL1 SNX9 
DGKB 
 
NCOA7 
 
THBS2 
 
MUM1L1 
   
GABPA 
 
SOBP 
DIP 
 
NDRG1 
 
TLN1 
 
MYPN 
   
GADD45A 
 
SOCS2 
DIXDC1 
 
NEFH 
 
TM9SF3 
 
NAP1L1 
   
GALNACT-2 SOCS7 
DKFZp667G2110 NEK1 
 
TMEM109 
 
NCOA1 
   
GALNT7 
 
SORL1 
DLGAP2 
 
NEK9 
 
TMEM28 
 
NCOR2 
   
GATA3 
 
SP1 
DNAJA4 
 
NID2 
 
TNFRSF21 
 
NEDD4 
   
GFRA2 
 
SP3 
DNAJB1 
 
NMT1 
 
TNS1 
 
NFASC 
   
GJA3 
 
SPG21 
DNAJC14 
 
NMT2 
 
TOX2 
 
NFIB 
   
GLCE 
 
SPRED2 
DNAJC8 
 
NOX4 
 
TRIM55 
 
NFKB1 
   
GLS 
 
SPTY2D1 
DOLPP1 
 
NPY2R 
 
TSNAX 
 
NHLH2 
   
GORASP2 
 
SSU72 
DPP4 
 
NRF1 
 
TSPAN9 
 
NOTCH2 
   
GOT2 
 
ST6GALNAC3 
DR1 
 
NRP1 
 
TTYH2 
 
NPTX1 
   
GPR177 
 
STAG2 
DRD2 
 
NTNG1 
 
TULP4 
 
NR5A2 
   
GRAMD3 
 
STAT5B 
DSCR1L1 
 
NTRK3 
 
TXNDC5 
 
ONECUT1 
   
GRIA2 
 
STIM1 
DSE 
 
NUTF2 
 
UBE2Q1 
 
ONECUT2 
   
GRIA4 
 
STX16 
DTD1 
 
ODZ1 
 
UBE2Z 
 
OSBPL3 
   
GRIN2A 
 
SUMO1 
DUSP6 
 
OPCML 
 
UBE4B 
 
OTUD7B 
   
GRM7 
 
SV2A 
DYNC1LI2 
 
OSBPL11 
 
UBFD1 
 
OXSR1 
   
GTF2H1 
 
SYNE2 
DYRK1B 
 
OTUD4 
 
UBN1 
 
P4HA2 
   
H2AFZ 
 
TBC1D2B 
EDD1 
 
PACSIN1 
 
UBR1 
 
PAK2 
   
HBP1 
 
TBL1X 
EFNA1 
 
PAK6 
 
UBXD8 
 
PAK4 
   
HIVEP2 
 
TCF7L2 
EGLN3 
 
PALMD 
 
UHRF1 
 
PANK3 
   
HLF 
 
TEAD1 
EGR3 
 
PB1 
 
ULK2 
 
PARG 
   
HNRPH3 
 
TFAP2B 
EHD4 
 
PCBP4 
 
UNC13A 
 
PCGF5 
   
HP1BP3 
 
TFG 
EIF5 
 
PCDH10 
 
USP31 
 
PCSK2 
   
HRNBP3 
 
TGFBR1 
ELAVL1 
 
PCGF6 
 
VAMP3 
 
PGAP1 
   
HS2ST1 
 
THAP4 
ELAVL2 
 
PCNP 
 
VAT1 
 
PGRMC2 
   
HYOU1 
 
TMED5 
ELF1 
 
PCNX 
 
VAV3 
 
PHF20L1 
   
IDH1 
 
TMED7 
ELL 
 
PCSK6 
 
VDAC3 
 
PHF21A 
   
IFRD2 
 
TMEM1 
ELOVL4 
 
PDE11A 
 
VGLL4 
 
PHLDB2 
   
IGF2R 
 
TMEM150 
ELOVL7 
 
PDE7B 
 
WAPAL 
 
PI4KII 
   
INOC1 
 
TMEM32 
EMB 
 
PDGFC 
 
WDR20 
 
PIK3R3 
   
INPP5A 
 
TMTC2 
EN1 
 
PDGFRB 
 
WDTC1 
 
PITPNM2 
   
IQCH 
 
TOB2 
EN2 
 
PDK4 
 
WIPF1 
 
PMP22 
   
IQGAP2 
 
TP53INP1 
ENTPD5 
 
PERQ1 
 
WNT4 
 
POU2F2 
   
IRS2 
 
TPPP 
EPAS1 
 
PHF13 
 
WSB1 
 
POU3F2 
   
IRX3 
 
TRAF3 
EPHA7 
 
PHF15 
 
XPO4 
 
PRDM1 
   
ITGA10 
 
TRIM36 
EPHB2 
 
PHF8 
 
XRN1 
 
PRUNE 
   
ITPKC 
 
TRIM39 
ERG 
 
PHLDB1 
 
YAP1 
 
PURA 
   
JAK1 
 
TTC7B 
ETS1 
 
PHOSPHO1 YIPF4 
 
RAB8A 
   
JAKMIP2 
 
TTYH3 
EXTL3 
 
PHTF2 
 
ZBTB38 
 
RANBP17 
   
JAZF1 
 
UBE2J2 
FAM117A 
 
PIAS3 
 
ZBTB4 
 
RANBP2 
   
JMJD2A 
 
UBL3 
FAM123B 
 
PIGZ 
 
ZC3H10 
 
RAP2C 
   
JOSD1 
 
UBQLN2 
FAM13C1 
 
PIM3 
 
ZC3H12B 
 
RCOR1 
   
JPH1 
 
UBQLN3 
FAM19A5 
 
PIP5K2B 
 
ZDHHC5 
 
RHOBTB1 
   
KCNK2 
 
USP37 
FAM43B 
 
PJA2 
 
ZDHHC7 
 
RHOQ 
   
KCNS2 
 
USP46 
FAM46A 
 
PLD3 
 
ZIC5 
 
RNF111 
   
KCTD6 
 
USP9X 
FAM58A 
 
PLEKHA1 
 
ZNF131 
 
RNF24 
   
KIAA0152 
 
VCP 
190 
 
FAM62A 
 
PLEKHA6 
 
ZNF248 
 
RNF38 
   
KIAA0355 
 
VDAC1 
FAM62B 
 
POLR3G 
 
ZNF263 
 
ROD1 
   
KIAA0427 
 
VIP 
FAM73B 
 
PPAPDC2 
 
ZNF324 
 
RP11-130N24.1 
  
KIAA0494 
 
WDFY3 
FAM91A1 
 
PPARA 
 
ZNF365 
 
RP11-217H1.1 
  
KIAA0523 
 
WHSC2 
FBN2 
 
PPARD 
 
ZNF395 
 
RUNX2 
   
KIAA1409 
 
XKR6 
FBS1 
 
PPP1R13B ZNF407 
 
RYBP 
   
KIAA1522 
 
XLKD1 
FBXL11 
 
PPP2R5D 
 
ZNF629 
 
SACS 
   
KLF9 
 
XPO1 
FBXL16 
 
PRDM10 
 
ZNRF2 
 
SAPS3 
   
L3MBTL3 
 
YPEL1 
FBXL2 
 
PRKCA 
   
SCRIB 
   
LASS2 
 
YTHDF3 
FBXL3 
 
ProSAPiP1 
  
SDC1 
   
LATS1 
 
ZBTB7A 
FBXO33 
 
PRRT2 
   
SFRS1 
   
LCOR 
 
ZCCHC8 
FBXW11 
 
PRRT3 
   
SH3BGRL2 
  
LENG8 
 
ZDHHC17 
FCMD 
 
PRRX1 
   
SHANK2 
   
LEPR 
 
ZDHHC21 
FGF5 
 
PSD3 
   
SHROOM4 
  
LEPROTL1 
 
ZIC1 
FLI1 
 
PSEN1 
   
SIX4 
   
LETMD1 
 
ZMIZ1 
FLJ20294 
 
PTBP1 
   
SLC12A5 
   
LOC133308 ZMYM2 
FLJ25476 
 
PTBP2 
   
SLC25A24 
   
LOC152485 ZNF148 
FMR1 
 
PTCH1 
   
SLC31A2 
   
LOC339745 ZNF364 
FNBP1 
 
PTER 
   
SLC35B3 
   
LOC374395 ZNF664 
  
PTGFRN 
           
Table S3.3A  
Predicted targets of miR-9 and isomiR-9. Tested targets were highlighted in yellow. 
Target prediction was performed using TargetScan Human and TargetScan Custom. 
 
 
 
miR-302a  
  
Common targets 
  
isomiR-302a 
ABHD3 
 
MTERFD2 
 
ABCA1 
 
TMUB2 
 
A2BP1 
ACAD9 
 
MTMR4 
 
AEBP2 
 
TNFAIP1 
 
ABR 
ACTL6A 
 
MUTED 
 
ANKRD13B TOX 
 
ADCYAP1 
ACVR1 
 
MYBL1 
 
APP 
 
TSHZ3 
 
AP3M1 
ALKBH5 
 
MYCN 
 
ARHGEF17 UBE2B 
 
ARF1 
ALX4 
 
MYLK 
 
ARID4A 
 
UBE2Q2 
 
ARFIP2 
ANK2 
 
MYST3 
 
ARID4B 
 
UBFD1 
 
ARHGEF3 
ANKRD13C MYT1L 
 
ASF1A 
 
UNK 
 
ARHGEF9 
ANKRD54 NCOA7 
 
ASF1B 
 
USP42 
 
ARMC8 
AOF1 NEO1 
 
ATAD2 
 
USP46 
 
ASH1L 
ARHGAP24 NEUROD1  ATP2B2 
 
VLDLR 
 
BACH2 
191 
 
ARHGAP29 NEUROD6  BNC2 
 
VSX1 
 
BAGE2 
ARHGEF18 NFIA 
 
C10orf12 
 
WDR37 
 
BAGE3 
ASXL2 NFYA 
 
C11orf9 
 
YOD1 
 
BAGE4 
ATP2C1 
 
NPAS3 
 
C16orf28 
 
YTHDF3 
 
BAGE5 
ATXN1 
 
NR2F2 
 
C6orf107 
 
ZBTB11 
 
BAZ1A 
BAHD1 
 
NR4A2 
 
C6orf85 
 
ZBTB41 
 
BTBD3 
BAMBI 
 
NUFIP2 
 
C7orf43 
 
ZBTB44 
 
C12orf34 
BCL11A 
 
ODZ2 
 
CAMK2N1 ZBTB47 
 
C13orf27 
BCL11B 
 
ORMDL3 
 
CC2D1A 
 
ZDHHC17 
 
C19orf48 
BCL2L11 
 
OSBPL5 
 
CCND1 
 
ZFP91 
 
C1orf21 
BCL6 
 
OTUD4 
 
CCND2 
 
ZFPM2 
 
C5orf25 
BLCAP 
 
OXR1 
 
CDC2L6 
 
ZFYVE26 
 
C6orf35 
BRMS1L 
 
PARP8 
 
CDCA7 
 
ZKSCAN1 
 
CACNG3 
BRP44L 
 
PCAF 
 
CFL2 
 
ZNF148 
 
CCDC6 
BTG1 
 
PCDHA1 
 
CNOT6 
 
ZNF385 
 
CDC25B 
C10orf104 PCDHA10 
 
CREB5 
 
ZNF436 
 
CDH2 
C11orf30 
 
PCDHA12 
 
CREBL1 
 
ZNF650 
 
CDH4 
C14orf101 PCDHA13 
 
CRTC2 
 
ZNF800 
 
CDKN1B 
C16orf72 
 
PCDHA2 
 
CUGBP2 
 
ZNFX1 
 
CEP350 
C19orf43 
 
PCDHA3 
 
CXXC6 
 
ZRANB1 
 
CLDN2 
C1orf9 
 
PCDHA4 
 
CYP26B1 
   
CNOT2 
C21orf25 
 
PCDHA5 
 
DDHD1 
   
CNR1 
CADM1 
 
PCDHA6 
 
DERL2 
   
CPD 
CADM2 
 
PCDHA7 
 
DNAJA2 
   
CXXC5 
CAMTA1 
 
PCDHA8 
 
EDNRB 
   
DDX3X 
CCNJ 
 
PCDHAC1 
 
EPAS1 
   
DLL4 
CDK2 
 
PCDHAC2 
 
ERBB4 
   
DNAJC13 
CLCN4 
 
PERQ1 
 
ESR1 
   
DOCK3 
CLIP4 
 
PFN2 
 
FAM13C1 
   
DPP4 
COL23A1 
 
PHF2 
 
FAM46C 
   
ELF4 
CORO2B 
 
PHF6 
 
FAM57A 
   
EMX2 
CPEB1 
 
PHLPPL 
 
FGD5 
   
FBXW11 
CPEB2 
 
PIGS 
 
FLT1 
   
FIGN 
CRIM1 
 
PLAGL2 
 
FNDC3A 
   
FNBP1L 
CRK 
 
PLEKHA3 
 
GATAD2B 
   
GAB2 
CUTL1 
 
PLEKHM1 
 
GRHL2 
   
GAS2 
CXCR4 
 
POLQ 
 
HN1 
   
GBAS 
DAZAP2 
 
PPP1R10 
 
HRBL 
   
H2AFY 
DCUN1D1 
 
PPP1R9A 
 
IGF2BP1 
   
HCN1 
DHX40 
 
PPP3R1 
 
IKZF2 
   
HCN4 
DKK1 
 
PPP6C 
 
INTS6 
   
HIVEP3 
DMTF1 
 
PRR16 
 
IQSEC2 
   
ITFG1 
DPP8 
 
PRRG1 
 
IQWD1 
   
ITGA9 
DPYSL5 
 
PRRX1 
 
IRF2 
   
ITPR3 
DRD1 
 
PTCHD1 
 
JAZF1 
   
KPNB1 
DUSP2 
 
PURA 
 
KBTBD8 
   
LASS3 
192 
 
DYRK2 
 
R3HDM1 
 
KIAA1212 
   
LCOR 
E2F7 
 
RAB11FIP1  KIAA1522 
   
LDOC1 
ECT2 
 
RAB5C 
 
KIF26B 
   
LETMD1 
EIF2C1 
 
RAB6A 
 
KIF3B 
   
LMBR1L 
ELAVL2 
 
RAB6C 
 
KLHL18 
   
LOC51035 
EPHA2 
 
RAB7A 
 
KPNA1 
   
MAT2A 
ETV1 
 
RAD23B 
 
LEFTY1 
   
MICALL1 
FAM117A 
 
RBBP6 
 
LEFTY2 
   
MLL5 
FAM73B 
 
RBBP7 
 
LHX6 
   
MTCH2 
FAM78A 
 
RBJ 
 
LMO3 
   
MUM1L1 
FBXL11 
 
RBM33 
 
LOC153222 
  
NEK1 
FBXO10 
 
RDBP 
 
LYPD6 
   
NKRF 
FBXO11 
 
RECK 
 
MAP3K14 
   
NOVA1 
FBXO41 
 
REEP3 
 
MBNL2 
   
NT5C3 
FEM1C 
 
RHOC 
 
MECP2 
   
OCRL 
FGF9 
 
RORB 
 
MED12L 
   
PCDH10 
FILIP1L 
 
RPS6KA1 
 
MEF2C 
   
PCGF5 
FLJ25476 
 
RPS6KA3 
 
MINK1 
   
PHF15 
FLJ45187 
 
RRAGD 
 
MKRN1 
   
PICALM 
FNDC3B 
 
RSBN1 
 
MLL 
   
POU4F1 
FOXF2 
 
RSBN1L 
 
MMP23B 
   
PPP2R3A 
FOXJ2 
 
RSRC2 
 
MMP24 
   
PPP3CA 
FOXJ3 
 
RTN1 
 
MNT 
   
PRC1 
FOXL2 
 
RUNX1 
 
MTF1 
   
PRKACB 
FRMD4A 
 
SCRT2 
 
MTMR3 
   
PTBP2 
GABPB2 
 
SDC1 
 
MTUS1 
   
PTPLB 
GLIS3 
 
SETD5 
 
NAPE-PLD 
  
QSER1 
GNB5 
 
SIPA1L3 
 
NEK9 
   
RAP1A 
HBP1 
 
SLAIN1 
 
NFIB 
   
RARB 
HDAC4 
 
SLC2A4 
 
NR2C2 
   
RASAL2 
HIC2 
 
SMAD2 
 
NR4A3 
   
RBM9 
HIF1AN 
 
SNIP 
 
NTN4 
   
RC3H1 
HIPK3 
 
SNRK 
 
OLFM3 
   
RDX 
HIVEP2 
 
SNX5 
 
OPCML 
   
RET 
HLF 
 
SOBP 
 
OSBPL8 
   
RFX4 
HLX1 
 
SP3 
 
PAK7 
   
RFXDC2 
HNRPH3 
 
SSX2IP 
 
PAN3 
   
RICTOR 
HNRPUL1 
 
ST8SIA2 
 
PAPOLA 
   
RKHD2 
HNRPUL2 
 
ST8SIA3 
 
PBX3 
   
ROCK1 
IGF1R 
 
SUV39H1 
 
PGBD5 
   
SEP02/ 
IHPK1 
 
SYDE1 
 
PKN2 
   
SLC24A3 
INHBB 
 
TAL1 
 
PLAG1 
   
SLC38A2 
INOC1 
 
TAPT1 
 
PLXNA1 
   
SMAD9 
ITGB4 
 
TBC1D8B 
 
PRDM4 
   
SOCS3 
ITGB8 
 
TESK2 
 
PRDM8 
   
SOX11 
JAKMIP1 
 
TIAM1 
 
PTPRD 
   
SP1 
193 
 
JOSD1 
 
TLE4 
 
PURB 
   
SPRED1 
KBTBD2 
 
TLOC1 
 
RAB11A 
   
SPTLC1 
KCNA1 
 
TMEM28 
 
RAB22A 
   
TBL1XR1 
KCND2 
 
TNKS2 
 
RABGAP1 
   
THRAP1 
KIAA0157 
 
TOB2 
 
RALGDS 
   
TMCO2 
KIAA1267 
 
TOX3 
 
RAPGEFL1 
  
TMEM87A 
KLF12 
 
TP53INP1 
 
RASSF2 
   
TMTC1 
KLF13 
 
TP53INP2 
 
RBL1 
   
TNRC6A 
KLHL28 
 
TP73L 
 
RGL1 
   
TNRC6B 
KLHL3 
 
TRIM36 
 
RGMA 
   
TOM1L2 
KPNA2 
 
TRIP11 
 
RNF38 
   
TUBG1 
KREMEN1 
 
TRPS1 
 
RNF6 
   
UBAP1 
LAMP2 
 
TRPV6 
 
RPS6KA5 
   
UBL3 
LARP4 
 
TUSC2 
 
SAR1B 
   
UHMK1 
LASS6 
 
TWF1 
 
SENP1 
   
VAMP3 
LATS2 
 
TXNIP 
 
SLC6A9 
   
VANGL2 
LEF1 
 
UBE2J1 
 
SLITRK3 
   
VASH2 
LHX8 
 
UBE2R2 
 
SNF1LK 
   
WDR26 
LMX1A 
 
UBE2W 
 
SNX21 
   
WNT5A 
LOC130074 ULK1 
 
SPOP 
   
XYLT1 
LOC150786 UNC5A 
 
SS18L1 
   
YTHDC1 
LOC162427 VEGFA 
 
SUV420H1 
  
ZBTB26 
LRP2 
 
WDR20 
 
SYNC1 
   
ZFR 
LUC7L2 
 
WDR45 
 
TARDBP 
   
ZMYM2 
LYCAT 
 
WEE1 
 
TFAP4 
   
ZNF180 
MAML1 
 
YPEL2 
 
TIPARP 
   
ZNF462 
MAP1B 
 
YWHAZ 
 
TMEM16F 
   
ZNF654 
MAP3K11 
 
ZBTB4 
      MAPK9 
 
ZBTB6 
      MAR08/ 
 
ZBTB7A 
      MBNL1 
 
ZBTB9 
      MCCD1 
 
ZDHHC9 
      MCL1 
 
ZFHX4 
      MFAP3L 
 
ZFP36L2 
      MIER3 
 
ZMYND11 
      MLL3 
 
ZNF2 
      MLLT6 
 
ZNF238 
      MOBKL1A ZNF512B 
      MRPS25 
 
ZNF697 
       
Table S3.3B  
Predicted targets of miR-302a and isomiR-302a. Tested targets were highlighted in 
yellow. Target prediction was performed using TargetScan Human and TargetScan 
Custom. 
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hESCs 
Predicted target to isomiR 
only 
Predicted targets common to 
both canonical miRNA and 
isomiR 
101 158/681 23.2% 414/681 60.1% 
183 366/636 57.5% 71/636 11.2% 
302a 130/445 29.2% 161/445 36.2% 
302a* 281/329 85.4% 13/329 4% 
378 83/203 40.9% 21/203 10.3% 
 
Average 46.4%  24.4% 
   
  
NSCs 
  
  
9 398/1224 32.5% 239/1224 19.5% 
9* 233/849 27.4% 338/849 39.8% 
21 119/329 36.1% 19/329 6% 
30a* 281/329 85.4% 13/329 4% 
101 158/681 23.2% 414/681 60% 
140 344/689 50.0% 23/689 33.4% 
151-3p 65/180 36.1% 4/180 2.2% 
320a 130/916 14.2% 68/916 7.4% 
378 83/203 40.9% 21/203 10.3% 
 
Average 38.4%  20.3% 
   
  
MSCs 
  
  
10a 100/286 35.0% 43/286 15% 
16* 121/520 23.3% 42/520 8.1% 
17 178/1168 15.2% 224/1168 19.2% 
23a 106/944 11.2% 518/944 54.9% 
23b 106/944 11.2% 518/944 54.9% 
26a 137/720 19.0% 365/720 50.7% 
28-3p 89/166 53.6% 3/166 1.8% 
29a 93/944 9.9% 357/944 37.8% 
31 216/449 48.1% 31/449 6.9% 
100 2/42 4.8% 0/42 0% 
140-3p 317/557 56.9% 50/557 9.0% 
151-5p 5/11 45.0% 3/11 27.3% 
191 13/49 26.5% 9/49 18.4% 
199b-3p 464/758 61.2% 110/758 14.5% 
214 474/881 53.8% 104/881 11.8% 
222 172/479 35.9% 36/479 7.5% 
337-3p 44/190 23.2% 59/190 31.1% 
376a 81/180 45.0% 8/180 4.4% 
376b 26/168 15.5% 63/168 37.5% 
376c 76/232 32.8% 13/232 5.6% 
379* 203/443 45.8% 76/443 17.2% 
382 58/184 31.5% 6/184 3.3% 
195 
 
409-3p 132/392 33.7% 35/392 8.9% 
455-3p 176/365 48.2% 14/365 3.8% 
495 555/1125 49.3% 192/1125 17.1% 
let-7a 130/949 13.7% 516/949 54.4% 
let-7d 87/906 9.6% 124/906 13.7% 
let-7f 130/949 13.7% 516/949 54.4% 
 
Average 31.2%  21% 
  
38.7%  21.9% 
 
Table S3.4 
Table shows the percentage of predicted targets that is common to both canonical 
miRNA and isomiRs as well as the percentage of the predicted target that is confined 
to only the isomiRs. Analysis was performed on the miRNAs and their isomiRs 
collected from the deep sequencing results of 3 different stem cell lines i.e., human 
embryonic stem cells (hESCs), neural stem cells (NSCs) and mesenchymal stem cells 
(MSCs).  
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1 CDH1 
ccaaaga 
(A1+6) 
miR-9 √ √ √ - √ x x x - 
 
2 DNMT3B 
accaaaa 
(A1+6) 
isomiR-9 √ √ √ √ √ - √ x - 
 
3 HMGA2 
accaaaga 
(A1+7) 
miR-9 √ √ √ √ √ √ √ √ √ 
 
4 NCAM2 
accaaaa 
(A1+6) 
isomiR-9 √ √ √ √ √ x √ √ - 
 
5 Lefty1 
gcactta 
(A1+6) 
miR-302a/ 
isomiR-302a  
√ √ √ x √ x √ x √ 
 
6 PTEN 
gtgcaata 
(A1+7) 
miR-367/ 
isomiR-367 
√ √ √ √ √ √ √ √ √ 
 
7 BTG1 
agcactta 
(A1+7) 
miR-302a √ √ √ √ √ √ √ √ - 
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Table S3.5 
The predicted target sites of miRNA in the 3' UTRs of the listed mRNAs are 
reasonably conserved. The seed target site sequences in the second column are A1 
plus 2 to 7 or 2 to 8 nucleotides. IsomiR-9 and isomiR-302a are 5' isomiRs and 
isomiR-367 is a 3' isomiR. CDH1 and HMGA2 are predicted targets of miR-9 but not 
isomiR-9. DNMT3B and NCAM2 are predicted targets of isomiR-9 but not miR-9. 
Lefty1 is a predicted target of both miR-302a and isomiR-302a. PTEN is a predicted 
target of both miR-367 and isomiR-367. BTG1 is a predicted target of miR-302a but 
not isomiR-302a. √ represents conserved, x represents not conserved and - is not 
available. UCSC Genome Browser (http://genome.ucsc.edu/) was used to analyse the 
seed target site conservation and generate the gene map. 
 
 
Neural Progenitor Stem Cells 
hsa-miR- Sequence Length Seq.no. 
let-7f TGAGGTAGTAGATTGTATAGTT 22 3135 
let-7a TGAGGTAGTAGGTTGTATAGTT 22 2798 
21i1 TAGCTTATCAGACTGATGTTGAC 23 2452 
423 TGAGGGGCAGAGAGCGAGACTTT 23 1512 
let-
7fi1 TGAGGTAGTAGATTGTATAGT 21 649 
9* ATAAAGCTAGATAACCGAAAGT 22 643 
9 TCTTTGGTTATCTAGCTGTATGA 23 587 
92b TATTGCACTCGTCCCGGCCTCC 22 530 
let-
7ai1 TGAGGTAGTAGGTTGTATAGT 21 525 
29a TAGCACCATCTGAAATCGGTTA 22 511 
130a CAGTGCAATGTTAAAAGGGCAT 22 509 
340 TTATAAAGCAATGAGACTGATT 22 487 
21 TAGCTTATCAGACTGATGTTGA 22 462 
let-7c TGAGGTAGTAGGTTGTATGGTT 22 399 
101i1 TACAGTACTGTGATAACTGAAG 22 334 
423i1 TGAGGGGCAGAGAGCGAGACTTTT 24 328 
151-3p CTAGACTGAAGCTCCTTGAGG 21 294 
26a TTCAAGTAATCCAGGATAGGCT 22 289 
let-
7fi2 TGAGGTAGTAGATTGTATAGTTA 23 261 
let-7b TGAGGTAGTAGGTTGTGTGGTT 22 253 
125b TCCCTGAGACCCTAACTTGTGA 22 246 
9*i1 TAAAGCTAGATAACCGAAAGTA 22 216 
130b CAGTGCAATGATGAAAGGGCAT 22 208 
423i2 TGAGGGGCAGAGAGCGAGACTT 22 203 
210 CTGTGCGTGTGACAGCGGCTGA 22 199 
let-7e TGAGGTAGGAGGTTGTATAGTT 22 198 
103 AGCAGCATTGTACAGGGCTATGA 23 196 
320a AAAAGCTGGGTTGAGAGGGCGA 22 190 
197 
 
24i1 TGGCTCAGTTCAGCAGGAACAGT 23 187 
103i1 AGCAGCATTGTACAGGGCTAT 21 178 
151-
3pi1 CTAGACTGAAGCTCCTTGAGGA 22 178 
let-7d AGAGGTAGTAGGTTGCATAGTT 22 156 
let-
7fi3 TGAGGTAGTAGATTGTATAGTTT 23 150 
340i1 TTATAAAGCAATGAGACTGAT 21 149 
let-
7ai2 TGAGGTAGTAGGTTGTATAGTTA 23 146 
let-7g TGAGGTAGTAGTTTGTACAGTT 22 146 
9*i2 ATAAAGCTAGATAACCGAAAGTA 23 145 
30di1 TGTAAACATCCCCGACTGGAAGCT 24 140 
423i3 TGAGGGGCAGAGAGCGAGACT 21 140 
25 CATTGCACTTGTCTCGGTCTGA 22 139 
30e* CTTTCAGTCGGATGTTTACAGC 22 117 
9i1 CTTTGGTTATCTAGCTGTATGA 22 116 
378i1 ACTGGACTTGGAGTCAGAAGGC 22 114 
7i1 TGGAAGACTAGTGATTTTGTTGTT 24 112 
21i2 TAGCTTATCAGACTGATGTTGACA 24 112 
101i2 TACAGTACTGTGATAACTGAAT 22 112 
27b TTCACAGTGGCTAAGTTCTGC 21 110 
140i1 ACCACAGGGTAGAACCACGGAC 22 110 
16 TAGCAGCACGTAAATATTGGCG 22 107 
181ai1 AACATTCAACGCTGTCGGTGAGTTT 25 104 
101i3 GTACAGTACTGTGATAACTGAA 22 102 
let-
7ai3 TGAGGTAGTAGGTTGTATAGTTT 23 100 
92bi1 TATTGCACTCGTCCCGGCCTC 21 96 
let-7i TGAGGTAGTAGTTTGTGCTGTT 22 95 
221*i1 ACCTGGCATACAATGTAGATTTCTGT 26 93 
100 AACCCGTAGATCCGAACTTGTG 22 91 
320ai1 AAAAGCTGGGTTGAGAGGGCGAT 23 89 
30e*i1 CTTTCAGTCGGATGTTTACAGT 22 84 
30a* CTTTCAGTCGGATGTTTGCAGC 22 83 
130ai1 CAGTGCAATGTTAAAAGGGCAC 22 81 
148a TCAGTGCACTACAGAACTTTGT 22 79 
92b*i1 AGGGACGGGACGCGGTGCAGTGT 23 77 
744 TGCGGGGCTAGGGCTAACAGCA 22 74 
9*i3 TAAAGCTAGATAACCGAAAGT 21 71 
30ai1 TGTAAACATCCTCGACTGGAAGCT 24 71 
532 CATGCCTTGAGTGTAGGACCGT 22 68 
9*i4 TAAAGCTAGATAACCGAAAGTAT 23 66 
24 TGGCTCAGTTCAGCAGGAACAG 22 66 
93 CAAAGTGCTGTTCGTGCAGGTAG 23 66 
198 
 
99b CACCCGTAGAACCGACCTTGC 21 63 
101 TACAGTACTGTGATAACTGAA 21 63 
320ai2 AAAAGCTGGGTTGAGAGGGCGAA 23 63 
92b*i2 AGGGACGGGACGCGGTGCAGTGTT 24 60 
151-
3pi2 CTAGACTGAAGCTCCTTGAG 20 58 
146bi1 TGAGAACTGAATTCCATAGGCTGT 24 57 
99bi1 CACCCGTAGAACCGACCTTGCG 22 54 
151-
3pi3 CTAGACTGAAGCTCCTTGAGGT 22 54 
185 TGGAGAGAAAGGCAGTTCCTGA 22 54 
9*i5 TAAAGCTAGATAACCGAAAGTAA 23 53 
101i4 TACAGTACTGTGATAACTGAAA 22 53 
335i1 TCAAGAGCAATAACGAAAAATG 22 51 
let-
7bi1 TGAGGTAGTAGGTTGTGTGGT 21 50 
9i2 TCTTTGGTTATCTAGCTGTATG 22 49 
21i3 TAGCTTATCAGACTGATGTTGACT 24 49 
191 CAACGGAATCCCAAAAGCAGCTG 23 49 
100i1 AACCCGTAGATCCGAACTTGT 21 45 
let-
7ei1 TGAGGTAGGAGGTTGTATAGT 21 44 
16i1 TAGCAGCACGTAAATATTGGCGT 23 43 
151-
3pi4 CTAGACTGAAGCTCCTTGAGGAA 23 43 
423i4 TGAGGGGCAGAGAGCGAGAC 20 42 
17 CAAAGTGCTTACAGTGCAGGTAG 23 41 
128 TCACAGTGAACCGGTCTCTTT 21 40 
191i1 CAACGGAATCCCAAAAGCAGCTGT 24 40 
744i1 TGCGGGGCTAGGGCTAACAGC 21 40 
let-
7gi1 TGAGGTAGTAGTTTGTACAGT 21 40 
28-3p CACTAGATTGTGAGCTCCTGGA 22 39 
30ai2 TGTAAACATCCTCGACTGGAAGC 23 39 
378i2 ACTGGACTTGGAGTCAGAAGGCA 23 39 
423i5 TGAGGGGCAGAGAGCGAGACTTTA 24 38 
let-
7bi2 TGAGGTAGTAGGTTGTGTGGTTT 23 38 
let-
7ei2 TGAGGTAGGAGGTTGTATAGTTT 23 38 
9i3 TCTTTGGTTATCTAGCTGTATGAA 24 37 
151-5p TCGAGGAGCTCACAGTCTAGT 21 37 
378 ACTGGACTTGGAGTCAGAAGG 21 37 
let-
7fi4 TGAGGTAGTAGATTGTATAG 20 37 
30di2 TGTAAACATCCCCGACTGGAAGC 23 36 
199 
 
106bi1 TAAAGTGCTGACAGTGCAGATA 22 36 
92bi2 TATTGCACTCGTCCCGGCCTCCT 23 35 
106b TAAAGTGCTGACAGTGCAGAT 21 35 
130ai2 CAGTGCAATGTTAAAAGGGCATT 23 35 
222i1 AGCTACATCTGGCTACTGGGTCT 23 35 
374ai1 TTATAATACAACCTGATAAGT 21 35 
let-
7ci1 TGAGGTAGTAGGTTGTATGGTTA 23 35 
92a TATTGCACTTGTCCCGGCCTGT 22 34 
181ai2 AACATTCAACGCTGTCGGTGAGTT 24 32 
340i2 TTATAAAGCAATGAGACTGA 20 32 
7 TGGAAGACTAGTGATTTTGTTGT 23 31 
146bi2 TGAGAACTGAATTCCATAGGCTGG 24 31 
374b ATATAATACAACCTGCTAAGTG 22 31 
423i6 TGAGGGGCAGAGAGCGAGA 19 31 
let-
7ei3 TGAGGTAGGAGGTTGTATAGTTA 23 31 
99a AACCCGTAGATCCGATCTTGTG 22 30 
26ai1 TTCAAGTAATCCAGGATAGGCTAT 24 29 
92bi3 TATTGCACTCGTCCCGGCCT 20 29 
769 TGAGACCTCTGGGTTCTGAGCT 22 29 
let-
7ai4 TGAGGTAGTAGGTTGTATAG 20 29 
9*i6 ATAAAGCTAGATAACCGAAAGTAT 24 28 
26bi1 TTCAAGTAATTCAGGATAGGTT 22 28 
92bi4 TATTGCACTCGTCCCGGCCTCA 22 28 
378i3 CTGGACTTGGAGTCAGAAGGC 21 27 
423i7 TGAGGGGCAGAGAGCGAGACTTTTT 25 27 
26ai2 TTCAAGTAATCCAGGATAGGCTA 23 26 
27ai1 TTCACAGTGGCTAAGTTCCG 20 25 
101i5 GTACAGTACTGTGATAACTGAAA 23 25 
130ai3 CAGTGCAATGTTAAAAGGGCA 21 25 
151-
3pi5 CTAGACTGAAGCTCCTTGAGT 21 25 
335i2 TCAAGAGCAATAACGAAAAAT 21 25 
335 TCAAGAGCAATAACGAAAAATGT 23 25 
29ai1 TAGCACCATCTGAAATCGGTT 21 24 
140i2 TACCACAGGGTAGAACCACGGAC 23 24 
let-
7bi3 TGAGGTAGTAGGTTGTGTGGTTA 23 24 
26ai3 TTCAAGTAATCCAGGATAGGCTT 23 23 
30a*i1 CTTTCAGTCGGATGTTTGCAGT 22 23 
92bi5 TATTGCACTCGTCCCGGCCTCT 22 23 
124i1 TAAGGCACGCGGTGAATGCCAA 22 23 
let- TGAGGTAGTAGGTTGTATGGT 21 23 
200 
 
7ci2 
92bi6 TATTGCACTCGTCCCGGCCTCCAT 24 22 
92bi7 TATTGCACTCGTCCCGGCCTCCTAT 25 22 
101i6 GTACAGTACTGTGATAACTGA 21 22 
101i7 TACAGTACTGTGATAACTGAAGT 23 22 
221*i2 ACCTGGCATACAATGTAGATTTCT 24 22 
21i4 AGCTTATCAGACTGATGTTGAC 22 21 
23ai1 ATCACATTGCCAGGGATTTCCA 22 21 
378i4 ACTGGACTTGGAGTCAGAAGGCAT 24 21 
379 TGGTAGACTATGGAACGTAGG 21 21 
21i5 TAGCTTATCAGACTGATGTTGAA 23 20 
27bi1 TTCACAGTGGCTAAGTTCTG 20 20 
130bi1 CAGTGCAATGATGAAAGGGCATT 23 20 
135b TATGGCTTTTCATTCCTATGTGA 23 20 
151-
5pi1 TCGAGGAGCTCACAGTCTAGTA 22 20 
320ai3 AAAAGCTGGGTTGAGAGGGCGAAT 24 20 
9*i7 ATAAAGCTAGATAACCGAAAG 21 19 
let-
7fi5 TGAGGTAGTAGATTGTAT 18 19 
92b*i3 AGGGACGGGACGCGGTGCAGT 21 18 
92b*i4 AGGGACGGGACGCGGTGCAGTGTTT 25 18 
98 TGAGGTAGTAAGTTGTATTGTT 22 18 
103i2 AGCAGCATTGTACAGGGCTATGAT 24 18 
130ai4 CAGTGCAATGTTAAAAGGGCATA 23 18 
320ai4 AAAAGCTGGGTTGAGAGGGCGT 22 18 
1260 ATCCCACCGCTGCCACCA 18 18 
let-
7ci3 TGAGGTAGTAGGTTGTATGGTTT 23 18 
92bi8 TATTGCACTCGTCCCGGCCTCCA 23 17 
92bi9 TATTGCACTCGTCCCGGCCTCCATC 25 17 
103i3 AGCAGCATTGTACAGGGCTATG 22 17 
125bi1 TCCCTGAGACCCTAACTTGTG 21 17 
181a AACATTCAACGCTGTCGGTGAGT 23 17 
195i1 TAGCAGCACAGAAATATTGGCA 22 17 
let-
7fi6 TGAGGTAGTAGATTGTATAGTTATC 25 17 
let-
7fi7 TGAGGTAGTAGATTGTATA 19 17 
100i2 AACCCGTAGATCCGAACTTGTGA 23 16 
423i8 TGAGGGGCAGAGAGCGAGACTTA 23 16 
542-3p TGTGACAGATTGATAACTGAAA 22 16 
let-
7ii1 TGAGGTAGTAGTTTGTGCTGT 21 16 
let-
7ii2 TGAGGTAGTAGTTTGTGCTGTTT 23 16 
201 
 
9i3 CTTTGGTTATCTAGCTGTATGAA 23 15 
29c TAGCACCATTTGAAATCGGTTA 22 15 
let-
7di1 AGAGGTAGTAGGTTGCATAGTTT 23 15 
9*i8 ATAAAGCTAGATAACCGAAAGTAA 24 14 
10ai1 TACCCTGTAGATCCGAATTTGT 22 14 
25*i1 AGGCGGAGACTTGGGCAATTGCT 23 14 
26ai4 TTCAAGTAATCCAGGATAGGC 21 14 
30c-2* CTGGGAGAAGGCTGTTTACTCT 22 14 
30e*i2 CTTTCAGTCGGATGTTTACAG 21 14 
99ai1 AACCCGTAGATCCGATCTTGT 21 14 
151-
3pi6 CTAGACTGAAGCTCCTTGAGGAT 23 14 
221*i3 ACCTGGCATACAATGTAGATTTCTG 25 14 
9i4 TCTTTGGTTATCTAGCTGTAT 21 13 
9i5 TCTTTGGTTATCTAGC 16 13 
23a ATCACATTGCCAGGGATTTCC 21 13 
23b ATCACATTGCCAGGGATTACCACT 24 13 
27a TTCACAGTGGCTAAGTTCCGC 21 13 
28-3pi1 CACTAGATTGTGAGCTCCTGGAA 23 13 
30a*i2 TTTCAGTCGGATGTTTGCAGC 21 13 
101i8 TACAGTACTGTGATAACTGAAGA 23 13 
130ai5 CAGTGCAATGTTAAAAGGGC 20 13 
151-
3pi7 CTAGACTGAAGCTCCTTGAGA 21 13 
151-
3pi8 TACTAGACTGAAGCTCCTTGAGG 23 13 
191i2 CAACGGAATCCCAAAAGCAGCT 22 13 
320ai5 AAAGCTGGGTTGAGAGGGCGA 21 13 
378i5 CTGGACTTGGAGTCAGAAGGCT 22 13 
423i9 TGAGGGGCAGAGAGCGAGACA 21 13 
15a TAGCAGCACATAATGGTTTGTG 22 12 
15ai1 TAGCAGCACATAATGGTTTGT 21 12 
23ai2 ATCACATTGCCAGGGATTTCCAA 23 12 
92bi10 TATTGCACTCGTCCCGGCC 19 12 
130bi2 CAGTGCAATGATGAAAGGGCA 21 12 
140i3 CCACAGGGTAGAACCACGGAC 21 12 
148b TCAGTGCATCACAGAACTTTGT 22 12 
151-
3pi9 TACTAGACTGAAGCTCCTTGAG 22 12 
191i3 CAACGGAATCCCAAAAGCAGCTGA 24 12 
450bi1 TTTTGCAATATGTTCCTGAAT 21 12 
744i2 TGCGGGGCTAGGGCTAACAGCAA 23 12 
1275i1 GTGGGGGAGAGGCTGT 16 12 
let- TGAGGTAGTAGGTTGTATAGTTAA 24 12 
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7ai5 
let-
7di2 AGAGGTAGTAGGTTGCATAGT 21 12 
let-
7fi8 TGAGGTAGTAGATTGTATAGTTC 23 12 
19b TGTGCAAATCCATGCAAAACTGA 23 11 
21i6 TTATCAGACTGATGTTGACTAGC 23 11 
29ai2 TAGCACCATCTGAAATCGGTTAT 23 11 
30di3 TGTAAACATCCCCGACTGGAAGCTT 25 11 
106bi2 TAAAGTGCTGACAGTGCAGA 20 11 
138 AGCTGGTGTTGTGAATCAGGCCG 23 11 
140i4 ACCACAGGGTAGAACCACGGA 21 11 
151-
3pi10 CTAGACTGAAGCTCCTTGA 19 11 
186i1 CAAAGAATTCTCCTTTTGGGCTT 23 11 
378i6 ACTGGACTTGGAGTCAGAAG 20 11 
423i10 TGAGGGGCAGAGAGCGAGAAA 21 11 
let-
7ai6 TGAGGTAGTAGGTTGTAT 18 11 
let-
7fi9 TGAGGTAGTAGATTGTATAGTTG 23 11 
9i6 TTTGGTTATCTAGCTGTATGA 21 10 
9*i9 ATAAAGCTAGATAACCGAAA 20 10 
20a TAAAGTGCTTATAGTGCAGGTAG 23 10 
24i2 TGGCTCAGTTCAGCAGGAAC 20 10 
25*i2 AGGCGGAGACTTGGGCAATTGC 22 10 
27bi2 TTCACAGTGGCTAAGTTCTGCA 22 10 
30d TGTAAACATCCCCGACTGGAAG 22 10 
100i3 AACCCGTAGATCCGAAC 17 10 
100i4 AACCCGTAGATCCGAACTTGTGT 23 10 
125bi2 TCCCTGAGACCCTAAC 16 10 
130bi3 CAGTGCAATGATGAAAGGGCATA 23 10 
151-
3pi11 CTAGACTGAAGCTCCTTGAGGAAA 24 10 
181bi1 AACATTCATTGCTGTCGGTGGGTT 24 10 
let-
7ai7 TGAGGTAGTAGGGTGTATAGTT 22 10 
let-
7ii3 TGAGGTAGTAGTTTGTGCTGTTA 23 10 
 
Table S3.6A 
Table lists the miRNAs of neural stem cells based on their sequencing number from 
highest to lowest. IsomiR-9 (22 nts) ranked number 42 and was sequenced higher than 
some of the canonical miRNAs. Yellow highlighted miRNAs denote canonical 
miRNAs. 
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Human Embryonic Stem Cells 
hsa-miR- Sequence Length Seq.no. 
302a*i1 TAAACGTGGATGTACTTGCTTT 22 1113 
130a CAGTGCAATGTTAAAAGGGCAT 22 888 
423 TGAGGGGCAGAGAGCGAGACTTT 23 529 
302a*i2 TAAACGTGGATGTACTTGCTT 21 491 
182 TTTGGCAATGGTAGAACTCACACT 24 432 
103 AGCAGCATTGTACAGGGCTATGA 23 393 
340 TTATAAAGCAATGAGACTGATT 22 381 
21i1 TAGCTTATCAGACTGATGTTGAC 23 324 
151-3p CTAGACTGAAGCTCCTTGAGG 21 290 
130b CAGTGCAATGATGAAAGGGCAT 22 257 
320a AAAAGCTGGGTTGAGAGGGCGA 22 221 
378i1 ACTGGACTTGGAGTCAGAAGGC 22 214 
182i1 TTTGGCAATGGTAGAACTCACACTGG 26 166 
101i1 TACAGTACTGTGATAACTGAAG 22 165 
151-3pi1 CTAGACTGAAGCTCCTTGAGGA 22 162 
182i2 TTTGGCAATGGTAGAACTCACAC 23 148 
183i1 ATGGCACTGGTAGAATTCACTG 22 133 
302a*i3 CTTAAACGTGGATGTACTTGCTT 23 132 
148a TCAGTGCACTACAGAACTTTGT 22 110 
302a*i4 CTTAAACGTGGATGTACTTGCT 22 109 
103i1 AGCAGCATTGTACAGGGCTAT 21 104 
25 CATTGCACTTGTCTCGGTCTGA 22 98 
302a* ACTTAAACGTGGATGTACTTGCT 23 96 
182i3 TTTGGCAATGGTAGAACTCACACTG 25 95 
302a*i5 TAAACGTGGATGTACTTGCTTTGA 24 86 
378i2 ACTGGACTTGGAGTCAGAAGGCA 23 86 
423i1 TGAGGGGCAGAGAGCGAGACTTTT 24 85 
30e*i1 CTTTCAGTCGGATGTTTACAGT 22 82 
93 CAAAGTGCTGTTCGTGCAGGTAG 23 81 
21 TAGCTTATCAGACTGATGTTGA 22 80 
101i2 GTACAGTACTGTGATAACTGAA 22 80 
302a*i6 ACTTAAACGTGGATGTACTTGC 22 80 
191 CAACGGAATCCCAAAAGCAGCTG 23 76 
221*i1 ACCTGGCATACAATGTAGATTTCTGT 26 72 
340i1 TTATAAAGCAATGAGACTGAT 21 72 
183i2 ATGGCACTGGTAGAATTCACT 21 69 
302a*i7 TAAACGTGGATGTACTTGCT 20 67 
183 TATGGCACTGGTAGAATTCACT 22 66 
335i1 TCAAGAGCAATAACGAAAAATG 22 65 
151-3pi2 CTAGACTGAAGCTCCTTGAGGAA 23 64 
302d TAAGTGCTTCCATGTTTGAGTGT 23 63 
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140i1 ACCACAGGGTAGAACCACGGAC 22 62 
320ai1 AAAAGCTGGGTTGAGAGGGCGAA 23 62 
302b TAAGTGCTTCCATGTTTTAGTAG 23 60 
335i2 TCAAGAGCAATAACGAAAAAT 21 58 
30e* CTTTCAGTCGGATGTTTACAGC 22 55 
302a TAAGTGCTTCCATGTTTTGGTGA 23 54 
320ai2 AAAAGCTGGGTTGAGAGGGCGAT 23 54 
1323 TCAAAACTGAGGGGCATTTTCT 22 53 
130ai1 CAGTGCAATGTTAAAAGGGCATA 23 52 
302ci1 AAGTGCTTCCATGTTTCAGTGGT 23 51 
30a* CTTTCAGTCGGATGTTTGCAGC 22 50 
151-3pi3 CTAGACTGAAGCTCCTTGAG 20 49 
378 ACTGGACTTGGAGTCAGAAGG 21 47 
183i3 TATGGCACTGGTAGAATTCACTG 23 45 
532 CATGCCTTGAGTGTAGGACCGT 22 42 
17 CAAAGTGCTTACAGTGCAGGTAG 23 39 
26a TTCAAGTAATCCAGGATAGGCT 22 38 
30a*i1 CTTTCAGTCGGATGTTTGCAGT 22 38 
106bi1 TAAAGTGCTGACAGTGCAGATA 22 38 
423i2 TGAGGGGCAGAGAGCGAGACTT 22 38 
28-3p CACTAGATTGTGAGCTCCTGGA 22 37 
367 AATTGCACTTTAGCAATGGTGA 22 34 
20b CAAAGTGCTCATAGTGCAGGTAG 23 33 
106b TAAAGTGCTGACAGTGCAGAT 21 33 
335 TCAAGAGCAATAACGAAAAATGT 23 33 
101i3 GTACAGTACTGTGATAACTGAAA 23 32 
378i3 CTGGACTTGGAGTCAGAAGGC 21 32 
31i1 AGGCAAGATGCTGGCATAGCTG 22 31 
423i3 TGAGGGGCAGAGAGCGAGACT 21 31 
29a TAGCACCATCTGAAATCGGTTA 22 30 
101 TACAGTACTGTGATAACTGAA 21 30 
101i4 TACAGTACTGTGATAACTGAAT 22 29 
185 TGGAGAGAAAGGCAGTTCCTGA 22 29 
31 AGGCAAGATGCTGGCATAGCT 21 27 
1270 CTGGAGATATGGAAGAGCTGTGT 23 27 
103i2 AGCAGCATTGTACAGGGCTATG 22 26 
130bi1 CAGTGCAATGATGAAAGGGCATT 23 26 
302bi1 TAAGTGCTTCCATGTTTTAGTA 22 26 
99bi1 CACCCGTAGAACCGACCTTGC 21 25 
124i1 TAAGGCACGCGGTGAATGCCAA 22 25 
141i1 TAACACTGTCTGGTAAAGATGGC 23 25 
151-3pi4 CTAGACTGAAGCTCCTTGAGGT 22 25 
191i1 CAACGGAATCCCAAAAGCAGCTGT 24 25 
302a*i8 TAAACGTGGATGTACTTGCTTTG 23 24 
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320ai3 AAAAGCTGGGTTGAGAGGGCGT 22 24 
374ai1 TTATAATACAACCTGATAAGT 21 24 
374b ATATAATACAACCTGCTAAGTG 22 24 
25*i1 AGGCGGAGACTTGGGCAATTGCT 23 23 
101i5 GTACAGTACTGTGATAACTGA 21 23 
191i2 CAACGGAATCCCAAAAGCAGCT 22 23 
302a*i9 TAAACGTGGATGTACTTGCTTTGAAACT 28 23 
708 AAGGAGCTTACAATCTAGCTGGG 23 23 
30ai1 TGTAAACATCCTCGACTGGAAGC 23 22 
30ai2 TGTAAACATCCTCGACTGGAAGCT 24 22 
30di1 TGTAAACATCCCCGACTGGAAGCT 24 22 
99b CACCCGTAGAACCGACCTTGCG 22 22 
302a*i10 TAAACGTGGATGTACTTGCTTTA 23 22 
222i1 AGCTACATCTGGCTACTGGGTCT 23 21 
378i4 ACTGGACTTGGAGTCAGAAGGCAT 24 21 
744 TGCGGGGCTAGGGCTAACAGCA 22 21 
101i6 TACAGTACTGTGATAACTGAAA 22 20 
130ai2 CAGTGCAATGTTAAAAGGGCATT 23 20 
182i4 TTTGGCAATGGTAGAACTCACACTGGT 27 20 
183i4 ATGGCACTGGTAGAATTCACTGT 23 20 
219-2-3p AGAATTGTGGCTGGACATCTGT 22 20 
302a*i11 TAAACGTGGATGTACTTGCTTTGAAAC 27 20 
let-7a TGAGGTAGTAGGTTGTATAGTT 22 20 
16 TAGCAGCACGTAAATATTGGCG 22 19 
17i1 CAAAGTGCTTACAGTGCAGGT 21 19 
31i2 AGGCAAGATGCTGGCATAGCTGT 23 19 
92b TATTGCACTCGTCCCGGCCTCC 22 19 
378i5 ACTGGACTTGGAGTCAGAAG 20 19 
423i4 TGAGGGGCAGAGAGCGAGACTTTA 24 19 
92a TATTGCACTTGTCCCGGCCTGT 22 18 
130bi2 CAGTGCAATGATGAAAGGGCATA 23 18 
151-3pi5 CTAGACTGAAGCTCCTTGAGGAAA 24 18 
302ai1 TAAGTGCTTCCATGTTTTGGTG 22 18 
302d*i1 ACTTTAACATGGAGGCACTTGCT 23 18 
221*i2 ACCTGGCATACAATGTAGATTTCT 24 17 
21i2 TAGCTTATCAGACTGATGTTGACA 24 16 
30c-2* CTGGGAGAAGGCTGTTTACTCT 22 16 
148ai1 TCAGTGCACTACAGAACTTTGTC 23 16 
302ai2 AAGTGCTTCCATGTTTTGGTGA 22 16 
302a*i12 TAAACGTGGATGGACTTGCTTT 22 16 
130bi3 CAGTGCAATGATGAAAGGGCA 21 15 
193a AACTGGCCTACAAAGTCCCAGT 22 15 
221 AGCTACATTGTCTGCTGGGTTTC 23 15 
302a*i13 TTAAACGTGGATGTACTTGCTT 22 15 
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302d* ACTTTAACATGGAGGCACTTGC 22 15 
340i2 TTATAAAGCAATGAGACTGA 20 15 
30e*i2 CTTTCAGTCGGATGTTTACAG 21 14 
130ai3 CAGTGCAATGTTAAAAGGGC 20 14 
28-5pi1 AAGGAGCTCACAGTCTATTGA 21 13 
151-3pi6 CTAGACTGAAGCTCCTTGAGA 21 13 
182i5 TTTGGCAATGGTAGAACTCACA 22 13 
302d*i2 ACTTTAACATGGAGGCACTTG 21 13 
503i1 TAGCAGCGGGAACAGTTCTGAAA 23 13 
1275i1 GTGGGGGAGAGGCTGT 16 13 
92b*i1 AGGGACGGGACGCGGTGCAGTGTT 24 12 
128 TCACAGTGAACCGGTCTCTTT 21 12 
130ai4 CAGTGCAATGTTAAAAGGGCA 21 12 
151 TCGAGGAGCTCACAGTCTAGT 21 12 
182i6 TTTGGCAATGGTAGAACTCACACTGGA 27 12 
302a*i14 TAAACGTGGATGTACTTGCTTTGAA 25 12 
302bi2 TAAGTGCTTCCATGTTTTAGT 21 12 
302bi3 TAAGTGCTTCCATGTTTTAGTAGT 24 12 
302di1 AAGTGCTTCCATGTTTGAGTGT 22 12 
363 AATTGCACGGTATCCATCTGTA 22 12 
378i6 ACTGGACTTGGAGTCAGAAGGCAA 24 12 
16i1 TAGCAGCACGTAAATATTGGCGT 23 11 
24 TGGCTCAGTTCAGCAGGAACAG 22 11 
103i3 AGCAGCATTGTACAGGGCTATGAT 24 11 
182i7 TTTGGCAATGGTAGAACTCACACTGT 26 11 
183i5 ATGGCACTGGTAGAATTCACTGA 23 11 
191i3 CAACGGAATCCCAAAAGCAGCTGA 24 11 
302ci2 AAGTGCTTCCATGTTTCAGTGG 22 11 
367i1 AATTGCACTTTAGCAATGGT 20 11 
378i7 CTGGACTTGGAGTCAGAAGGCA 22 11 
548fi1 AAAACTGTAATTACTTTTGGAC 22 11 
708*i1 AACTAGACTGTGAGCTTCTAGA 22 11 
769 TGAGACCTCTGGGTTCTGAGCT 22 11 
19b TGTGCAAATCCATGCAAAACTGA 23 10 
21i3 TAGCTTATCAGACTGATGTTGAA 23 10 
25*i2 AGGCGGAGACTTGGGCAATTGC 22 10 
28-3pi1 CACTAGATTGTGAGCTCCTGGAA 23 10 
92b*i2 AGGGACGGGACGCGGTGCAGTGT 23 10 
106b* CCGCACTGTGGGTACTTGCTGC 22 10 
107 AGCAGCATTGTACAGGGCTATCA 23 10 
210 CTGTGCGTGTGACAGCGGCTGA 22 10 
221*i3 ACCTGGCATACAATGTAGATTTC 23 10 
320ai4 AAAAGCTGGGTTGAGAGGGCGAAT 24 10 
1260 ATCCCACCGCTGCCACCA 18 10 
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Table S3.6B 
Table lists the miRNAs of embryonic stem cells based on their sequencing number 
from highest to lowest. IsomiR-302a (22 nts) ranked number 118 and was sequenced 
higher than some of the canonical miRNAs. Yellow highlighted miRNAs denote 
canonical miRNAs. 
 
 
No Predicted targets unique to isomiR-9 Note 
1 ADRA2C Adrenal receptor 
2 AVPR1A Restricted, not brain 
3 BACE2 Ubiquitous 
4 C20ORF77 / 
5 CACNG3 Brain/ Kidney tumour 
6 CGI-09 / 
7 CPT1A Widespread 
8 CSN3 Connective tissue 
9 CYP2U1 / 
10 DDX50 / 
11 GALNACT-2 Heart 
12 GFRA2 / 
13 GJA3 Kidney tumour 
14 GPR177 / 
15 IFRD2 Ubiquitous 
16 IQCH Restricted 
17 IRX3 / 
18 KIAA0523 Glioma 
19 LOC133308 / 
20 LOC374395 / 
21 LYSMD2 / 
22 MGC4655 Widespread 
23 N4BP3 Restricted, include brain 
24 NDST3 Leukaemia 
25 PPP2R2D Widespread 
26 PWWP2B Widespread 
27 RAB31 Widespread 
28 RFT1 Head and neck tumour 
29 RUTBC3 Widespread 
30 SEP15/ Widespread 
31 SF3A3 Splicing factor/ Ubiquitous 
32 SLC25A26 Widespread 
33 SMPD4 / 
34 SNX9 Widespread 
35 SSU72 Ubiquitous 
36 SYNE2 Widespread 
37 TCF7L2 Widespread 
38 THAP4 Widespread 
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39 UBE2J2 Widespread 
40 UBQLN3 Brain/ testis/ germ cell tumour 
41 VCP Ubiquitous 
42 XLKD1 Widespread 
43 ZCCHC8 Widespread 
44 ZNF364 Widespread 
 
Table S3.7 Table below lists all the unique targets of isomiR-9. 
 
 
miR- ES NS MS  miR- ES NS MS  miR- ES NS MS 
9 – 870 –  92b 25 885 –  335 156 101 8 
9* – 1299 –  92b* 22 188 –  335* – – 10 
10a – 14 35  106b 71 88 18  379 – 21 6 
10a* – – 2  106b* 15 – –  379* – – 16 
16 30 150 112  125a-5p – – 3  411 – – 1 
16* – – 9  125a-3p – – 3  411* – – 26 
20a – 10 3  125b – 273 97  423-5p 702 2361 10 
20a* – – 1  125b* – – 12  423-3p – – 5 
21 430 3127 880  140-5p – – 3  424 – – 72 
21* – – 3  140-3p 62 157 9  424* – – 3 
22 – – 429  151-5p 17 57 2686  425 – – 8 
22* – – 6  151-3p 663 761 25  425* – – 3 
23b – 13 75  154 – – 1  493 – – – 
23b* – – 1  154* – – 1  493* – – 119 
25 98 139 3  186 – 11 4  501-5p – – 1 
25* 33 24 –  186* – – 1  501-3p – – 1 
27b – 140 3  193a-5p – – 2  654-5p – – 5 
27b* – – 1  193a-3p 15 – 107  654-3p – – 4 
28-5p – – 41  199b-5p – – 3  708 23 – 2 
28-3p 47 52 32  199-3p – – 20  708* 11 – – 
29a 30 546 179  221 15 – 36  769-5p 11 29 – 
29a* – – 4  221* 99 129 1  769-3p – – 1 
30a 44 110 27  222 21 35 50  let-7d – 183 1323 
30a* 88 119 20  222* – – 1  let-7d* – – 1 
30b – – 1  302a 88 – –  let-7i – 137 40 
30b* – – 2  302a* 2306 – –  let-7i* – – 1 
30e – 215 5  302b 115 – –  
    30e* 151 – 8  302b* 5 – –  
    92a 18 34 –  302d 75 – –  
    92a-1* 6 – –  302d* 46 – –  
    Table S5.1  
Table lists the total number of sequencing results in hESCs, NSCs and MSCs. Deep 
sequencing was performed by Elcie Chan.  
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1. Common elements in "302a/b/c/d", "302a*", "302b*/d*" and "367": 
BCL11A 
ZFHX4 
 2. Common elements in "302a/b/c/d", "302a*" and "367": 
FNDC3B 
PPP1R9A 
ZNF148 
 3. Common elements in "302a/b/c/d", "302a*" and "302b*/d*": 
INTS6 
KLHL28 
MYBL1 
PLEKHA3 
PURA 
PURB 
TRPS1 
 4. Common elements in "302a/b/c/d" and "302a*": 
ATP2B2 
BAHD1 
BCL11B 
C11orf30 
C16orf72 
CNOT6 
E2F7 
ELAVL2 
ESR1 
FAM13C1 
FBXO11 
KREMEN1 
MBNL1 
NPAS3 
NR2F2 
PCDHA1 
PCDHA10 
PCDHA12 
PCDHA13 
PCDHA2 
PCDHA3 
PCDHA4 
PCDHA5 
PCDHA6 
PCDHA7 
PCDHA8 
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PCDHAC1 
PCDHAC2 
PLAG1 
RAB7A 
RORB 
SP3 
TARDBP 
TFAP4 
YTHDF3 
ZNF436 
 5. Common elements in "302a*", "302b*/d*" and "367": 
APRIN 
BMPR2 
C18orf25 
GRM7 
LUZP1 
NOVA1 
STAG2 
TNPO1 
TOB1 
 6. Common elements in "302a*" and "302b*/d*": 
BMP2 
BRD1 
CREBBP 
CROP 
CUL4B 
DAZAP1 
DOLPP1 
ETV6 
GNAZ 
GPM6B 
INTS2 
RYBP 
SAMD4B 
SOX6 
TAOK3 
ZIC1 
ZMIZ1 
 
Table S5.2 
List of predicted targets of miR-302 cluster that are common between members. 
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Figure S2.1  
Gel images of digested pGEM-T with 3' UTR and their sequencing results. 
Segment of the 3' UTR were amplified by PCR and ligated into pGEM-T easy vector 
and sequenced. Sequencing results were analysed using human blat search (USCS 
genome bioinformatics). 
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Figure S2.2  
Gel images of digested pGL3 reporter vectors. 
pGL3 miRNA reporter vector constructs with inserts were validated by BsrGI and 
FseI digestion. Vector maps digested by the enzymes were generated by NEB cutter. 
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Figure S2.3 
pMIR-miRNA reporter vectors were digested by XhoI and SacI to validate the 
presence of inserts. 
 
 
 
Figure S2.4 
pMIR-Report-miR9 and -isomiR9 sponges were digested by ClaI and HindIII to 
validate the presence of inserts.  
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Figure S2.5 
Gel image to validate the successful removal of 4 of the 6 MBS in sponge constructs. 
 
 
 
Figure S2.6 
Gel image to look for the presence of inserts in pcDNA expression vectors. 
 
 
 
 
Figure S2.7 
Gel image of PCR products of coding region and 3’UTR of DNMT3B. 
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Figure S2.8 
pcDNA-DNMT3B clone 1 to 6 were digested by BamHI and XbaI to look for clones 
that have the insert. Inserts were present in clone 1, 3 and 6. 
 
 
 
Figure S2.9 
Gel image of PCR product of miR-302 cluster and validation of ligation into pGEM-T 
easy vector and its sequencing result. 
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Figure S3.1  
Figure illustrates the number of miRNA binding sites (miBS) in the genes that were 
predicted targets of isomiR-9. There are 44 predicted target genes that are solely 
target by isomiR-9, and were not predicted target of any canonical miRNAs. 
 
 
 
Figure S5.1  
MiRNA target prediction of Sp3 transcription factor by 3 independent prediction 
databases, namely MicroCosm, Pictar and Targetscan.  
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Figure S5.2 Gel image of digested pMIR-ZNF148-3' UTR. 
pMIR-ZNF148-UTR reporter was validated by XhoI and SacI digestions which 
released a 500bp DNA fragment of ZNF148 3'UTR. Clones that were successfully 
ligated with ZNF148 -3'UTR include 1, 3, 5, 6, 9 and 10.  
 
 
 
Figure S5.3 
MiR-302 cluster human genome DNA sequence located in chromosome 4. Red texts 
represent sequence of the members of miR-302 cluster gene, namely miR-302b, miR-
302c, miR-302c, miR-302d and miR-367. 
 
 
Figure S5.4 Gel image of digested pTRIPz-302 cluster. 
pTRIPz-302 cluster was digested by XhoI and MluI that released the miR-302 cluster 
consisting of a 975bp DNA fragment. This image validated the successful ligation of 
miR-302 cluster in pTRIPZ lentiviral vector. 
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hsa-miR-302b-5p and hsa-miR-302c-5p 
 
  UUUAACAUGGGGGUACCUGCUG >hsa-miR-302c-5p MIMAT0000716 
ACUUUAACAUGGAGGCACUUGC  >hsa-miR-302d-5p MIMAT0004685 
ACUUUAACAUGGAAGUGCUUUC  >hsa-miR-302b-5p MIMAT0000714 
 
hsa-miR-302c-5p MIMAT0000716 
 
hsa-miR-302b-5p MIMAT0000714 
 
hsa-miR-302d-5p MIMAT0004685 
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Figure S6.1 The dominant mature form of hsa-miR-302b-5p and hsa-miR-302c-5p 
represent the isomiRs of each others. 
 
 
hsa-miR-518a-3p, hsa-miR-518f-3p and hsa-miR-518e-3p 
GAAAGCGCUUCCCUUUGCUGGA  >hsa-miR-518a-3p MIMAT0002863 
GAAAGCGCUUCUCUUUAGAGG  >hsa-miR-518f-3p MIMAT0002842 
 AAAGCGCUUCCCUUCAGAGUG  >hsa-miR-518e-3p MIMAT0002861 
 
>hsa-miR-518a-3p MIMAT0002863 
GAAAGCGCUUCCCUUUGCUGGA 
 
 
>hsa-miR-518f-3p MIMAT0002842 
GAAAGCGCUUCUCUUUAGAGG 
 
 
>hsa-miR-518e-3p MIMAT0002861 
AAAGCGCUUCCCUUCAGAGUG 
 
 
 
 
Figure S6.2 hsa-miR-518a-3p, hsa-miR-518f-3p and hsa-miR-518e-3p  
Other examples where the dominant mature form represent the isomiRs of each others.  
